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Strategies aimed at inhibiting the expression of the c-myc oncogene could provide the basis for 
alternative cancer treatment. In this regard, silencing c-myc expression using small interfering 
RNA (siRNA) is an attractive option. However, the development of a clinically viable, siRNA-
based, c-myc silencing system is largely dependent upon the design of an appropriate siRNA 
carrier that can be easily prepared. Nanostructures formed by the electrostatic association of 
siRNA and cationic lipid vesicles represent uncomplicated, well-recognised siRNA delivery 
systems. Therefore, this study has focused on traditional cationic liposomes as the foundation for 
the development of a simple, but effective anti-c-myc onconanotherapeutic agent. 
Novel liposome formulations contained equimolar quantities of the cytofectin, N,N-
dimethylaminopropylamidosuccinylcholesterylformylhydrazide (MS09), and cholesterol (Chol); 
with or without 2 mol % pegylation. Liposomes which contained 
dioleoylphosphatidylethanolamine (DOPE) as the co-lipid were included for comparative 
purposes. Pegylated and non-pegylated MS09/Chol (1:1) suspensions were reproducibly 
prepared by lipid film hydration to give unilamellar vesicles that were stable for at least 10 
months at 4 ˚C. 
Liposomes successfully bound siRNA to form lipoplexes of less than 200 nm in size, with zeta 
potentials between -16 and -44 mV. These assumed globular and bilamellar structures in which 
siRNA was partially protected. Although all formulations were well tolerated at ≤14 nM siRNA, 
pegylation severely inhibited siRNA delivery in cancer cell lines, MCF-7 and HT-29, which 
overexpress c-myc.  
The non-pegylated MS09/Chol (1:1) lipoplex, at the MS09:siRNA (w/w) ratio of 16:1, was most 
effectively taken up by MCF-7 and HT-29 cells, with negligible effect in non-transformed cells 
when applied at 12 nM siRNA. Lipoplexes directed against the c-myc transcript (anti-c-myc 
siRNA), mediated a dramatic reduction in c-myc mRNA and protein levels. This was 
accompanied by a loss of migratory potential and apoptotic cell death. Moreover, oncogene 
knockdown and anti-cancer effects were superior to that of a commercially available transfection 
reagent, Lipofectamine™ 3000. Although the DOPE-containing counterpart performed with 
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comparable efficacy under standard in vitro conditions, it was incapable of siRNA delivery at 
physiological serum concentration. Hence, the anti-c-myc MS09/Chol (1:1) lipoplex reported 
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CHAPTER 1 - INTRODUCTION 
1.1 Background to the study 
The c-myc gene encodes a nuclear phosphoprotein that is widely recognised for its role as a 
transcription factor. The c-Myc protein is believed to participate in the regulation of 10 – 15 % of 
all genes (Zeller et al., 2006). These include genes involved in cell cycle progression (Berns et 
al., 1997, Hermeking et al., 2000), metabolism (Kim et al., 2004), cell growth (Liu et al., 2008b, 
Schuhmacher et al., 1999, Van Riggelen et al., 2010), differentiation (Wilson et al., 2004), 
adhesion (Gebhardt et al., 2006), and apoptosis (Morrish et al., 2003). Due to its function in 
regulating essential cellular functions, expression of the c-myc gene and activity of the c-Myc 
protein is, under normal circumstances, tightly controlled. However, abnormal c-myc expression 
can occur due to genetic events which include translocations (Battey et al., 1983), 
rearrangements (Dalla-Favera et al., 1983) and amplification (Treszl et al., 2004), as well as 
flaws in pathways implicated in regulation of this gene or the protein that it encodes (Smith et 
al., 1993). 
Research carried out in the 1980s showed an association between the deregulated expression of 
c-myc and tumourigenesis (Adams et al., 1985, Leder et al., 1986). Further work showed that 
abnormal c-myc expression causes neoplastic changes by eliminating check-points in the cell 
cycle (Li and Dang, 1999, Gil et al., 2005), prompting genomic instability (Kuzyk and Mai, 
2014) and through association with other oncogenes (Vaux et al., 1988, Wang et al., 2011). In 
fact, tumour cells often rely on c-myc expression for the maintenance of the cancerous state. This 
phenomenon, known as oncogene addiction, was emphasised by studies which show that c-myc 
inactivation caused tumour regression in transgenic mice (Arvanitis and Felsher, 2006) by 
inhibiting cellular proliferation, and inducing senescence or apoptosis and differentiation 
(Felsher, 2010). Moreover, the effects of systemic c-myc inhibition were found to be mild in 
normal tissues, and were well tolerated over time (Soucek et al., 2008). These findings, together 
with an estimation that c-myc is deregulated in up to 70 % of human cancers (Dang, 2012), 
motivate strongly for the therapeutic value of inhibiting oncogenic c-myc. 
In theory, the oncogenic activity of c-myc can be eliminated by inhibiting expression of the 
activated gene, inhibiting inter-protein associations that are critical for c-Myc function, or by 
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disrupting pathways that support c-myc deregulation in cancer cells; and this has provided a basis 
for the design and evaluation of several potential anti-cancer strategies. The antisense 
oligonucleotides have featured in some of the earliest reports of c-myc inhibition (Holt et al., 
1988, Loke et al., 1988, Wickstrom et al., 1988). These short, single-stranded DNA molecules 
hybridise to complementary regions of c-myc messenger RNA (mRNA), and prevent its 
translation either by acting as a physical impediment or by engaging  ribonuclease (RNase) H 
activity (Dias and Stein, 2002). The application of antisense technology to c-Myc inhibition has 
expanded with nucleotide modifications designed to confer greater stability and specificity 
(Cutrona et al., 2003, Hudziak et al., 2000). However, Nobel Prize-winning work which 
described an endogenous gene silencing mechanism, known as RNA interference (RNAi), (Fire 
et al., 1998) presented further possibilities. 
Short RNA duplexes, known as small interfering RNA (siRNA), associate with a network of 
cytoplasmic proteins to form the RNA-induced silencing complex (RISC), through which they 
guide the degradation of mRNA bearing a complementary sequence (Elbashir et al., 2001). In 
theory, effective silencing of c-myc, or any oncogene, may be achieved using endogenous 
cellular machinery, provided that the appropriately designed siRNA molecule is successfully 
introduced. However several factors militate against the success of naked siRNA molecules in 
vivo. Naked siRNA molecules are highly susceptible to serum nucleases (Cao and Ji, 2009) and 
are rapidly cleared by the kidneys (Huang et al., 2011). Furthermore, the size (approximately 
14 kDa) and net negative charge of the siRNA prevent its passage across biological membranes 
(Akhtar and Benter, 2007). Therefore, an appropriate carrier is required to protect the siRNA 
molecules from damage and elimination as well as to disguise its negative charge. 
The fact that nucleic acids can electrostatically associate with positively charged agents led to the 
investigation of a wide variety of cationic molecules as potential carrier vehicles. These include 
cationic cell-penetrating peptides (Eguchi et al., 2009), polymers (Urban-Klein et al., 2005), 
dendrimers (Taratula et al., 2009), and lipids (Zheng et al., 2014). Among them the cationic 
lipids have received the most attention, both in laboratory-scale experiments and clinical trials 
(Hope, 2014, Leung et al., 2014, Singh et al., 2015). The earliest cationic lipid-based delivery 
system is the cationic liposome, that is formed from the self-assembly of cationic and neutral or 
helper lipids (Felgner et al., 1987). These form nanostructures, known as lipoplexes, when 
 3 
 
associated with siRNA. More recently cationic lipids have served as the nucleation centres or 
outer coatings of more elaborate lipid nanoparticles in which siRNA is encapsulated (Chen et al., 
2010, Morrissey et al., 2005, Zhang et al., 2013). However, traditional siRNA lipoplexes are 
arguably easier and less time-consuming to prepare. Other favourable characteristics which 
include safety, biocompatibility, and, importantly, amenability to modification have sustained the 
interest in the field of cationic liposomal-siRNA delivery (Shim et al., 2013). 
In a recent review of siRNA delivery systems for cancer treatment, Xu and Wang (2015) outline 
the properties of the ideal siRNA carrier. The vector system must have low toxicity, afford 
stability in the presence of serum, avoid recognition by the immune system, avoid renal 
clearance, reach and successfully enter the diseased cells to deliver its contents to the RNAi 
machinery. Although numerous studies documenting novel liposomal-siRNA systems have 
shown promise, none have resulted in a commercially available treatment (Singh et al., 2015). 
Major barriers to the application of cationic liposomal systems as nanomedicines include poor 
stability in the bloodstream and early recognition by the immune system. The net positive charge 
of lipoplexes encourages association with anionic serum proteins such as albumin and 
lipoproteins. The effect of these interactions is two-fold. Firstly, opsonisation by serum 
components can cause destabilisation of the lipoplex structure, and consequently, damage to the 
nucleic acid cargo before it reaches the diseased cells. Secondly, lipoplexes often aggregate to 
form large particles that accumulate in the lung and are rapidly cleared by the reticuloendothelial 
system. This reduces the effective dose and circulation time (Li et al., 1999, Semple et al., 1998). 
In an attempt at addressing this matter, two main strategies have emerged. The first and most 
common method involves surface modification of liposomes with biocompatible polymers, such 
as poly(ethylene glycol) (PEG), which sterically inhibit contact between serum proteins and the 
liposomal bilayer (Papahadjopoulos et al., 1991, Torchilin et al., 1994). The second strategy 
involves increasing the mechanical strength of the bilayer so as to render it more resistant to the 
destabilising action of serum proteins. This may be achieved through the incorporation of rigid, 







As such, the following observations were made: 
• Deregulated expression of the c-myc proto-oncogene initiates transformation of normal 
cells, promotes tumourigenesis and is a common feature of a wide variety of cancers.    
• Inhibition of c-myc expression may induce loss of the neoplastic phenotype, and this fact 
may be exploited in the design and development of more effective cancer treatment 
strategies.   
• Silencing of c-myc expression in cancer cells can be achieved by the endogenous 
mechanism of RNAi via the introduction of correctly designed siRNA molecules. 
• The success of any anti-c-myc siRNA strategy hinges on faithful delivery of siRNA 
molecules. 
• Cationic liposomes have shown promise as siRNA carriers. However, unfavourable 
liposome-serum interactions and early elimination represent major limiting factors.  
• It was concluded that further design and optimisation of liposome formulations is 
necessary before their full potential as siRNA carriers can be profitably harnessed. 
 
Initially, much research was centred on enhancing liposome performance by improving the 
cationic lipid component. Consequently, numerous cationic lipids were synthesised with features 
which include novel ionisable headgroups that impart the positive charge and improve 
interactions with siRNA (Desigaux et al., 2007, Mével et al., 2010), cleavable linkages that 
minimise toxicity (Zheng et al., 2014), and pH-sensitive moieties to promote siRNA release 
within the cell (Sato et al., 2012). It was later shown that variations in the nature and quantity of 
the helper lipid and addition of surface appendages, when combined with a given cationic lipid 
gives liposomes with markedly different stabilities, siRNA carrying and protecting capability, 
cellular uptake characteristics and transfection efficacy (Khatri et al., 2014, Wang et al., 2013a). 
Consequently, the potential for formulation enhancement with a given, promising cationic lipid 
is extensive. The monocationic cholesterol derivative N,N-dimethylaminopropylamidosuccinyl-
cholesterylformylhydrazide (MS09) is one such lipid. Having only been investigated in co-
formulation with the conventional helper lipid dioleoylphosphatidylethanolamine (DOPE), 
MS09 showed potential in siRNA delivery that merits further development (Daniels et al., 2013). 
Hence, this study has focused on the effect of substituting Chol, as the helper lipid in pegylated 
and non-pegylated MS09 liposomes, in an attempt to achieve lipoplexes capable of safely and 
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successfully delivering siRNA molecules directed against a clinically relevant gene, c-myc, into 
cancer cells.  
 
1.2 Aim and objectives 
The aim of this study was to formulate cationic delivery systems, based on the cationic lipid, 
MS09; and to evaluate their potential as siRNA carriers in vitro, towards the development of a 
simple, yet effective anti-c-myc liposomal onconanotherapeutic agent. In order to achieve this 
aim, the objectives of the study were as follows: 
• To formulate liposomes containing MS09 and bilayer-stabilising agents, namely, the 
helper lipid, Chol, and a pegylated lipid. 
• To determine the optimum ratio of MS09 to Chol for liposome formation. 
• To assess siRNA-binding, lipoplex formation and siRNA-protecting capabilities of 
liposomes. 
• To characterise liposomes and siRNA lipoplexes according to size, morphology and zeta 
potential.  
• To investigate cell tolerance and the siRNA-delivery capabilities of liposomes, in 
transformed and non-transformed human cell lines. 
• To compare the characteristics of new liposome formulations with that of liposomes 
containing the conventional helper lipid, DOPE, and a commercially available liposomal 
transfection reagent.  
• To apply the best-performing lipoplex to the delivery of anti-c-myc siRNA in cell lines 
representative of cancers that are known to overexpress c-myc. 
• To quantify the effect of transfection with the selected lipoplex on oncogenic c-myc 
expression at the mRNA and protein levels. 




1.3 Significance of the study 
Cancer is a leading cause of death world-wide. According to the American Cancer Society, 
deaths due to cancer outnumber those due to acquired immune deficiency syndrome (AIDS), 
malaria and tuberculosis combined (American Cancer Society, 2015). At present, cancer 
treatment mainly involves surgical removal of tumours, the administration of anti-cancer drugs 
and/or radiation depending on the type and stage of the disease. Despite advances in 
understanding tumourigenesis and disease progression, current cancer treatments are limited by 
harsh and possibly persistent side-effects, the possibility of recurrences, and are heavily 
dependent on early detection and diagnosis for success (DeSantis et al., 2014). With the global 
cancer burden projected to increase to 21.7 million new cases and 13 million deaths by the year 
2030, it is clear that more effective treatment strategies are required (American Cancer Society, 
2015). 
Research into the genetics of cancer cells has identified the altered activity of the c-myc proto-
oncogene as an important element in the initiation and maintenance of the cancerous state. 
Silencing of oncogenic c-myc by endogenous cellular machinery using appropriately designed 
siRNA molecules could reverse transformation, and presents a potential therapeutic alternative. 
The current study is important to the field of cancer gene therapy for the following reasons. 
Given that aberrant c-myc expression is a feature of a wide variety of malignancies, advances in 
the design of appropriate c-myc-silencing systems may eventually prove useful in treating a 
broad range of cancers (Vita and Henriksson, 2006). It is worth mentioning at this point that 
further development of the only lipid nanoparticle-based siRNA therapy against c-myc that has 
been reported to date (Tolcher et al., 2015) was terminated in 2016 following early-phase clinical 
trials. Therefore, safe and clinically feasible lipid-based anti-c-myc systems remain to be 
developed. The design, optimisation and evaluation of new liposomal formulations for siRNA 
delivery may potentiate this goal.  
 
1.4 Novelty of the study 
This study reports on new cationic liposome formulations containing the known cytofectin, 
MS09, and helper lipid, Chol, with or without PEG-modification for the purposes of siRNA 
delivery. While MS09 has been investigated in a serum-deficient in vitro siRNA application 
(Daniels et al., 2013), the effect of its co-formulation with Chol on siRNA delivery, and its 
 7 
 
further application in c-myc gene silencing under normal cell culture conditions has not 
previously been explored.  
1.5 Outline of dissertation 
This dissertation is presented in the form of five chapters. 
Chapter 1 provides the context within which the current study is relevant. The aims and 
objectives of the study together with its novelty and significance in the field of cancer gene 
therapy are outlined. 
Chapter 2 is a literature review that is focused on the c-myc proto-oncogene, the role of the 
c-Myc oncoprotein in human cancer and its potential as a therapeutic target in the treatment of 
cancer. Due emphasis is placed on nucleic acid-mediated inhibition of c-myc.   
Chapter 3 gives detailed information of all experimental work performed, fully outlining all 
materials and protocols undertaken. 
Chapter 4 presents all results obtained with statistical analyses. These are interpreted and 
discussed in detail. 




CHAPTER 2 – LITERATURE REVIEW 
Oncogenic c-Myc: structure, function and potential for nucleic acid-mediated inhibition in 
cancer treatment 
2.1 Introduction 
The c-myc proto-oncogene is the most famous member of the myc gene family which includes 
L-myc (Nau et al., 1985), N-myc (Schwab et al., 1983), B-myc (Ingvarsson et al., 1988) and 
s-myc (Sugiyama et al., 1989). c-myc was first identified in 1982, as a cellular homologue of 
v-myc, the oncogene responsible for the transforming activity of avian retroviruses (Vennstrom 
et al., 1982). The c-myc gene encodes a nuclear phosphoprotein (Beimling et al., 1985, Ramsay 
et al., 1984), c-Myc, that is a key regulator of cellular activity, largely through its capacity as a 
transcription factor (Dang, 1999, Dang et al., 2006). 
Shortly after its discovery, the possibility of oncogenic activation of c-myc due to chromosomal 
translocation was raised (Battey et al., 1983), and abnormal c-myc expression was correlated 
with the initiation of cancer (Adams et al., 1985). c-myc has since been recognised as one of the 
most frequently deregulated genes in human cancers. Consequently, much attention has been 
given to the idea that the development of an appropriate strategy for inhibiting oncogenic activity 
of the c-Myc protein may translate into effective treatment for cancer (McKeown and Bradner, 
2014). In this regard, synthetic nucleic acids, having long been recognised as tools for 
modulating gene expression (Juliano, 2016), were considered.  
This review discusses the structural and functional aspects of the c-myc gene, its protein product, 
its importance in cancer and, as such, sets the scene to focus on strategies for nucleic acid-
mediated c-myc inhibition. 
 
2.2 Structure of the c-myc gene 
The human c-myc gene is located on chromosome 8q24 (Neel et al., 1982). It is organised in the 
form of three exons and two introns (Watt et al., 1983) as shown in Figure 2.1. Transcription can 
be initiated from any of four promoter sequences (Nanbru et al., 2001). However, P2, from 
which, at minimum 75 % of c-myc mRNA originates, is the major promoter (Bentley and 
Groudine, 1986). The c-myc locus encodes alternate translation start codons, which give rise to 
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c-Myc protein isoforms (Blackwood et al., 1994). The nuclease hypersensitivity element (NHE) 
III1 is a key regulator of c-myc expression. It serves as a binding site for transcription initiation 
factors (Postel et al., 1989), and harbours a guanine-rich motif that modulates transcription via 
equilibrium between quadruplex and duplex DNA conformation (Seenisamy et al., 2004). 
 
Figure 2.1: A representation of the human c-myc gene. The arrows indicate promoters. NHE III1 refers to 
the nuclease hypersensitivity element III1. CTG and ATG are the alternative start codons for the p67 and 
p64 protein isoforms, respectively. pA1 and pA2 represent polyadenylation signals. Redrawn and adapted 
from Chen et al. (2014) and Nanbru et al. (2001).  
 
2.3 Structure of the c-Myc protein 
The c-myc gene specifies any of three protein isoforms, depending on the promoter sequence and 
translation start site involved. The major c-Myc protein, designated as p64, is of 64 kDa and 
occurs when translation of c-myc mRNA from any of the four promoters begins at the AUG 
codon of exon 2. As shown in Figure 2.2, the 439 amino acid polypeptide chain of p64 is broadly 
divided into the amino-terminal domain (NTD), central domain and carboxy-terminal domain 
(CTD). 
The CTD permits binding between the c-Myc transcription factor and regulatory regions of its 
target genes. This region harbours the basic helix-loop-helix (HLH) leucine zipper (LZ) motif 
that is characteristic of the Myc protein family. Importantly, the HLHLZ motif permits 
dimerization with its obligate partner protein, the Myc-associated factor X (Max) (Blackwood 
and Eisenman, 1991). The basic amino acid residues of the CTD specify binding of the 
c-Myc/Max dimer to CACGTG enhancer box (E-box) consensus sequences (Papoulas et al., 




Figure 2.2: Structural organisation of human c-Myc protein, p64. Redrawn and adapted from Pelengaris 
et al. (2002) and Zhang et al. (2017b).  
 
Several conserved peptide sequences, known as Myc boxes, play a major role in modulating the 
level and activity of the c-Myc protein, primarily by serving as docking sites for various protein 
factors. Myc box I (MBI) and Myc box II (MBII), within the NTD, have been the most widely 
studied. MBI harbours sites for phosphorylation (Henriksson et al., 1993) and O-glycosylation 
(Chou et al., 1995) that regulate the protein’s lifespan. MBI also associates with proteins such as 
p107 (Gu et al., 1994) and TATA-binding protein (TBP) (McEwan et al., 1996), which either 
promote or repress its activity on target genes. Recently, the existence of a second transactivation 
domain (TAD), Myc box 0 (MB0), believed to induce the expression of a different set of target 
genes from MBI, was reported (Zhang et al., 2017b). MBII is associated with assembly of the 
transcription machinery (further details are provided in section 2.4), and has been linked with 
cellular transformation (Penn et al., 1990). 
Three other conserved motifs, Myc box IIIa (MBIIIa), Myc box IIIb (MBIIIb) and Myc box IV 
(MBIV), have been identified within the central region. MBIIIa is required for transcriptional 
repression, negatively regulates apoptosis and contributes towards cellular transformation in 
vitro and in vivo (Herbst et al., 2005). MBIIIb serves as a binding site for the WD40-repeat 
protein, WDR5, and this facilitates the interaction with target chromosomal regions (Thomas et 
al., 2015). The same group later demonstrated that MBIV is necessary for the association of 
c-Myc with the transcriptional co-regulator, host cell factor-1 (HCF-1) (Thomas et al., 2016). 
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The NTD is the main point of variation among the three isoforms. A 67 kDa polypeptide 
resulting from translation of c-myc mRNA at the CUG start site of exon 1, has an extended 
N-terminus. This isoform is designated as p67 (Blackwood et al., 1994, Hann et al., 1988). The 
third isoform, c-Myc S, is a smaller protein of 45 kDa that is translated from an AUG start codon 
downstream of the p64 translation initiation site (Spotts et al., 1997). Although c-Myc S lacks a 
functional TAD, it is capable of mediating many biological functions that the other isomers carry 
out (Xiao et al., 1998). In vivo studies later performed by Benassayag and coworkers (2005), 
showed that all three isoforms simultaneously exist within normal cells in ratios that depend on 
the cell status. In 2010, it was reported that a post-translational cleavage of the full length c-Myc 
polypeptide results in Myc-nick, which lacks a CTD. The absence of a nuclear localisation signal 
(NLS) restricts Myc-nick to the cytoplasm where it appears to influence cytoskeletal changes 
involved in cell differentiation (Conacci-Sorrell et al., 2010).   
 
2.4 c-Myc as a transcription factor 
It is estimated that c-Myc participates in the regulation of 10-15 % of all genes (Zeller et al., 
2006), and these encompass genes transcribed by any of the three RNA polymerases (Oskarsson 
and Trumpp, 2005). Chromatin immunoprecipitation coupled with pair-end ditag sequencing 
analysis in human B cells showed that over 4000 genomic loci could serve as c-Myc binding 
sites (Zeller et al., 2006). Consequently, many and varied target genes and gene networks of 
c-Myc have been identified and, in this way, its influence within the cell has become more fully 
understood.  
One of the earliest elucidated roles of c-Myc was its involvement in the cell cycle. Serial analysis 
of gene expression in primary human umbilical vein endothelial cells identified genes encoding 
the cell cycle regulators, cyclin-dependent kinase 4, cyclin E binding protein 1, and cyclin B as 
direct targets (Menssen and Hermeking, 2002). The same study showed that c-Myc may preserve 
the integrity of the genome during replication through its induction of DNA repair genes. c-Myc 
regulates energy generation and metabolism, and was found to directly activate genes involved in 
mitochondrial replication and biogenesis (Kim et al., 2008). c-Myc also co-ordinates various 
biosynthetic pathways. Its role in protein synthesis has been highlighted by studies which show 
that c-Myc directly activates the transcription of genes encoding ribosomal RNA (rRNA) 
(Grandori et al., 2005) and ribosomal proteins (Guo et al., 2000), and controls the maturation of 
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rRNA (Schlosser et al., 2003). In addition, c-Myc is implicated in the transcription of genes 
involved in the synthesis of lipids (Edmunds et al., 2014, Morrish et al., 2010) and nucleotides 
(Liu et al., 2008b). c-Myc influences cell adhesion and structure through its activity on the 
expression of genes which encode proteins of the extracellular matrix and cytoskeleton (Coller et 
al., 2000). More recently, Wang et al. (2013b) showed that c-Myc regulates microRNA 
(miRNA) expression through its interaction with the promoter of the gene that encodes Drosha, 
which is the enzyme responsible for processing primary-miRNA precursors. The above are 
intended as examples of key biological functions mediated by c-Myc and, by no means, cover 
the complexities of the c-Myc target gene network (Dang et al., 2006). In fact, in one study, 49 
direct targets were identified to be genes which encoded other transcription factors (Zeller et al., 
2006). As such c-Myc is believed to impact, either directly or indirectly, almost all cellular 
processes and is referred to as a ‘global regulator of transcription’ (Dang et al., 2006). 
Given that its role as a transcription factor has been widely publicised, a few accepted 
mechanisms of c-Myc-mediated transcription are briefly discussed. The interaction of c-Myc 
with Max is essential for its activity (Amati et al., 1993). X-ray structures revealed that c-Myc 
forms a heterodimer with Max via the LZ protein motif, and this positions the basic peptide 
helices of c-Myc for insertion into the major groove of the DNA target E-box (Nair and Burley, 
2003). Once the c-Myc/Max dimer has bound to the E-box, transcription of the target gene is 
either activated or repressed, depending on the interaction of c-Myc with other protein factors.  
An accepted mechanism of c-Myc-mediated transactivation (Figure 2.3) proposes that MBII 
recruits the transformation/transcription domain-associated protein (TRRAP) which in turn 
associates with histone acetyltransferases such as, general control of amino acid synthesis 
protein-5 (GCN5) and TIP60 (McMahon et al., 1998; McMahon et al., 2000). The acetylation of 
histones renders the DNA at the target location accessible for binding of the chromatin 
remodelling complex (Li et al., 2007) and encourages transcription by RNA polymerases (Arabi 




Figure 2.3: c-Myc mediated-transcriptional activation. c-Myc, when associated with Max, recruits 
histone acetyltransferases GCN5 or TIP60 via TRRAP; or the p300/CBP complex to activate transcription 
of target genes. The grey arrow indicates transcription initiation and progression. Redrawn and adapted 
from Cole and Cowling (2008) and Dang (2012). 
 
It was initially accepted that c-Myc exerted its role in transcription via the collaboration of 
protein complexes with its NTD. However, Vervoorts and coworkers (2003) demonstrated that 
the cAMP response element binding protein (CBP), which has histone acetyltransferase activity, 
binds to the CTD of c-Myc. CBP, in association with p300, serves as a positive cofactor for 
c-Myc function and is believed to interact with the RNA polymerase II (RNA pol II) complex 
(Cowling and Cole, 2007).  
Genes repressed by c-Myc are generally those that restrict cell growth and proliferation. These 
include genes which encode inhibitors of the cell cycle (Claassen and Hann, 2000), tumour-
suppressive miRNAs (Zhang et al., 2012) and cell-adhesion molecules (Gebhardt et al., 2006). 
The most common mechanism of transrepression involves the association of c-Myc with the 
Myc-interacting zinc finger protein-1 (Miz-1) transcription factor (Figure 2.4).  
Miz-1 binds to the initiator element (Inr) of promoter sequences, where it activates transcription 
of genes and is associated with strong growth inhibitory effects in the cell (Peukert et al., 1997, 
Si et al., 2010). The c-Myc CTD binds to Miz-1 (Gartel and Shchors, 2003) and this 
competitively inhibits the binding of p300 (Staller et al., 2001). Instead Dnmt3a is recruited, and 
this methylates the promoter sequences (Brenner et al., 2005). In this way, the regulatory region 
of the gene cannot access an important transcriptional co-factor and receives a modification that 




Figure 2.4: c-Myc-mediated transcriptional repression. c-Myc, when associated with Max, binds to 
Miz-1, a) preventing its association with p300, and b) recruits Dnmt3 that c) methylates the promoter 
region and, as such, prevents d) Miz-1 from promoting transcription of the target gene. Inr denotes an 
initiator element. Redrawn and adapted from Tansey (2014). 
 
Other mechanisms of c-Myc-mediated gene repression were put forward following studies on 
growth arrest genes (Gartel and Shchors, 2003). It was shown that c-Myc, in the absence of Max, 
inhibits the transcriptional activity of another zinc finger transcription factor namely, Sp1, by 
either binding to Sp1 or the Smad-Sp1 complex (Feng et al., 2002, Gartel et al., 2001).        
Although most c-Myc activity in normal cellular processes and cancer has been attributed to its 
role in transcription, it is worth mentioning that evidence exists for transcription-independent 
functions of c-Myc (Cole and Cowling, 2008). In this regard, Cowling and Cole (2007) reported 
that c-Myc can regulate translation by inducing mRNA cap methylation. In addition, c-Myc 
directly controls DNA replication by recruiting components of the pre-replicative complex 
during DNA replication (Dominguez-Sola et al., 2007).  
 
2.5 c-Myc in normal cells 
c-myc is among the first genes to be expressed when cells are exposed to mitogens and is 
therefore known as an ‘immediate early response gene’ (Henriksson and Lüscher, 1996, 
Lemaitre et al., 1996). c-Myc levels in normal cells vary in response to internal signals for cell 
proliferation and the external environment (Gardner et al., 2002). In quiescent cells, c-myc is 
expressed at low levels such that its protein product is hardly detectable. However, with 
mitogenic stimuli c-myc mRNA and protein levels increase rapidly. The c-myc expression 
continues through the cell cycle and drops to basal levels as cells return to their resting state 




Shichiri et al. (1993) showed that cell proliferation is sensitive to small changes in c-myc 
expression, and that regulated expression of c-myc is essential for maintaining normal cellular 
status. Therefore c-Myc levels and activity in the cell are, under normal conditions, stringently 
regulated. Control points include the transcriptional regulation of the c-myc gene itself (Eick and 
Bornkamm, 1986, Bentley and Groudine, 1986), the activity of translation initiation factor eIF4E 
which ensures that only faithful c-myc mRNA transcripts are exported to the cytoplasm 
(Culjkovic et al., 2006); the short half-life of c-myc mRNA (Dani et al., 1984), post-translational 
modifications such as phosphorylation, acetylation and ubiquitinylation (Vervoorts et al., 2006); 
and proteins which either directly interact with c-Myc (Dai et al., 2007) or influence its 
dimerization with Max (Grandori et al., 2000). 
 
2.6 Activation of c-myc in human cancer 
Genetic alterations of the c-myc gene and molecules or pathways responsible for its regulation 
can cause deviations from the rigorously controlled expression of c-myc, such that the protein 
product is expressed at abnormally high levels, is constitutively expressed at varying levels 
and/or no longer responds to external stimuli. This phenomenon is known as oncogenic 
activation (Pelengaris et al., 2002). The major mechanisms of c-myc activation are discussed 
below. 
The earliest genetic alteration of c-myc identified was translocation, which places the gene under 
the control of very active gene regulatory elements. A defining feature of Burkitt’s Lymphoma is 
the juxtaposition of c-myc to the constitutively expressed immunoglobulin (Ig) heavy or light 
chain genes of chromosomes 2, 14 or 22 in B cells (Dalla-Favera et al., 1982). In other B cell-
associated cancers, translocated c-myc may occur in the proximity of genes that do not encode 
immunoglobulins. These include the XBP1, KRAS, FAM46C and CCND1 genes that contribute 
towards maturation of B cells and disease development (Walker et al., 2014). Translocation can 
also place c-myc under the control of super-enhancer elements (Walker et al., 2014), which 
interact with c-myc via a common, conserved enhancer-docking site located upstream of the 
c-myc promoter (Schuijers et al., 2018). Moreover, instability of the c-myc oncogene has been 
associated with the H-DNA-forming tendency of sequences prevalent at common translocation 
breakpoints (del Mundo et al., 2017). 
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Rearrangements which occur as a result of recombination of genetic material within chromosome 
8, are also responsible for oncogenic activation of c-myc in cancers of the blood, albeit to a lesser 
extent (Ott et al., 2013). Point mutations in the region of MBI are common to lymphomas. In 
particular, mutation of the Thr58 phosphorylation site prevents ubiquitin/proteasome-directed 
degradation of c-Myc, extends its lifespan and, therefore, encourages tumourigenesis (Bahram et 
al., 2000). 
Elevated c-myc expression can occur as a result of gene amplification. This phenomenon is a 
hall-mark of many solid tumours. Several surveys have attempted to quantify c-myc copies in 
different malignancies and present an overview of its frequency. For example, Treszl and 
coworkers (2004) detected extra copies of the c-myc gene in 61 % of nodular melanoma samples 
tested. Naidu and colleagues (2002) observed c-myc amplification in 25 % of 440 primary breast 
carcinomas. Low to moderate c-myc amplification was detected in 32 % of tumours taken from 
149 colon cancer patients (Augenlicht et al., 1997). Abnormal copy numbers of the c-myc gene 
were also reported in cancers of the brain (Herms et al., 2000), head and neck (Baltaci et al., 
2016), liver (Chan et al., 2004), lung (Seo et al., 2014), stomach (Hara et al., 1998), prostate 
(Jenkins et al., 1997), bladder (Sardi et al., 1998) and ovaries (Baker et al., 1990). Although 
c-myc amplification has been observed in several primary carcinomas (Abba et al., 2004, Hara et 
al., 1998), this event is more frequent in late-stage or metastatic cancers (Bitzer et al., 2002, 
Bubendorf et al., 1999, Treszl et al., 2004, Wang et al., 2002). 
Defects in molecules and pathways responsible for c-myc regulation can up-regulate c-myc 
expression, in the absence of genetic alterations of the c-myc gene itself (Smith et al., 1993). A 
notable example is the APC/β-catenin pathway that negatively regulates c-myc expression under 
normal conditions (He et al., 1998). Inactivation of this pathway is most prominent in colorectal 
carcinoma in which 83 % of tumours harbour mutations in the adenomatous polyposis coli 
(APC) tumour suppressor gene (Rowan et al., 2000). Mutations of β-catenin, which is a 
transcriptional co-repressor, have been reported in cases of medulloblastoma (Zurawel et al., 
1998), endometrioid ovarian carcinoma (Palacios and Gamallo, 1998) and hepatoblastoma 
(Udatsu et al., 2001). The aberrant expression of several other c-myc regulators, which include 
haematological and neurological expressed 1 (HN1) (Zhang et al., 2017a); the RNA helicase 
DDX6 (Taniguchi et al., 2018); the RNA-binding protein, negative elongation factor E 
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(NELFE) (Dang et al., 2017); the bromodomain and extra-terminal (BET) domain protein, 
BRD4 (Ba et al., 2018); transcription factors such as OVOL1 and OVOL2 (Ito et al., 2017); 
and tumour-suppressor miRNAs such as miRNA 320a (Xie et al., 2017); represent other 
avenues by which c-myc overexpression occurs in various forms and sub-forms of human 
cancer. 
Overexpression of the mRNA-stabilising, coding region determinant-binding protein (CRD-BP) 
also accounts for constitutive expression of c-myc in several types of cancer (Doyle et al., 2000, 
Ioannidis et al., 2004, Ross et al., 2001). In vitro experiments have shown that the CRD-BP 
binds to the coding region stability determinant of c-myc mRNA and extends its half-life by 
protecting it against degradation by endonucleases (Bernstein et al., 1992). Stabilisation of c-myc 
mRNA in breast cancer has been linked with abnormally high levels of the signaling protein p62. 
When overexpressed, p62 inhibits the expression of let-7a and let-7b miRNAs that are ordinarily 
necessary for c-myc mRNA degradation (Xu et al., 2017). More recently Abdullah et al. (2018) 
reported that atypical expression of the tyrosine-protein kinase, Src, which acts on the RNA-
binding protein, IMP1, stabilised the c-myc transcript and, as such, stimulated cell cycle entry in 
oestrogen receptor-positive breast cancer cells. 
In addition to the effect of enhanced c-myc mRNA stability, oncogenic activation can occur with 
abnormal longevity of the c-Myc protein. Gu et al. (2017) reported a positive correlation 
between overexpression of the Ca2+/calmodulin-dependent protein kinase II γ (CAMKIIγ), which 
stabilises c-Myc by direct phosphorylation at MBI, and T cell lymphomagenesis. In prostate 
cancer, downregulation of the E3 ubiquitin ligase adaptor speckle-type POZ protein (SPOP) is 
a common aberration and this prevents c-Myc being marked for degradation (Geng et al., 
2017). c-Myc stability caused by elevated expression of the ubiquitin-specific protease 22 
(USP22) (Kim et al., 2017a); proteasome activator subunit 3 (PSME3) (Guo et al., 2017); zinc 
finger protein 746 (ZNF746) (Jung et al., 2018); and the calcium-dependent phospholipid-
binding protein, Annexin A2 (Ma et al., 2017); has been associated with the progression of 
breast, pancreatic, colon and oesophageal cancers, respectively. Abnormal c-Myc stability 
may also be conferred through the action of non-protein factors. Yang et al. (2017) reported 
that overexpression of a non-coding circular RNA, circ-Amotl1, which occurs both in patient 
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tumour samples and cancer cell lines, appeared to encourage c-Myc stability by increasing its 
retention in the nucleus. 
A further mechanism of c-myc activation in some cancers involves insertion of viral sequences 
near the c-myc locus. Ferber and colleagues (2003) showed that the integration of the human 
papilloma virus 18 (HPV 18) sequence in cervical tumours is a non-random event, and this 
typically occurs at common fragile sites in the genome that are susceptible to other genetic 
changes. The c-myc locus is one such site, at which 30 % of HPV 18 insertions were detected. In 
a study on invasive genital carcinoma cell lines, elevated c-myc mRNA and protein levels were 
observed only in instances in which insertion of viral DNA occurred in the vicinity of the c-myc 
gene (Peter et al., 2006). 
 
2.7 Oncogenic effects of c-Myc  
Given that c-myc is intrinsic to normal cell maintenance, abnormalities in its expression have far-
reaching consequences. Following activation of the c-myc gene, the most noticeable effect is on 
cell proliferation. The aberrantly expressed c-Myc protein (henceforth referred to as oncogenic 
c-Myc) forces cells to enter the cell cycle and hastens its passage through the G1, G2 and 
S-phases. Rapid cell division requires a simultaneous increase in the rate of DNA replication, 
and this often results in replication errors and DNA damage. It was proposed that c-myc 
overexpression caused the accumulation of abnormal DNA replication intermediates, a 
phenomenon known as replication stress (Robinson et al., 2009). Other studies have shown that 
c-myc overexpression causes damage to DNA by mechanisms that are either dependent (Vafa et 
al., 2002) or independent of the generation of reactive oxygen species (Ray et al., 2006). 
Ordinarily, hyper-proliferation and DNA damage activate protective mechanisms such as 
apoptotic pathways (Eischen et al., 1999, Zindy et al., 1998) and DNA damage response 
signaling (Adachi et al., 2001, Sankar et al., 2009). Therefore, it was initially believed that 
defects in these pathways, and the effects of other oncogenes, assisted in c-Myc-mediated 
tumourigenesis. However, it is possible for oncogenic c-Myc to negate the effects of these 
pathways by itself, given that, under normal conditions, it regulates pathways that restrain 
replication stress (Campaner and Amati, 2012) and can attenuate the activity of the tumour 
suppressor, p53 (Vafa et al., 2002). c-Myc leads cells towards immortalisation by preventing the 
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incremental shortening of telomeres that normally occurs each time a cell divides. In this regard, 
c-Myc directly controls the expression of human telomerase reverse transcriptase (hTERT), 
which is the rate limiting component of the telomerase complex (Khattar and Tergaonkar, 2017). 
In c-Myc driven cancers, oncogenic c-Myc brings about what authors describe as ‘metabolic 
reprogramming,’ a phenomenon in which normal cellular processes are enhanced to support the 
growth and energy demands of rapidly dividing cells and survival in the tumour 
microenvironment (Li and Simon, 2013). For example, cancer cells are known to consume 
glucose at higher rates than normal cells, and are often characterised by greater reliance on 
glycolysis as opposed to mitochondrial oxidative phosphorylation as a means of energy 
generation (Vander Heiden et al., 2009). Hu and colleagues (2011) showed, using a switchable 
model of c-myc-driven liver cancer, that the expression of several genes involved in glycolysis 
are upregulated in tumours, but these are repressed when c-myc expression is switched off. 
Moreover, cells transformed by c-myc were shown to undergo extensive apoptosis with glucose 
deprivation and, as such, are said to display glucose addiction (Shim et al., 1998). Cancer cells 
may also utilise glutamine as an alternative energy source. The induction of c-myc in a B-cell 
model of Burkitt’s lymphoma caused increase in mitochondrial glutaminase levels because 
c-Myc repressed the transcription of regulatory miRNAs (Gao et al., 2009). As with glucose, 
oncogenic c-Myc can establish a dependency on glutamine in cancer cells (Wise et al., 2008). 
While these represent isolated illustrations of oncogenic c-Myc-induced metabolic changes, a 
multiomics-based study by Satoh et al. (2017) highlighted its role in global metabolic 
reprogramming in cancer cells. This group showed that c-Myc expression in colorectal 
carcinoma induced at least 215 metabolic reactions by altering the expression of 121 metabolic 
genes and 39 transporter genes. 
Along with changes in nutrient consumption and energy generation, oncogenic c-Myc 
accelerates biosynthesis. This is evidenced by studies which show that forced expression of 
c-myc caused cells to double their size, protein (Iritani and Eisenman, 1999) and RNA content 
(Nie et al., 2012). In fact, increased ribosomal content appears to be an important step towards 
cancer in pre-neoplastic cells that overexpress c-myc (Barna et al., 2008). Furthermore, 
oncogenic c-Myc can create a dependency in cancer cells on accelerated synthesis of 
biomolecules, by inducing abnormal transcription of the relevant genes. Such dependencies have 
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been observed with respect to protein (Aleco et al., 2016, Pourdehnad et al., 2013) and lipid 
(Hall et al., 2016) synthesis. This heightened metabolism has been correlated with c-Myc-driven 
suppression of circadian rhythm in cancer cells (Altman et al., 2015, Dang, 2016). Oncogenic 
c-Myc, in association with Miz-1, was shown to bind to non-target E-box motifs of core clock 
genes and, as such, inhibit their expression (Shostak et al., 2016). 
Oncogenic c-Myc protects cancer cells and creates a suitable environment for them to thrive. 
Casey et al. (2016) provided evidence that c-Myc promotes survival of neoplastic cells by 
suppressing the regular anti-tumour immune response. c-Myc overexpression was shown to 
upregulate the expression of two immune checkpoint proteins on the cell surface i.e. the 
programmed death-ligand 1 (PD-L1) and the cluster of differentiation 47 (CD47), which prevent 
cancer cell recognition and elimination, respectively. The oncoprotein plays a key role in 
maintaining cells within a tumour mass by triggering what is referred to as an  ‘angiogenic 
switch’. This involves upregulating the expression of the vascular endothelial growth factor 
(VEGF), while reducing the expression of thrombospondin-1, to induce pre-existing blood 
vessels to develop into a complex vascular network within the tumour (Baudino et al., 2002, 
Dews et al., 2006). Other sources show that c-Myc is able to trigger angiogenesis and stromal 
remodelling by activating an inflammatory response (Shchors et al., 2006, Soucek et al., 2007). 
These findings are supported by recent work which directly implicates c-Myc-mediated 
upregulation of inflammatory pathways in tumour growth (Merve et al., 2017) and metastasis 
(Sun et al., 2018). 
Metastasis is a well-documented consequence of c-myc overexpression. c-Myc induces 
epithelial-to-mesenchymal transition (EMT), which is a process by which cells acquire 
invasiveness and motility, through co-operation with other proteins such as the transforming 
growth factor-β (TGFβ) (Smith et al., 2009) and sterol regulatory element-binding protein 1 
(SREBP1) (Zhai et al., 2018). c-Myc-driven EMT in myelomas was shown to induce 
vasculogenic mimicry, a process by which new blood vessels are formed de novo (Lin et al., 
2017). c-Myc also promotes tumour cell invasiveness by EMT-independent processes that rely 
on cell adhesion and/or cytoskeletal reorganisation. For example, c-Myc activates the 
transcription of the galactoside-binding protein, galectin-1, that encourages the spread of 
oesophageal cancer to the lymph nodes (Yan et al., 2009), and co-operates with the S-phase 
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kinase-associated protein 2 (Skp2) to promote transcription of the RhoA GTPase that encourages 
cancer cell motility in metastatic breast cancer (Chan et al., 2010). 
The general consensus is that these effects can collectively account for the initiation, progression 
and maintenance of cancer. However, all possible oncogenic effects of c-Myc may not 
necessarily manifest in all c-myc-driven cancers. This notion is supported by research which 
suggest that c-Myc activity can be cell-specific (Kyo et al., 2000). Hence, it appears that c-Myc 
may transform different cell types in different ways (Dang, 2013). 
Two different models of c-Myc-driven tumourigenesis have emerged over the past five years. 
According to the general amplifier model, oncogenic c-Myc amplifies the expression of all genes 
that are being expressed in a cell. In this way, all cellular processes are accelerated resulting in 
extreme disorder within the cell (Lin et al., 2012, Nie et al., 2012). The idea that oncogenic 
c-Myc promiscuously activates transcription is supported by earlier research by Fernandez et al. 
(2003). This group demonstrated that overexpression of c-Myc increased the affinity with which 
it bound to E-box elements of genes that represent, under normal conditions, low affinity targets. 
More recently, Sabò et al. (2014) reported that while c-Myc does have the ability to interact with 
all active promoters, it does not necessarily do so, and changes cell status by either activating or 
repressing the transcription of discrete sets of genes. The notion that oncogenic c-Myc acts in a 
gene-specific manner was further supported by Lorenzin and colleagues (Lorenzin et al., 2016, 
Walz et al., 2014) and provides the basis for an alternative model of c-Myc driven 
tumourigenesis. 
 
2.8 c-myc as a target in cancer therapy 
Several properties of c-myc, as an oncogene, render it a suitable target for cancer treatment. 
Firstly, the ideal treatment for any disease should target the cause, rather than the symptoms. Its 
protein product is strongly implicated in the initiation and maintenance of the majority of human 
cancers and, in its capacity as a transcription factor, functions downstream of other oncogenes 
(Hermeking, 2003). Hence, preventing its oncogenic activity is, in theory, addressing the root of 
the problem. Secondly, an oncogene is potentially more suitable a target in cancer therapy than a 
tumour suppressor gene because it is easier to inhibit accelerated functions in cancer cells than to 
restore functions that they have lost (Hermeking, 2003). Thirdly, the fact that cancer cells often 
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display a dependency on the continuous expression of c-myc for their maintenance may be 
exploited in the development of anti-cancer strategies. In this regard, experiments performed 
with conditional transgenic mouse models showed that c-myc inactivation brought about tumour 
regression and can, in some instances, reverse cancer (Arvanitis and Felsher, 2006). Importantly, 
Soucek et al. (2008) responded to concerns surrounding the impact of systemic c-myc inhibition 
in normal cells with a study which showed that side effects on normal regenerating cells were 
transient and well tolerated over time. Finally, given that c-myc is one of the most frequently 
altered genes in human cancer, a strategy directed against c-myc may potentiate the treatment of 
a broad range of cancers (Vita and Henriksson, 2006).  
 
2.9 Nucleic acids targeting oncogenic c-myc 
Direct inhibition of oncogenic c-Myc was initially considered to be difficult to accomplish. 
Firstly, its primary cellular activity i.e. transcription in the nucleus, is not easily accessible to 
therapeutic agents. Secondly, the protein lacks enzyme activity and suitable ligand-binding 
domains that could be targeted by traditional small molecule drugs (McKeown and Bradner, 
2014). Although advances in understanding the intricacies of c-Myc regulation and interaction 
with protein factors have presented new areas of attack for novel small molecule inhibitors 
(Berthon et al., 2016, Chen et al., 2014, Neidle, 2016), the option of directly inhibiting 
expression of the activated c-myc gene with synthetic nucleic acids continues to receive 
attention. In fact, the very idea of nucleic acids as therapeutic agents emerged largely in response 
to conditions such as cancer that were difficult to treat with conventional treatment (Juliano, 
2016). 
Nucleic acids designed for the purpose of gene inhibition are typically small DNA or RNA 
molecules. Their use is primarily based on the concept that homology between the nucleic acid 
molecule and a region of either c-myc DNA or mRNA causes binding, and blocks the processes 
of transcription or translation, respectively. The discussion to follow has attempted to review the 
various categories of synthetic nucleic acids that can effect c-myc inhibition, and trace their 




2.9.1. Antisense oligonucleotides 
Antisense oligonucleotides (ASOs) represent a major class of nucleic acids that has been applied 
to the inhibition of c-myc. These short, single-stranded nucleotides are designed with 
complementarity to a region of the mRNA. The ASO binds to the mRNA and either acts as a 
substrate for RNase H, which catalyses the cleavage of mRNA; or physically blocks translation. 
ASOs may be either DNA or RNA in nature. However, ASOs employed for the purpose of c-myc 
inhibition are predominantly DNA oligomers. Moreover, the use of unmodified, phosphodiester 
nucleotides is discouraged primarily due to poor biological stability. Hence, in most studies 
modified ASOs were synthesised (Figure 2.5) with the aim of improving stability whilst 
maintaining specificity for the target sequence (Dias and Stein, 2002). 
 
Figure 2.5: Representation of a) conventional phosphodiester nucleotides and chemically modified 
nucleotides b) phosphorothioate-linked nucleotides, c) phosphorodiamidate morpholino nucleotides 
and d) peptide nucleic acids. B represents a nitrogenous base. Redrawn and adapted from Dias and Stein 
(2002). 
 
2.9.1.1 Phosphorothioate antisense oligonucleotides 
One of the earliest modifications explored, involved attaching individual nucleosides via a 
phosphorothioate (PS) linkage (Figure 2.5b). This gave an oligomer with approximately ten 
times greater nuclease resistance than conventional phosphodiester nucleotides (Campbell et al., 
1990). Wickstrom et al. (1988) synthesised a 15-nucleotide phosphorothioate antisense 
oligonucleotide (PS-ASO) directed against a hairpin-loop which contained the initiation codon of 
c-myc mRNA. When introduced into human leukemia cells in culture, the PS-ASO reduced 
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c-Myc levels and inhibited growth in a sequence-specific, dose-dependent manner. This early 
work suggested the possibility of using c-myc-specific PS-ASOs as anti-cancer agents. 
Anti-c-myc PS-ASOs have since been associated with delivery agents (Junghans et al., 2005, 
Leonetti et al., 2001, Pastorino et al., 2001, Pastorino et al., 2003, Zhang et al., 2018) and 
applied in conjunction with anti-cancer drugs (Citro et al., 1998, Leonetti et al., 1999, Pastorino 
et al., 2008, Yuan et al., 2014) and physical agents, such as ultrasound (Jing et al., 2015) to 
improve efficacy. Notable success was achieved with INX-3280, a 15-nucleotide PS-ASO 
against c-myc (Webb et al., 2001), developed by Inex Pharmaceuticals Corporation, which 
entered clinical trials for treatment of lymphoma and solid tumours. It did not, however, progress 
beyond the Phase II trial. A modified form, INXC-6295, was later subjected to preclinical studies 
in solid tumours, but was also not developed further (Whitfield et al., 2017). 
The use of oligonucleotides as inhibitors of gene expression has expanded with the design of 
second generation nucleotide analogues. In particular, the phosphorodiamidate morpholino 
oligomer (PMO), and peptide nucleic acid (PNA) have been incorporated in the design of 
anti-c-myc sequences.  
 
2.9.1.2 Phosphorodiamidate morpholino oligomers 
The PMO contains a six-membered morpholine ring instead of the deoxyribose moiety and 
individual nucleosides are attached by phosphorodiamidate linkage (Figure 2.5c). Unlike the PS 
backbone, that has affinity for serum and cellular proteins (Levin, 1999), the 
phosphorodiamidate group is neutral at physiological pH. This reduces the possibility of 
non-specific effects that limit the use of PS-ASOs (Amantana and Iversen, 2005). PMOs are 
nuclease, protease and esterase resistant and have demonstrated reasonable stability in biological 
fluids (Hudziak et al., 1996). PMO-mediated gene silencing is not dependent upon the action of 
RNase H. Instead PMOs inhibit gene expression by causing mis-splicing of pre-mRNA or 
inhibition of ribosomal assembly (Amantana and Iversen, 2005). The first report of an anti-c-myc 
PMO was made by Hudziak and coworkers (2000). This group showed that a 20-nucleotide 
PMO reduced c-Myc levels and induced cell cycle arrest in cancer cells in vitro. In animal 
models, this PMO, designated as AVI-4126, sensitised tumour cells to the activity of anti-cancer 
drugs (Knapp et al., 2003), reduced tumour size (Iversen et al., 2003), and inhibited metastasis 
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(Sekhon et al., 2008). AVI-4126 was favourably evaluated in clinical safety studies (Iversen et 
al., 2003) and progressed to phase II clinical trials (Stephens, 2004). However, it is unknown as 
to why AVI-4126 was not further developed (Moreno and Pêgo, 2014). 
 
2.9.1.3 Peptide nucleic acids 
The PNA is another class of steric inhibitors of gene expression. Here, the sugar-phosphate 
backbone is replaced by repeating units of N-(2-aminomethyl)glycine, and the nitrogenous bases 
are attached to the polyamide skeleton through methylene carbonyl groups (Figure 2.5d). PNAs 
are known to form highly stable duplexes or triplexes with RNA and DNA respectively, because 
they are uncharged and do not electrostatically repel the anionic phosphates in naturally-
occurring nucleic acids. Consequently, sequence-specific PNAs may inhibit gene expression at 
the levels of transcription and translation (Shakeel et al., 2006). 
PNAs directed against c-myc have been investigated mainly with a focus on the treatment of 
Burkitt’s lymphoma. In an attempt to overcome any adverse effects resulting from c-myc 
inhibition in normal cells, Cutrona and coworkers (2003) synthesised a PNA complementary to 
the Eµ intronic enhancer at the Ig locus which drives aberrant c-myc expression in Burkitt’s 
lymphoma. The PNA inhibited the expression of c-myc in vitro by preventing binding of specific 
nuclear factors to the Eµ DNA sequence; and inhibited tumour growth in mice with Burkitt’s 
lymphoma xenografts (Boffa et al., 2006). The same animal model was used to evaluate a PNA 
specific for the Emu Ig enhancer (Boffa et al., 2005). In these studies PNAs were designed to 
interact with target DNA duplexes at the c-myc locus, rather than with target regions of c-myc 
mRNA. Hence, this represents an antigene approach as opposed to the antisense strategies that 
have been discussed up until this point. 
PNAs directed against c-myc have also been linked to hormones and nuclear localisation 
peptides in order to enhance their cell-specificity (Boffa et al., 2000) and nuclear translocation 
capabilities (Cutrona et al., 2000) respectively. More recently, anti-c-myc PNAs were loaded into 




2.9.2 Clamp-forming oligonucleotides 
The clamp-forming oligonucleotide (CFO) is a useful tool in antisense technology. It consists of 
two covalently linked ASOs in which one oligomer is designed to hybridise with a target mRNA 
sequence through conventional Watson-Crick base-pairing, while the other forms Hoogsteen 
base pairs. In this way the CFO surrounds the target sequence as a ‘molecular clamp’ 
(Figure 2.6), and this either prevents complete assembly of the translation machinery or 
physically obstructs elongation of the polypeptide chain (Stewart et al., 2001).  
 
Figure 2.6: Clamp-forming oligonucleotide bound to a complementary sequence on its target mRNA. 
Redrawn and adapted from Hélène et al. (1997). 
 
Stewart and colleagues (2001) designed PS-modified CFOs with complementarity to exons 2 and 
3 of murine c-myc mRNA. These were modified with psoralen, to permit irreversible binding to 
the intended mRNA regions through the formation of crosslinks upon activation with ultraviolet 
light. Gel mobility shift assays and thermal denaturation studies highlighted the sequence-
specific association of the ultraviolet-activated CFOs and c-myc mRNA. Treatment of B16-F0 
murine melanoma cells with activated CFOs reduced c-myc expression and inhibited growth far 
more effectively than standard ASOs. For in vivo application, CFOs were modified with the 
DNA-intercalating agent, acridine, to facilitate strong binding with mRNA at the target regions. 
CFOs targeting different c-myc regions showed variable anti-tumor activity, with the most 
effective CFO inhibiting tumor growth by 77 % alone, and 82 % in combination with the 
anti-cancer drug, cisplatin (Stewart et al., 2002). 
CFOs may also be employed as antigene agents. A recent in vitro experiment with human cells 
showed that CFOs designed with homology to the NHE III1 inhibited c-myc expression by 
stabilising the quadruplex structure of DNA at the target site and, as such, limited the activity of 
the c-myc promoter (Hao et al., 2016).  
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2.9.3 Triplex-forming oligonucleotides  
The triplex-forming oligonucleotide (TFO) is a single-stranded oligonucleotide which binds, via 
Hoogsteen-type hydrogen bonds, to purine-rich sequences in the major groove of double 
stranded DNA (Jain et al., 2008). The use of TFOs as antigene agents exploits the fact that 
regulatory regions of most human genes, including c-myc, contain polypurine/polypyrimidine 
tracts and, that the formation of triple helices at these sites prevents the binding of protein factors 
required for transcription (McGuffie et al., 2000). 
TFOs were designed to bind to several important control elements of the c-myc gene, however 
TFOs against the P2 promoter have proven most effective (Catapano et al., 2000). The 
performance of c-myc-specific TFOs has been enhanced through PS modification (Kim et al., 
1998, McGuffie et al., 2000), complexation with diaminopropane to stabilise DNA triplexes 
(Thomas et al., 1995) and conjugation with the DNA-intercalating agents, acridine (Helm et al., 
1993) and daunomycin (Carbone et al., 2004). The acridine-TFO conjugate was evaluated in 
human ovarian and cervical carcinoma cell lines, and exerted growth inhibitory effects at a lower 
concentration than the free TFO (Helm et al., 1993). Triple helices formed with the daunomycin-
conjugated TFO showed greater stability than its unmodified counterpart. Association with a 
cationic lipid improved its intracellular accumulation and reduced transcription of c-myc by 
approximately 70 % (Carbone et al., 2004). In a related study, daunomycin-conjugated anti-
c-myc TFOs inhibited growth, induced apoptosis and reduced clonogenic ability in prostate 
cancer cell lines without affecting the growth of normal cells (Napoli et al., 2006). Later, the 
conjugation of an anti-c-myc TFO to an ultrasmall gold nanoparticle, which facilitates 
intranuclear delivery, was shown to improve its efficacy in a breast cancer cell line (Huo et al., 
2014). 
In general, the TFO binds the purine-rich target strand either in parallel or anti-parallel 
orientation, depending on its nucleotide sequence (Figure 2.7). McGuffie and Catapano (2002) 
designed a GTC TFO that was able to simultaneously bind the P2 promoter in both orientations. 
This TFO formed a triplex at the target site with higher affinity than a conventional P2-targeted 
TFO, and proved effective at concentrations far lower than was reported for other TFOs 




Figure 2.7: Interaction of a triplex-forming oligonucleotide (TFO) with the target region within the major 
groove of the DNA helix. The TFO may bind either in a parallel or anti-parallel orientation to the purine-
rich strand. Redrawn and adapted from Buske et al. (2011). 
 
In addition to their well-documented role as steric inhibitors of transcription, TFOs may direct 
site-specific damage to DNA, inducing replication-independent DNA repair synthesis. This 
property was exploited in order to augment the activity of an anti-cancer nucleoside analogue, 
gemcitabine, by increasing its incorporation within DNA at the P2 promoter. Treatment of 
metastatic breast cancer cells with a combination of a P2-targeted TFO and gemcitabine, reduced 
cell survival and anchorage-independent growth more effectively than either agent alone 
(Christensen et al., 2006). This strategy was later shown to inhibit tumour growth in a mouse 
model of human colon cancer (Boulware et al., 2014).  
 
2.9.4 Decoy oligonucleotides 
Decoy oligonucleotides are designed to bear resemblance to transcription factor recognition 
sequences in order to competitively prevent the transcription factor from binding to regulatory 
regions of its target genes (Mann and Dzau, 2000). A double-stranded DNA decoy based on the 
E-box consensus sequence (Figure 2.8) was evaluated in breast carcinoma and neuroblastoma 
cell lines. The DNA decoy reduced cell proliferation in a dose-dependent manner, when 




Figure 2.8: Inhibition of gene expression with aid of a decoy oligonucleotide. a) The decoy oligomer with 
transcription factor-binding motif sequesters the transcription factor, b) preventing it from binding 
regulatory regions of the DNA and, as such, c) prevents transcription of the target gene. Redrawn and 
adapted from Fichou and Férec (2006). 
 
Besides competing with regular binding sites of the c-Myc protein, decoy oligonucleotides may 
be designed to sequester protein factors involved in aberrant transcription of the c-myc gene. 
Such an approach was reported by Seki et al. (2006) who designed an 18-mer DNA decoy which 
harbours a consensus sequence at which the T-cell factor (TCF) binds to the c-myc promoter. 
When introduced into human cell lines via lipid-based delivery the DNA decoy efficiently 
entered the nucleus, and remained within cells for 72-96 hours. Decoy-mediated inhibition of 
TCF activity reduced the expression of TCF downstream target genes including c-myc and, 
importantly, growth inhibitory effects were limited to cancer cells. 
Simonsson and Henriksson (2002) suggested that a 22-mer guanine-rich DNA oligonucleotide, 
directed to the NHE III1 reduced c-myc expression partly through its decoy-like behavior. The 
synthetic oligonucleotide, like the sense strand at this site, is able to fold into a quadruplex. 
When delivered into c-myc-overexpressing cells, equilibrium is established between its single-
stranded and quadruplex forms. In single-stranded form, the oligonucleotide functions as a TFO 
i.e. it hybridises with the cytosine-rich strand of the NHE III1 and blocks assembly of the RNA 
pol II complex. However, when folded as a quadruplex, it prevents promoter activity by serving 
as an alternative transcription factor-docking site. 
More recently, Johari et al. (2017) demonstrated the potential for c-Myc decoy oligonucleotides 
to be used in differentiation therapy, a form of cancer treatment that relies on restoring cancer 
cells to the normal cell phenotype instead of inducing cancer cell death.  
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2.9.5 Ribozymes and deoxyribozymes 
Catalytic DNA and RNA molecules have also been investigated as gene silencing agents. The 
hammerhead ribozyme, approximately 30 nucleotides in length, is the smallest naturally 
occurring self-splicing RNA molecule. The finding that a synthetic hammerhead RNA motif can 
be engineered to recognise and cleave an RNA sequence other than its own, led to its use in gene 
silencing experiments (Citti and Rainaldi, 2005). Cheng et al. (2000) synthesised a gene 
encoding a hammerhead ribozyme targeting c-myc mRNA, and this was inserted into a plasmid 
vector. Introduction of the vector by commercial lipid-based transfection into human liver cancer 
cells reduced c-myc expression and this was accompanied by growth inhibition. 
Unlike ribozymes, catalytic DNA molecules i.e. deoxyribozymes, do not exist in nature and are 
identified through in vitro selection processes (Silverman, 2005). Deoxyribozymes are 
considered more favourable gene silencing agents than their RNA counterparts due to the greater 
biological stability inherent to DNA molecules (Tack et al., 2008). Sun et al. (1999) reported that 
an anti-c-myc 32-mer single-stranded DNA oligomer successfully cleaved c-myc mRNA, 
reduced c-Myc protein levels and inhibited proliferation of smooth muscle cells. 
Thus far, attempts at enhancing the overall efficiency of anti-c-myc catalytic nucleic acids have 
focused on improving intracellular delivery through association with carrier agents (Hudson et 
al., 1996, Tack et al., 2008). Furthermore, studies with anti-c-myc ribozymes and 
deoxyribozymes have been confined to in vitro experiments. 
 
2.9.6 Small interfering RNA (siRNA) 
Small interfering RNA (siRNA) is a short double-stranded RNA (dsRNA) molecule with 
dinucleotide overhangs at the 3ˈ end (Figure 2.9). It is one of several classes of small RNA 
molecules that mediate the naturally occurring gene silencing mechanism known as RNA 
interference (RNAi). siRNA associates with a network of cytoplasmic proteins to form the RNA-
induced silencing complex (RISC), in which it guides the degradation of mRNA bearing a 




Figure 2.9: A representation of a siRNA molecule showing the core duplex and characteristic overhangs 
of two nucleotides at the 3′ end. Redrawn and adapted from DeVincenzo (2012).  
 
In theory, effective silencing of any oncogene may be achieved using endogenous cellular 
machinery, provided that the appropriately designed siRNA molecule is successfully introduced 
(Aagaard and Rossi, 2007). This, together with evidence that siRNA is manifold more potent a 
gene silencing agent than antisense oligomers (Bertrand et al., 2002), has encouraged extensive 
research into developing siRNA as a viable treatment for cancer over the past decade 
(Zuckerman and Davis, 2015). In fact, the development of siRNA-based strategies for the 
purposes of c-myc inhibition has been described as a current ‘active field of research’ (Whitfield 
et al., 2017). Therefore much attention has been given to RNAi and potential anti-c-myc siRNA 
approaches in this review.  
 
2.9.6.1 RNA interference (RNAi) 
The discovery of RNAi stems from reports, in the early 1990s, of endogenous gene silencing in 
plants and fungi with the introduction of transgenes and homologous RNA sequences 
respectively (Napoli et al., 1990, Romano and Macino, 1992). However, it was the Nobel Prize-
winning work of Fire and Mellow which showed that gene silencing was initiated by dsRNA. 
Their work demonstrated that silencing of the unc22 gene in Caenorhabditis elegans was many-
fold more effective with the introduction of dsRNA than with either the sense or antisense strand 
alone; gene silencing relied homology between mRNA and the introduced dsRNA; the RNAi 
effect was hereditary and that the dsRNA worked non-stoichiometrically i.e. only a few 
molecules of dsRNA were necessary per cell to silence the gene (Fire et al., 1998). Further 
insight into the mechanism of RNAi came with the identification of the cleavage product of long 
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dsRNA namely, the siRNA molecule, as a key intermediate in the gene silencing process 
(Elbashir et al., 2001). 
Long dsRNA can occur within cells as a result of viral invasion and replication, or due to 
hybridisation of repetitive sequences as in the case of transposons. In the initiation phase of the 
RNAi pathway, the dsRNA is recognised and cleaved by the RNase III endonuclease DICER in 
the cytoplasm to yield siRNA molecules (Bernstein et al., 2001). 
The effector phase, outlined in Figure 2.10, begins when DICER collaborates with other proteins 
such as transactivating response (TAR) RNA-binding protein (TRBP), to associate the siRNA 
with the Argonaute 2 (Ago2) protein (Chendrimada et al., 2005). These proteins are the main 
constituents of RISC in humans (MacRae et al., 2008). Although the composition of RISC often 
varies between species, the presence of Argonaute (Ago) proteins is a common feature (Ambrus 
and Frolov, 2009). 
Only one of the strands of the siRNA duplex remains associated with RISC, and serves as a 
guide strand that eventually specifies the mRNA target. This is the strand that is less 
thermodynamically stable at its 5ʹ end (Khvorova et al., 2003). Noland and coworkers (2011) 
proposed that, in humans, the DICER/TRBP dimer repositions the siRNA molecule along the 
helicase domain of DICER. This region senses thermodynamic stability of both strands of the 
siRNA duplex, and this possibly orientates the 3ʹ end of the guide strand towards the 
Piwi/Argonaute/Zwille (PAZ) domain of Ago2, which binds siRNA through specific recognition 
of the dinucleotide 3ʹ overhangs (Lingel et al., 2004, Yan et al., 2003). The siRNA duplex is 
unwound, and the second strand of the siRNA molecule, known as the passenger strand, is 
eliminated by the endonuclease activity of Ago2 during RISC activation (Rand et al., 2005). The 
guide strand directs the active RISC to the target region of mRNA through complementary base 
pairing interactions. Ago2 catalyses the hydrolysis of phosphodiester bonds of the guide strand-
associated region of mRNA between nucleotides 10 and 11, relative to the 5ʹ end of the guide 
strand (Elbashir et al., 2001). The mRNA fragments are released from the protein complex and 
are broken down further by cytosolic nucleases, while the active RISC may act upon additional 




Figure 2.10: Schematic representation of the effector phase of RNAi mediated by siRNA molecules. 
Redrawn and adapted from Stevenson (2003). 
 
In order for siRNA to be effective in silencing disease-causing genes, intact siRNA must 
successfully enter the cytoplasm of affected cells. In many instances, the most suitable mode of 
administering an siRNA treatment would involve injection into the bloodstream (Xu and Wang, 
2015). However siRNA is highly susceptible to nuclease digestion (Cao and Ji, 2009). It has 
been reported that unmodified siRNA in serum has a half-life of 6 minutes (Soutschek et al., 
2004). Intravenously introduced siRNA molecules can accumulate in and be eliminated by the 
kidneys (Van de Water et al., 2006). A further obstacle is that the siRNA molecule will not 
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simply diffuse across the cell membrane due to inherent physical features such as its size 
(approximately 14 kDa), hydrophilicity and negative charge (Xu and Wang, 2015). 
Modifications of the siRNA molecule which include the introduction of PS linkages, O-methyl 
or fluoro groups were shown to extend longevity in serum (Braasch et al., 2003, Czauderna et 
al., 2003). Conjugation of small biomolecules such as cholesterol, cell-penetrating peptides and 
RNA aptamers to siRNA, improved pharmacokinetic behavior, intracellular delivery and 
tumour cell-specificity, respectively (Crombez et al., 2009, Soutschek et al., 2004, Zhou et al., 
2008). However chemical alterations to the siRNA molecule can be time-consuming, costly and 
possibly compromise RNAi activity (Shim et al., 1998). For this reason much effort has been 
focused on the design of delivery agents for unmodified siRNA molecules which will mask its 
negative charge, protect its integrity, prevent its early removal from the body and facilitate 
cellular entry. In this regard nanodelivery systems have received much attention, many of which 
are based on the principle that siRNA can electrostatically associate with positively charged 
agents (Wang et al., 2010). While cationic polymers, co-polymers, dendrimers (Navarro et al., 
2013) and peptides (Crombez et al., 2009) have been assessed, anti-c-myc siRNA delivery, like 
siRNA delivery in general, is predominantly lipid-based (Hope, 2014, Leung et al., 2014, Singh 
et al., 2015). 
 
2.9.6.2 Anti-c-myc siRNA delivery 
Arguably, the most famous lipid-based delivery agent is the liposome, the simplest of which is a 
self-assembled phospholipid bilayer that encircles an aqueous core in which a variety of 
molecules may be entrapped (Batzri and Korn, 1973). It is this carrying capability that was 
exploited for the delivery of several therapeutically important molecules including siRNA. A 
neutral liposome (Figure 2.11a) composed of dioleoylphosphatidylcholine (DOPC), Chol and 
distearoylphosphatidylethanolamine-poly(ethylene glycol) (DSPE-PEG) was used to encapsulate 
and deliver anti-c-myc siRNA in vivo (Reyes-González et al., 2015). Pegylation, the introduction 
of the PEG polymer, served to create a hydration shell around the liposome that sterically 
inhibits adverse interparticle associations which reduce nanoparticle longevity in the body (Suk 
et al., 2016). Systemic administration of the DOPC/Chol/DSPE-PEG/siRNA complex reduced 
the growth of ovarian cancer xenograft tumours, and did not inhibit the growth of cells with low 
c-myc expression (Reyes-González et al., 2015). Anti-c-myc siRNA delivered via pegylated 
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DOPC liposomes has also shown promise in the treatment of cisplatin-resistant tumours in vivo 
(Vivas-Mejia et al., 2018). 
Figure 2.11: Lipid-based delivery agents for anti-c-myc siRNA a) pegylated, neutral liposome, b) cationic 
liposome, c) liposome-polycation-DNA (LPD) nanoparticle and d) lipid calcium phosphate (LCP) 
nanoparticle. Images were created using DesignSpark Mechanical 2.0 software. 
 
Felgner et al. (1987) first reported that the hydration of a mixture containing a synthetic cationic 
lipid and zwitterionic phospholipid gave vesicles that bear a net positive charge, and paved the 
way for the use of cationic liposomes in nucleic acid delivery. Unlike neutral liposomes in which 
siRNA must be encapsulated, cationic liposomes electrostatically associate with siRNA to form 
nanostructures, known as lipoplexes (Khatri et al., 2014) (Figure 2.11b). Zhang et al. (2009) 
used the commercially available cationic liposomal reagent, Lipofectamine™ 2000, in association 
with anti-c-myc siRNA, to demonstrate the therapeutic value of siRNA-mediated c-myc 
inhibition in human colon cancer. 
Besides being limited to use in cationic liposome formulations, cationic lipids have contributed 
to the development of more elaborate lipid nanoparticles. For example, Chen et al. (2010) used a 
traditional cationic liposome made up of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) 
and Chol to envelope a core of protamine-bound anti-c-myc siRNA and calf thymus DNA. This 
tumour cell-targeting moiety 
protamine 
calf thymus DNA 












is known as a liposome-polycation-DNA (LPD) nanoparticle (Figure 2.11c). Surface 
modifications included post-inserted PEG chains for steric stabilisation, and a peptide directed to 
aminopeptidase N, that is overexpressed by cancer cells. Effective siRNA delivery, c-myc 
inhibition and tumour cell apoptosis was noted after these nanoparticles were intravenously 
administered in a xenograft model. Co-formulation of doxorubicin with siRNA in targeted LPD 
nanoparticles further improved treatment efficacy (Chen et al., 2010). Following the concept of 
stabilised core/shell lipid nano-assemblies, Zhang et al. (2013) used a DOTAP/Chol/PEG 
formulation as the outer coating of a calcium phosphate core containing anti-c-myc siRNA. The 
resulting lipid calcium phosphate (LCP) nanoparticle was directed to sigma receptor-positive 
tumour cells by attachment of anisamide to the distal ends of PEG chains (Figure 2.11d). Similar 
to the findings of Chen et al. (2010), co-encapsulation of anti-c-myc siRNA and a 
chemotherapeutic agent, in this case, gemcitabine, gave a more pronounced anti-cancer effect. 
Physical agents may prove useful in promoting deposition of systemically introduced liposomal 
anti-c-myc siRNA nanoparticles in tumours. Yang et al. (2015) modified a tumour-targeted 
formulation of 3β[N-(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol), Chol and 
DSPE-PEG with a photolabile-caged cell-penetrating peptide to deliver anti-c-myc siRNA. The 
application of near-infrared light at the tumour site activated the cell-penetrating ability of the 
peptide to allow entry into cancer cells. Liposomes were also used as ultrasound cavitation 
agents for site-specific release of anti-c-myc siRNA conjugated to a cell-penetrating peptide (Xie 
et al., 2016). In both instances, treatment delayed tumour progression in fibrosarcoma xenograft 
models. 
Anti-c-myc siRNA has been included in multi-targeted anti-cancer strategies, which involve the 
combined delivery of siRNAs against several genes implicated in cancer. Song et al. (2005) 
showed that a mixture of siRNAs against c-myc, MDM2 and VEGF selectively inhibited tumour 
growth more effectively than the individual siRNAs. Li et al. (2008) co-encapsulated siRNA 
molecules against the same targets in a pegylated LPD nanocarrier for systemic administration in 
a murine model of metastatic lung cancer. This treatment simultaneously silenced all three genes 
in cancerous tissue, reduced metastasis by approximately 80 %, and extended survival time, with 
minimal toxicity. Similar results were obtained when siRNAs against the aforementioned 
oncogenes were pooled in pegylated LCP nanoparticles (Yang et al., 2011). Later, a mechanistic 
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study showed that this system impaired the growth of tumours in mice by simultaneously 
inhibiting cell proliferation and angiogenesis (Yang et al., 2012). 
Besides delivery via synthetic lipid vesicles, siRNA can also be loaded in exosomes. Exosomes 
are vesicles that are naturally released by cells for the purposes of intercellular communication, 
and have come to represent an emerging nanocarrier system for a variety of medically relevant 
molecules (Ha et al., 2016). The potential for exosome-mediated anti-c-myc siRNA delivery was 
demonstrated by Lunavat et al. (2016). This group generated exosome-mimetic nanovesicles that 
successfully entered cells in culture and inhibited c-myc expression. 
Other organic anti-c-myc nanodelivery systems reported are often complex polymer- and 
peptide-based nanocomposites. For example, Raichur et al. (2015) used a layer-by-layer 
approach to associate anti-c-myc siRNA with poly(lactic-co-glycolic acid) hollow nanoparticles. 
In vitro experiments showed that the nanoparticles were taken up by aggressive cancer cells and 
reduced c-myc expression with loss of cell viability. More recently, anti-c-myc siRNA has been 
incorporated in a multifunctional peptide assembly (Bjorge et al., 2017) and linked with 
packaging RNA prior to encapsulation in folate-conjugated, pegylated chitosan nanoparticles (Li 
et al., 2017). 
It is also worth mentioning that the use of inorganic nanoparticles in siRNA delivery has been 
explored in recent years. These are often modified with organic components to improve surface 
properties and reduce toxicity (Chaudhary et al., 2014, Fraga et al., 2014, Zhou et al., 2009). 
Attachment of siRNA involves either covalent conjugation, or electrostatic association with 
positively charged groups introduced on the surface of the nanoparticle (Conde et al., 2012, Xia 
et al., 2018). Anti-c-myc siRNA carried by PEG- (McCully et al., 2015) and poly(ethylene 
imine)-functionalised (Shaat et al., 2016) gold nanoparticles was shown to reduce c-myc 
expression in human cervical and liver cancer cell lines, respectively. In separate in vivo 
experiments, gold nanoparticles modified with polymer shells (Kim et al., 2017b), glucose 
residues (Conde et al., 2015) and a RGD tumour-specific peptide (Conde et al., 2013) delivered 
anti-c-myc siRNA and suppressed the growth of lung tumours. Polymer-functionalised selenium 
(Huang et al., 2018) and graphene oxide (Imani et al., 2018) nanoparticles have also been 




2.9.6.3 siRNA-directed transcriptional silencing  
Further possibilities for the use of siRNA as tools for gene inhibition emerged from evidence that 
siRNA molecules homologous to regulatory regions of genes can cause gene silencing at the 
level of transcription. This phenomenon is known as siRNA-directed transcriptional silencing 
(RdTS) (Morris et al., 2004). The only report to date of RdTS applied to c-myc inhibition was 
presented by Napoli et al. (2009). siRNA molecules were designed with complementarity to 
DNA sequences at the major transcription start site. This achieved c-myc silencing in prostate 
cancer cells when introduced using a commercially available cationic liposome formulation. 
Importantly, oncogene inhibition was accompanied by anti-cancer effects which included loss of 
proliferative activity and clonogenic capability. It was shown that the promoter-targeted siRNA 
molecules formed a complex with non-coding promoter-associated RNA, which was initiated 
upstream of the transcription start site, and prevented the assembly of the pre-initiation complex 
in a mechanism that was dependent upon Ago2. 
 
2.9.7 Dicer-substrate siRNA (DsiRNA) 
The natural precursor of siRNA i.e. long dsRNA is not a suitable therapeutic agent because it is 
known to induce an immune response (Clemens, 1997). However, it was reported that short 
dsRNA molecules, lacking the dinucleotide overhangs that typify siRNA, of between 25 and 30 
nucleotides in length, can induce RNAi with greater efficiency than siRNA (Kim et al., 2005). 
The blunt-ended RNA duplex is known as dicer-substrate siRNA (DsiRNA). A possible 
explanation for this observation was linked with the finding that the dsRNA-processing enzyme, 
DICER, participates in siRNA loading and RISC assembly. It was put forward that the blunt-
ended duplexes were acted upon by the enzyme DICER to yield typical siRNA molecules and 
that this initial activity, which is unnecessary when pre-formed siRNA is introduced, renders 
DICER more efficient in its subsequent activities (Rose et al., 2005). However, in a more recent 
study, DsiRNA and conventional siRNA were found to act with comparable efficiency (Carneiro 
et al., 2015). 
Like conventional siRNA, DsiRNA  requires a vehicle for successful entry. Of significance to 
this discussion is the fact that pharmaceutical company, Dicerna, reported on a DsiRNA specific 
for the c-myc oncogene, DCR-MYC, delivered using a proprietary EnCore™ lipid nanoparticle. 
DCR-MYC in this delivery platform is the first, and only anti-c-myc RNAi system, to date, to 
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have reached clinical trials (Tolcher et al., 2015). Although the outcome of the initial trial was 
encouraging, a subsequent trial showed unsatisfactory knockdown efficiency and its 
development was discontinued (Whitfield et al., 2017). 
 
2.9.8 Short hairpin RNA (shRNA) 
Knockdown of c-myc expression can also be achieved through DNA-directed RNAi, a strategy 
which generates specific siRNA molecules in vivo (Ambesajir et al., 2012). This involves the 
construction of a RNA pol-driven plasmid expression vector into which an antigene sequence of 
at least 19 nucleotides is inserted, together with appropriate termination signals. When 
introduced into cells, the antigene sequence is transcribed in the nucleus as a stem-loop structure, 
which is essentially 2 complementary sequences, 19-22 ribonucleotides in length, linked by a 
short loop of 4-11 ribonucleotides. This is known as short hairpin RNA (shRNA). The shRNA is 
exported to the cytoplasm where it is processed by DICER into siRNA molecules and these 
associate with the RNAi machinery (Taxman et al., 2010). 
Most experiments with anti-c-myc shRNA plasmids have involved their introduction into cells in 
culture with the aid of commercial cationic lipid transfection reagents. In one such study, 
plasmid-driven anti-c-myc shRNA silenced c-myc expression by as much as 80 %, reduced 
colony forming ability and promoted apoptosis in MCF-7 breast cancer cells (Wang et al., 2005). 
A similar plasmid system impaired proliferation, invasion and motility in the hepatocellular 
carcinoma cell line, HepG2 (Zhao et al., 2013). Hao et al. (2008) found that transfection of colon 
cancer cells with anti-c-myc shRNA plasmids not only reduced c-myc expression, but also that of 
the human telomerase reverse transcriptase gene (hTERT), which is under the transcriptional 
regulation of c-myc, and also contributes towards carcinogenesis when abnormally expressed. 
As with siRNA, the effect of multigene silencing using shRNA expression plasmids was also 
explored. Song et al. (2011) engineered a single plasmid to direct the transcription of shRNAs 
against c-myc, VEGF, hTERT, and BIRC5, which encodes survivin. This produced a more 
effective anti-cancer effect than shRNA plasmids targeting individual oncogenes. Similarly, Tai 
et al. (2012) observed a synergistic anti-cancer effect, in colon cancer cells, when cells were 
co-transfected with two shRNA plasmids, each separately targeting c-myc and VEGF. 
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Thus far, only one in vivo experiment with anti-c-myc shRNA has been reported. In this study a 
poly(ethylene imine)-grafted polyglycidal methacrylate nanoparticle was used as a carrier of the 
shRNA expression vector. Anti-c-myc shRNA delivered in this manner showed anti-cancer 
activity in murine models of breast and colon cancer (Tangudu et al., 2015). 
Although anti-c-myc shRNA approaches reported to date have primarily relied on RNAi, it is 
worth mentioning that an shRNA-based system, directed against the P2 promoter, induced 
transcriptional gene silencing of c-myc in hepatocellular carcinoma when delivered via a 
virosomal carrier (Zakaria et al., 2017). 
 
2.10 Final comments 
Synthetic nucleic acids designed to inhibit the expression of c-myc have, in many instances, 
induced potent anti-cancer effects in vitro and in vivo. To date, ASOs, PMOs and DsiRNA were 
evaluated as alternative cancer treatment in clinical trials, but did not progress further. Whitfield 
et al. (2017) mentioned, in a recent review, that several groups and companies are pursuing the 
idea of inhibiting c-myc at the level of translation as a means of designing a clinically viable anti-
c-myc agent. Hence RNAi-based strategies are currently significant. Although longer lasting 
oncogene inhibition can be achieved with DNA-directed RNAi (Takahashi et al., 2009), mature 
siRNA molecules are easily synthesised, and pose fewer delivery concerns as they are of lower 
molecular weight and do not require genome integration (Wang et al., 2010, Xu and Wang, 
2015). Hence, siRNA is considered more suitable for therapeutic use (Xu and Wang, 2015). 
Research to date has emphasised that the development of a siRNA-based approach is largely 
dependent upon the design of an appropriate nanodelivery system. Of all siRNA carriers 
explored thus far, the greatest body of knowledge has been generated in the field of lipid-based 
siRNA delivery, and this has led to the evaluation of several lipid-based RNAi complexes in 
clinical trials (Barata et al., 2016, Zatsepin et al., 2016). 
Particle stabilisation with Chol and PEG have emerged as important features of lipid-based, anti-
c-myc siRNA nanoparticles. In addition, most lipid-based nanoparticles reviewed were designed 
with cancer cell-targeting moieties. While these may render delivery to tumour cells more 
effective and possibly alleviate short-term effects of c-myc inhibition in normal cells, it may not 
be an entirely necessary feature. This is with reference to findings that presented the feasibility of 
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systemic c-myc inhibition with a non-discriminate c-myc inhibitor (Soucek et al., 2008) and, that 
systemic administration of anti-c-myc siRNA in non-targeted, pegylated liposomes did not 
inhibit the growth of cells with low c-Myc levels (Reyes-González et al., 2015). Passive 
targeting, that relies on optimising physical features of the lipid-based nanoparticle to exploit the 
enhanced permeability and retention  effect, can also facilitate effective intratumoural delivery of 
siRNA (Torchilin, 2011, Maruyama, 2011). In fact, a major issue with the EnCore™ liposomal 
system, taken up in the clinical trial, was tumour penetration (Zatsepin et al., 2016). 
Furthermore, a passive targeting strategy may pave the way for less elaborate anti-c-myc siRNA 
lipid nanoparticles that can be more easily and economically produced (Deshpande et al., 2013). 
Hence, the current study is aimed at developing traditional cationic lipoplexes as simple but 
effective lipid-based anti-c-myc siRNA delivery agents.
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CHAPTER 3 – MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Liposome preparation and characterisation 
DOPE and Chol were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). The 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(DSPE-PEG2000) was purchased from Avanti Polar Lipids (Albaster, AL, USA). The 
2-[-(2-hydroxyethyl)-piperazinyl]-ethanesulphonic acid (HEPES) was from Merck (Darmstadt, 
Germany). Uranyl acetate solution (2 % w/v in distilled water) and formvar-coated copper grids 
were supplied by the Microscopy and Microanalysis Unit in the School of Life Sciences (UKZN, 
Westville). 
3.1.2 siRNA duplexes and resuspension 
The following was purchased from Thermo Scientific Dharmacon Products (Lafayette, CO, 
USA): siGENOME non-targeting siRNA #1 (D-001210-01-20), ON-TARGETplus SMARTpool 
Human MYC (4609) siRNA (L-003282-02-0020), siCONTROL Tox siRNA (D-001500-01), 
5× siRNA buffer (B-002000-UB-100, 0.3 M KCl, 30 mM HEPES, 1 mM MgCl2, pH 7.5) and 
Molecular Grade RNase-free water (B-003000-WB-100). siGENOME non-targeting siRNA #1, 
with a recognition sequence of 5ʹ-UAG CGA CUA AAC ACA UCA A-3ʹ, has at least four 
mismatches to all known human, mouse and rat genes. ON-TARGETplus SMARTpool Human 
MYC (4609) siRNA is a mixture of four anti-c-myc siRNA duplexes (Table 3.1). 
ON-TARGETplus siRNA has a patented dual strand modification designed to reduce off-target 
effects, and favour RISC-loading of the antisense strand. 
Table 3.1: Individual anti-c-myc siRNA duplexes in SMARTpool reagent. 
Dharmacon 
code 






J-003282-23 5ʹ-ACG GAA CUC UUG UGC GUA A-3ʹ 13 429.8 371 130 
J-003282-24 5ʹ-GAA CAC ACA ACG UCU UGG A-3ʹ 13 429.9 369 973 
J-003282-25 5ʹ-AAC GUU AGC UUC ACC AAC A-3ʹ 13 414.9 374 334 




The sequence and physical properties of siCONTROL Tox siRNA are proprietary. The 
fluorescein isothiocyanate (FITC) labelled dsRNA oligomer (oligo), BLOCK-iT™ Fluorescent 
Oligo (2013), was obtained from Invitrogen (Carlsbad, CA, USA) as a 20 µM stock suspension 
in 100 mM KOAc, 30 mM HEPES-KOH, pH 7.4, and 2 mM MgOAc. The RNA duplex has the 
same length, charge and configuration as standard siRNA, and is designed for the assessment and 
optimisation of cationic lipid-mediated delivery. The sequence of BLOCK-iT™ Fluorescent 
Oligo is proprietary, and is not homologous to any known gene. 
3.1.3 Liposome-siRNA interactions 
Ultrapure™ agarose powder was obtained from Invitrogen (Carlsbad, CA, USA). The ethidium 
bromide (EtBr) solution (10 mg/ml) and tris(hydroxymethyl)-aminomethane hydrochloride 
(Tris-HCl) were purchased from Merck (Darmstadt, Germany). SYBR Green II RNA gel stain 
(10 000× concentrate in dimethylsulphoxide (DMSO)) was from Cambrex BioScience Rockland 
Inc. (Rockland, ME, USA). Ethylenediaminetetra acetic acid (EDTA) (disodium salt, dihydrate) 
was from Calbiochem (Darmstadt, Germany). Electrophoresis purity grade sodium 
dodecylsulphate (SDS) was purchased from Bio-Rad Laboratories (Richmond, CA). Xylene 
cyanol was supplied by SaarChem (Muldersdrift, SA). Sucrose and bromophenol blue were 
obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Foetal bovine serum (FBS) 
was sourced from HyClone UK Ltd. (Cramlington, Northumberland). All other chemicals and 
reagents were of analytical grade and ultrapure water (Direct-Q® 3 ultrapure water purification 
system, Millipore S.A.S., Molsheim, France) was used throughout. 
3.1.4 Cell culture and in vitro assays 
Human embryonic kidney 293 (HEK293) cells were supplied by the University of 
Witwatersrand, Medical School, South Africa. Michigan Cancer Foundation 7 (MCF-7) cells 
(ATCC® HTB-22™) and Human colorectal adenocarcinoma, HT-29, cells (ATCC® HTB-38™) 
were from the American Type Culture Collection (Manassas, VA, USA). Human colorectal 
adenocarcinoma, Caco-2, cells were purchased from Highveld Biologicals (PTY) Ltd. 
(Lyndhurst, South Africa). The following were obtained from Lonza BioWhittaker (Verviers, 
Belgium): sterile-filtered Eagle’s Minimum Essential Medium (EMEM) with L-glutamine, 
trypsin-EDTA solution (200 mg/L EDTA, 170.000 U trypsin/L) and penicillin/streptomycin 
mixture (10 000 U/ml penicillin, 10 000 µg/ml streptomycin). Phosphate buffered saline (PBS) 
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tablets were purchased from Calbiochem (Darmstadt, Germany). Sterile DMSO was supplied by 
Highveld Biologicals (PTY) Ltd (Lyndhurst, South Africa). The alamarBlue® (AB) cell viability 
reagent was sourced from Invitrogen (Carlsbad, CA, USA). The 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) and Certistain® acridine orange (AO) zinc chloride 
double salt were purchased from Merck (Darmstadt, Germany). The 5× cell culture lysis reagent 
(25 mM Tris-phosphate, pH 7.8; 2 mM dithiothreitol; 2 mM 1,2-diaminocyclohexane-N-N-Nʹ-
Nʹ-tetra-acetic acid; 10 % (v/v) glycerol; 1 % (v/v) Triton X-100) was supplied by Promega 
Corporation (Madison, WI, USA). The following was purchased from Sigma-Aldrich Chemical 
Co. (St. Louis, MO, USA): bicinchoninic acid (BCA) solution, copper (II) sulphate solution and 
the protein standard, bovine serum albumin (BSA) (1 mg BSA/ml in 0.15 M NaCl, 0.05 % 
NaN3). Lipofectamine™ 3000 (LF3K) reagent was purchased from Invitrogen Life Technologies 
(Carlsbad, CA, USA). All sterile plasticware for tissue culture was obtained from Corning Inc. 
(Corning, NY, USA).  
3.1.5 Gene expression assays 
3.1.5.1 Reverse transcription quantitative real-time PCR (RT-qPCR) 
The TRIzol® reagent (15596-026) was obtained from Life Technologies (Carlsbad, CA, USA). 
All reagents and consumables for RT-qPCR were purchased from Bio-Rad Laboratories (PTY) 
Ltd (Parkwood, Gauteng, South Africa). The iScript™ genomic DNA (gDNA) Clear 
complementary DNA (cDNA) Synthesis Kit (1725035) consisted of the following: a 5× reverse 
transcription (RT) supermix which contains Moloney murine leukemia virus reverse 
transcriptase, deoxyribonucleoside triphosphates (dNTPs), oligo deoxythymidine (dT), random 
primers and RNase inhibitor; a 5× no-RT control supermix which contains all aforementioned 
components except reverse transcriptase; deoxyribonuclease (DNase) I solution; DNase buffer 
solution; and nuclease-free water. The SsoAdvanced™ Universal SYBR® Green Supermix 
(1725272) was supplied as a 2× concentrated reagent containing antibody-mediated hot-start 
Sso7d fusion polymerase, dNTPs, MgCl2, SYBR Green I dye, enhancers, stabilisers and passive 
reference dyes, including ROX and fluorescein. The following primers were supplied as 20× 
stock solutions: PrimePCR™ SYBR® Green Assay: MYC, Human (Unique Assay ID: 
qHsaCID0012921); PrimePCR™ SYBR® Green Assay: ACTB, Human (Unique Assay ID: 
qHsaCED0036269). The following single-stranded synthetic DNA templates were supplied as 
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20× stock solutions (20 × 106 copies/µl): PrimePCR™ Template for SYBR® Green Assay: MYC, 
Human; PrimePCR™ Template for SYBR® Green Assay: ACTB, Human. Hard-Shell® 96-well, 
low profile, semi-skirted polymerase chain reaction (PCR) plates with a clear shell and white 
wells (HSL9605), 0.2 ml PCR tube strips with domed caps (TBC1202) and Microseal® 'B' 
adhesive seals (MSB1001) were also purchased. 
3.1.5.2 Enzyme-linked immunosorbent assay (ELISA) 
Radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 8.0, with 150 mM NaCl, 
1.0 % Igepal CA-630 (NP-40), 0.5 % sodium deoxycholate, and 0.1 % SDS) and 
3,3′,5,5′-Tetramethylbenzidine (TMB) liquid substrate were from Sigma-Aldrich (St. Louis, MO. 
USA). Na2CO3 and NaHCO3 were from Merck (Darmstadt, Germany). The following was 
purchased from Bio-Rad Laboratories (PTY) Ltd (Parkwood, Gauteng, South Africa): 10× Tris-
buffered saline (TBS); 10 % Tween 20, nonionic detergent; and blotting-grade blocker (non-fat 
dry milk). The following was from Life Technologies (Carlsbad, CA, USA): c-Myc epitope tag 
antibody 9E11 (AHO0052), a mouse monoclonal antibody raised against a synthetic peptide 
corresponding to amino acid residues 408-439 of the C-terminus of c-Myc; and goat anti-mouse 
IgG2A secondary antibody, horseradish peroxidase (HRP) conjugate (M32207). The β-actin 
antibody (8H10D10), a mouse monoclonal antibody raised against a synthetic peptide 
corresponding to the amino terminal residue of human β-actin, was purchased from Whitehead 
Scientific (PTY) Ltd. (Cape Town, South Africa). 
 
3.2 Methods 
3.2.1 Synthesis of MS09 
MS09 was prepared from cholesterylformylhydrazide hemisuccinate (MS08) via an active ester 







































Figure 3.1: Scheme outlining the synthesis of MS09 from MS08 (redrawn and adapted from Singh and 
Ariatti (2006) using ChemWindow
®




3.2.2 Liposome preparation 
Liposomes were prepared by a method adapted from Gao and Huang (1991). Stock solutions 
(10 µg/µl in chloroform) of each lipid component were prepared. These were combined as shown 
in Table 3.2, and concentrated to a thin film in vacuo (Büchi Rotavapor-R rotary evaporator), 
with additional drying in a Büchi-TO pistol drier (200 mTorr, 25 ˚C, 2 h) to eliminate residual 
chloroform. The film was rehydrated (4 ˚C, 48 h) in sterile HEPES buffered saline (HBS, 
20 mM HEPES, 150 mM NaCl, pH 7.5; 0.5 ml). The suspension was vortexed (2 min) and, 
thereafter, sonicated (25 ˚C, 10 min) in an Elma, Transsonic (T460/H) bath-type sonicator 
(Singen, Germany) operating at 35 kHz. Liposome preparations were stored at 4 ˚C, and were 
sonicated (25 ˚C, 5 min) prior to use.
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Table 3.2: Composition of pegylated and non-pegylated cationic liposomes 
Liposome 
Lipid components 
(µmol/ 0.5 ml liposome suspension) 
Cytofectin concentration Total lipid concentration 
µmol/ml µg/µl mM µmol/ml µg/µl mM 
MS09 DOPE Chol DSPE-PEG2000 
MS09/DOPE 2 2 - - 4 2.52 4.00 8.00 5.50 8.00 
MS09/Chol (1:1)a 2 - 2 - 4 2.52 4.00 8.00 4.06 8.00 
MS09/Chol (1:2)a 1.33 - 2.67 - 2.66 1.68 2.66 8.00 3.74 8.00 
MS09/Chol (1:3)a 1 - 3 - 2 1.26 2.00 8.00 3.58 8.00 
MS09/DOPE/PEG 1.96 1.96 - 0.08 3.92 2.46 3.92 8.00 5.82 8.00 
MS09/Chol/PEG (1:1)a 1.96 - 1.96 0.08 3.92 2.46 3.92 8.00 4.42 8.00 
MS09/Chol/PEG (1:2)a 1.3 - 2.6 0.08 2.6 1.64 2.6 8.00 4.12 8.00 
MS09/Chol/PEG (1:3)a 0.98 - 2.94 0.08 1.96 1.24 1.96 8.00 3.98 8.00 
Note: aThe ratio in brackets represents the ratio of MS09 to Chol on a molar basis 
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3.2.3 Characterisation of liposomes 
3.2.3.1 Cryogenic transmission electron microscopy (cryo-TEM) of liposomes 
Liposome suspensions were diluted (1:15) in HBS, and aliquots (1 µl) were placed on formvar-
coated copper grids. Samples were stained with uranyl acetate (1 µl) and allowed to stand at 
room temperature for 2 min. Excess liquid was removed using filter paper. Samples were flash-
frozen by plunging into liquid propane (-170 ˚C), cooled by liquid nitrogen, using a spring-
loaded Leica EM CPC cryopreparation system (Leica Microsystems, Vienna, Austria). Grids 
were immediately transferred to a Gatan cryo-transfer holder (Gatan Inc., Pleasanton, CA, US). 
Samples were viewed with a JEOL JEM.1010 transmission electron microscope (JEOL Ltd., 
Tokyo, Japan) at an accelerating voltage of 100 kV, without warming above -150 ˚C. Images 
were captured using an Olympus MegaView III digital camera in conjunction with SIS iTEM 
Universal Imaging Platform software (Shinjuku, Japan). 
3.2.3.2 Zeta Potential Nanoparticle Tracking Analysis (Z-NTA) 
Particle size, zeta (ζ) potential and concentration of liposomes were simultaneously determined 
using the NanoSight NS500 system fitted with a ZetaSight™ (Malvern Instruments, 
Worcestershire, UK) module. Liposome suspensions were diluted in a filter-sterilised buffer 
containing 0.2 mM HEPES, 1.5 mM NaCl, pH 7.5 in accordance with instrument sensitivity 
limits. Dilutions were as follows: MS09/DOPE, MS09/Chol (1:1), MS09/DOPE/PEG and 
MS09/Chol/PEG (1:1), 1:7000; MS09/Chol (1:2) and MS09/Chol (1:3), 1:200; 
MS09/Chol/PEG (1:2) and MS09/Chol/PEG (1:3), 1:300. Samples (1 ml) were introduced into 
the viewing chamber of the instrument using the on-board sample pump. Particles were 
visualised with a focused laser beam (405 nm, 60 mW) and the on-board sCMOS camera. Two 
videos of particle motion were recorded, with the NTA 3.0 build 69 software (Malvern 
Instruments, Worcestershire, UK), at each of 5 pre-set measurement positions within the 
chamber upon the application of 10 V, under both positive and negative polarity. Capture 
duration was set at 60 s for position 1, and at 30 s for positions 2-5. Temperature was maintained 
at 25 ˚C during measurements. In all instances, sample viscosity of 0.9 cP and a dielectric 
constant of 80.0 was assumed. Post-capture, the software corrected for electro-osmotic and 
thermal effects, and calculated zeta potential from individual particle velocities by applying the 
Henry equation with Smoluchowski approximation. Hydrodynamic diameters were 
simultaneously calculated from particle tracks using Stokes-Einstein equation. Particle 
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concentrations were estimated based on the number of particles in the field of view in relation to 
the scattering volume. The system was flushed with ultrapure water before loading each sample. 
The quality of the ultrapure water was routinely monitored to confirm the absence of 
contaminants. Three independent measurements were performed per sample so as to ensure that 
properties of the sample were not perturbed by electric field cycles of the previous run, and data 
was presented as the average of the three experiments. Modal size and zeta potential values are 
given in Chapter 4, section 4.3. Concentrations were reported as follows: 
Concentration (particles/ml) = concentrationNTA 3.0 build 69 × dilution factor 
Concentrations were used to estimate the average number of lipid molecules per liposomal 
vesicle as follows: 
Average number of lipid molecules/vesicle = #$%&'( )* +,-,. %)+'/$+'01/%+23'(24' #$%&'( )* 3'0,/+'0/%+  
aCalculated from the total lipid concentration of liposome suspensions (Table 3.2) and Avogrado’s constant.  
Calculations assumed the absence of particulate contaminants, and estimates are given in 
Appendix B, Table B1. A sample calculation is given in Appendix C. Note that estimates were 
made only in the case of stable formulations.  
A summary of all other Z-NTA generated data (Tables B2 and B3) together with selected flow 
profiles, and plots of zeta potential and size vs. concentration is presented in Appendix B. 
 
3.2.4 Resuspension of siRNA 
The siRNA was resuspended as per manufacturer’s instruction. Briefly, siRNA was deposited as 
a pellet by centrifuging (90 × g, 4 ˚C, 60 s) in an Eppendorf 5424 R instrument (Merck, 
Darmstadt, Germany). The pellet was resuspended by adding 1× siRNA buffer (60 mM KCl, 
6 mM HEPES, 0.2 mM MgCl2, pH 7.5; 1 ml) followed by agitation (room temperature, 30 min) 
on a platform shaker (Stuart Scientific STR6, Surrey, UK) operating at 50 revolutions per minute 
(rpm), to obtain a final siRNA concentration of 20 µM (0.268 µg/µl, 20 pmol/µl). siRNA stock 
suspensions were dispensed into RNase-free tubes in aliquots (50 µl) and stored at -80 ˚C 
(NuAire -86 ˚C Ultralow Freezer, Lasec Laboratory and Scientific Equipment Co.).  
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3.2.5 Liposome-siRNA binding studies 
After characterising all eight liposome suspensions, the following four formulations were 
investigated further: MS09/DOPE, MS09/Chol (1:1), MS09/DOPE/PEG, and 
MS09/Chol/PEG (1:1). 
3.2.5.1 Gel retardation assays 
3.2.5.1.1 Lipoplex assembly 
Lipoplexes were assembled at MS09:siRNA (w/w) ratios ranging from 4:1 to 28:1 (for the 
MS09/DOPE formulation) and 8:1 to 32:1 (for all other formulations) in increments of 4. The 
corresponding N/P (+/
-
) charge ratios were calculated based on the assumption that MS09, with 
molecular weight of 629 g/mol, carries one positive charge per molecule at physiological pH; 
while an RNA nucleotide has an average molecular weight of 340 g/mol and carries one negative 
charge (a sample calculation is given in Appendix C). Varying amounts of liposome were added 
to a fixed quantity of siGENOME non-targeting siRNA (0.3 µg, 22.5 pmol) to correspond with 
the aforementioned ratios. Volumes were adjusted to 10 µl with HBS. After brief vortexing 
(30 s), mixtures were allowed to stand at room temperature for 30 min to permit the formation 
and maturation of electrostatic complexes. The set-up for the preparation of individual liposome-
siRNA complexes is given in Appendix D, Tables D1-D4. 
3.2.5.1.2 Preparation of 2 % agarose gels 
Agarose powder (0.4 g) was dissolved in water (18 ml) with heating to boiling point. This was 
cooled to 75 ˚C, and 10× electrophoresis buffer (0.36 M Tris-HCl, 0.3 M NaH2PO4, 
0.1 M EDTA, pH 7.5; 2 ml) was added. The mixture was poured into a gel casting tray fitted 
with an eight-well comb (Bio-Rad, Richmond, CA) and allowed to set (room temperature, 
40 min). 
3.2.5.1.3 Agarose gel electrophoresis 
Lipoplexes (10 µl in HBS) were mixed with gel loading buffer (40 % sucrose, 0.25 % xylene 
cyanol, 0.25 % bromophenol blue; 2.5 µl) and samples (10 µl) were loaded onto 2 % agarose 
gels. Electrophoresis was carried out for 30 min in a Mini-Sub® Cell GT electrophoresis cell 
(Bio-Rad, Richmond, CA) containing Tris-phosphate-EDTA (TPE) running buffer (36 mM Tris-
HCl, 30 mM NaH2PO4, 10 mM EDTA, pH 7.5), using a PowerPac™ Basic power supply unit 
(Bio-Rad, Richmond, CA) operating at 50 V. Gels were stained with EtBr solution (0.1 µg/ml in 
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water) for 30 min with gentle agitation (10 rpm, room temperature) on a platform shaker (Stuart 
Scientific STR6, Surrey, UK). Gels were viewed under ultraviolet transillumination (300 nm) in 
a Vacutec Syngene G:Box (Syngene, Cambridge, UK) gel documentation system. Images were 
captured with GeneSnap software, version 7.05.02 (Syngene, Cambridge, UK) following 
exposure time of 1 s. Densitometric analysis was performed with GeneTools software, version 
4.00.00 (Syngene, Cambridge, UK). Bands of siRNA that migrated within the gel represent 
unbound siRNA. The fluorescence intensities of these bands were expressed as a percentage of 
the intensity of naked siRNA (0.3 µg, 22.5 pmol) that was loaded in lane 1 of each gel. Hence, 
the amount of liposome-associated siRNA at each MS09:siRNA (w/w) ratio was determined as 
follows:  
%	bound	siRNA	 = 	100	 − 	%	free	siRNA	
3.2.5.2 Dye displacement assays 
3.2.5.2.1 EtBr displacement assay 
EtBr (0.4 µg) was added to HBS (200 µl) in 96-well flat-bottom black polystyrene plates. 
Baseline fluorescence (0 %) was established upon measuring the fluorescence intensity of this 
solution in a GloMax® Multi+ Detection System (Promega Biosystems, Sunnyvale, CA, USA) 
using Instinct software, at excitation and emission wavelengths of 525 nm and 600 nm, 
respectively. siGENOME non-targeting siRNA (1.0 µg, 75 pmol) was introduced, and 
fluorescence intensity at this point was taken to represent 100 % relative fluorescence. Undiluted 
liposome suspension was added, stepwise, in 1 µl aliquots, solutions thoroughly mixed after each 
addition, and allowed to equilibrate in the dark, at room temperature for 4 min before readings 
were taken. The total volume of liposome suspension introduced was limited to 11 µl, which was 
approximately 5 % of the initial EtBr-siRNA-HBS mixture by volume, so as to minimise dilution 
effects. The percentage relative fluorescence upon each addition of liposome was plotted as a 
function of micrograms of cytofectin.  
3.2.5.2.2 SYBR Green displacement assay 
The experiment outlined in 3.2.5.2.1 was repeated using SYBR Green II as the RNA-
intercalating dye (Dorasamy et al., 2009). The SYBR Green II stock solution was diluted 
(1:10 000) in HBS, and 202 µl was used to establish baseline fluorescence. Fluorescence 
intensities upon introduction of siGENOME non-targeting siRNA and liposome were measured 
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at excitation and emission wavelengths of 497 nm and 520 nm, respectively, and results were 
reported as described in section 3.2.5.2.1 above. 
3.2.5.2.3 Effect of increasing NaCl concentration on liposome-siRNA interactions 
The SYBR Green displacement assay was adapted to investigate the strength of liposome-siRNA 
interactions as follows: Lipoplex suspensions (20 µl in HBS) were assembled with siGENOME 
non-targeting siRNA (1.0 µg, 75 pmol) and liposome at MS09:siRNA (w/w) ratios at which 
individual formulations attained points of inflection by dye displacement. The fluorescence of 
SYBR Green II (1:10 000 in HBS; 200 µl) was recorded before and after the addition of 
lipoplexes (20 µl). Changes in fluorescence were monitored upon addition of 5 M NaCl, 
stepwise, in aliquots (1 µl). In this way a final NaCl concentration range of 150-400 mM, in 
increments of 20 mM, was explored. NaCl concentration was not raised beyond 400 mM so as to 
avoid significant dilution effects with further addition of the NaCl solution. Baseline 
fluorescence was accounted for, and results were reported as the percentage increase in 
fluorescence relative to the initial SYBR Green II-lipoplex mixture. 
 
3.2.6 Characterisation of lipoplexes 
3.2.6.1 Cryo-TEM 
Lipoplexes (10 µl in HBS) were prepared from liposome stock suspensions (1 µl), and 
siCONTROL Tox siRNA at MS09:siRNA (w/w) ratios ranging from 12:1 to 32:1. After 
incubation (room temperature, 30 min) reaction mixtures were diluted to 20 µl in HBS. Aliquots 
(1 µl) were cryopreserved and viewed as described for liposomes in 3.2.3.1.  
3.2.6.2 Z-NTA 
Lipoplexes (10 µl in HBS) were prepared from liposome stock suspensions (1 µl), and 
siCONTROL Tox siRNA at MS09:siRNA (w/w) ratios ranging from 12:1 to 32:1. After 
incubation (room temperature, 30 min) reaction mixtures were diluted (1:700) in sterile buffer 
containing 0.2 mM HEPES, 1.5 mM NaCl, pH 7.5, to give particle numbers appropriate to the 
sensitivity limits of the NS500 system. Videos of particle motion were captured, and data 
analysis was carried out as described for liposome suspensions in 3.2.3.2.  
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Particle concentrations were used to estimate the average number of vesicles and siRNA 
molecules that constitute a single liposome-siRNA nanocomplex, of a given lipoplex suspension, 
as follows: 
1. Average	number	of	vesicles/nanocomplex	










Average estimates of the number of siRNA molecules per nanocomplex were only made in the 
case of lipoplexes assembled above points which gave maximum dye displacement. At these 
MS09:siRNA (w/w) ratios, it was accepted that lipoplexes were fully formed (Hattori et al., 2013) 
and all siRNA molecules were taken to be liposome-associated. The absence of contaminants 
was assumed in all instances. Sample calculations are given in Appendix C, and estimated values 
are shown in Appendix B, Table B4.  
 
3.2.7 Assessment of batch-to-batch variation 
Three independent preparations of each of the MS09/DOPE, MS09/Chol (1:1), 
MS09/DOPE/PEG and MS09/Chol/PEG (1:1) formulations were made as described in 3.2.2. 
These were subjected to Z-NTA characterisation and the SYBR Green dye displacement assay as 
detailed in 3.2.3.2 and 3.2.5.2.2, respectively. 
3.2.8 Liposome storage stability studies 
Freshly prepared liposome suspensions, MS09/DOPE, MS09/Chol (1:1), MS09/DOPE/PEG and 
MS09/Chol/PEG (1:1), were characterised by Z-NTA and the SYBR Green dye displacement 
assay as per protocols given in 3.2.3.2 and 3.2.5.2.2, respectively. The suspensions were stored at 
4 ˚C, and the aforementioned experiments were repeated after 5 and 10 months.  
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3.2.9 Nuclease protection assays 
Lipoplexes (10 µl in HBS), each containing siGENOME non-targeting siRNA (0.3 µg, 
22.5 pmol), were assembled at MS09:siRNA (w/w) ratios of 12:1-32:1. (The corresponding 
N/P (+/
-
) ratios were between 6.5 and 17.3). These were incubated (37 ˚C, 4 h) with FBS at a 
final concentration of 10 % (v/v). As a control, naked siRNA (0.3 µg, 22.5 pmol) was treated in 
the same way. Nuclease activity was terminated by the addition of EDTA at a final concentration 
of 10 mM. Complexes were destabilised by heating (55 ˚C, 25 min) with SDS at a final 
concentration of 0.5 % (w/v). Reaction mixtures were cooled to room temperature and gel loading 
buffer (3.5 µl) was added. A detailed account of sample preparation and treatment is presented in 
Appendix D, Tables D5-D8. Samples (10 µl) were subjected to electrophoresis on 2 % agarose 
gels, followed by densitometry, as described in section 3.2.5.1.3. The siRNA bands that migrated 
within the gel represent intact siRNA. The fluorescence intensities of these bands were expressed 
as a percentage of that of untreated siRNA (0.3 µg, 22.5 pmol). 
 
3.2.10 Cell culture and maintenance 
3.2.10.1 Reconstitution 
Cells in cryogenic ampoules were removed from the biofreezer and placed in a water bath 
(37 ˚C, 5 min) to thaw. All work pertaining to cell culture was conducted in a class II biological 
safety cabinet. Cells were transferred into sterile centrifuge tubes and centrifuged (1000 × g, 
25 ˚C, 3 min) in an Eppendorf 5702 R instrument. The supernatant was discarded and the pellet 
resuspended in 1 ml growth medium (EMEM supplemented with 10 % (v/v) FBS, 100 U/ml 
penicillin, and 100 µg/ml streptomycin), which was used for cell propagation and in vitro 
experiments throughout the study, unless otherwise specified. Cells were introduced into 25 cm2 
cell culture flasks containing growth medium (4 ml) and maintained at 37 ˚C in a humidified 
atmosphere with 5 % CO2 (Steri-Cult CO2 incubator with class 100 HEPA filtration, Thermo 
Electron Corporation).  
3.2.10.2 Change of medium 
Medium was replaced within 24 h of reconstitution, to eliminate residual DMSO and non-
adherent cells. Spent medium was discarded and cells were rinsed with PBS (10 mM phosphate 
buffer, pH 7.4, 140 mM NaCl, 3 mM KCl; 2 ml). Fresh medium (5 ml) was introduced and cells 
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were returned to the incubator (37 ˚C). Cell growth was monitored on a daily basis using a Nikon 
TMS inverted microscope (Nikon Instruments, Tokyo, Japan). Any changes in the colour of the 
growth medium were also noted. Medium was changed every 24-48 h in accordance with these 
observations. Images of the cells were captured at 200× magnification using an inverted 
fluorescence microscope (CKX41, Olympus, Japan) operating in bright field mode, in 
conjunction with Analysis Five Software (Olympus Soft Imaging Solutions, Olympus, Japan). 
3.2.10.3 Trypsinisation 
Once cells had reached semi-confluency, spent medium was decanted and cells were rinsed with 
PBS (2 ml). Trypsin-EDTA solution (1 ml) was introduced, and cells were maintained at 37 ˚C 
for 1-5 min, depending on the cell type. Changes in cell morphology were monitored under the 
inverted microscope. When cells had rounded-off, medium (2.5 ml) was added to halt further 
enzyme activity. Cells were dislodged from the surface of the culture vessel with gentle tapping. 
The contents of the flask were drawn-up and expelled using a sterile pipette, so as to ensure an 
even distribution of cells in the medium, before being either seeded into multi-well plates for 
in vitro assays, divided among two or more flasks for further propagation, or cryopreserved.  
3.2.10.4 Cryopreservation 
Cells were trypsinised as described in 3.2.10.3 and recovered as a pellet after centrifugation 
(1000 × g, 25 ˚C, 2 min) in an Eppendorf 5702 R instrument. The pellet was resuspended in 
medium (1 ml) containing 10 % (v/v) DMSO and transferred into cryovials. These were cooled at 
a rate of -1 ˚C/min in a Nalgene™ Cryo 1 ˚C freezing container (Thermo Fisher Scientific, 
Waltham, Massachusetts, US) filled with 100 % isopropyl alcohol until a temperature of – 80 °C 
was attained. Cells were stored in a NuAire -86 ˚C Ultralow Freezer (Lasec Laboratory and 
Scientific Equipment Co.) for short term storage. 
 
3.2.11 Transfection 
3.2.11.1 Transfection with MS09 liposomes 
For experiments in 48-well plates, cells were seeded at densities of approximately 
4 × 104 cells/well. These were maintained at 37 ˚C for 24 h in order to reach semi-confluency. 
The initial transfection experiments were conducted within a broad final siRNA concentration 
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range (57–14 nM). siRNA (0.2 µg per 48-well format) was used as an arbitrary starting point. 
This amount was sequentially halved.  
Lipoplexes were assembled 30 min prior to their introduction to the cells. Transfecting 
complexes contained 0.2 µg (15 pmol), 0.1 µg (7.5 pmol) or 0.05 µg (3.7 pmol) siRNA and 
appropriate amounts of liposome to give lipoplexes at MS09:siRNA (w/w) ratios of 12:1–32:1. 
Volumes were adjusted to 10 µl with HBS. In theory, lipoplex suspensions were formulated at 
siRNA concentrations of 1.5 µM, 0.75 µM and 0.37 µM so as to give final concentrations of 
57 nM, 29 nM and 14 nM, respectively, assuming no loss due to pipetting errors (refer to 
Appendix C for calculations). The corresponding theoretical cytofectin and total lipid 
concentrations to which cells were exposed are presented in Table 3.3 (a sample calculation is 
given in Appendix C).  
Cells were prepared by draining the wells and adding fresh medium (0.25 ml/well). Lipoplexes 
(10 µl) were added and cells were incubated at 37 ˚C until assay-specific end-points. Quantities 



























MS09/DOPE 26.2:1 12:1 6.5:1 14.7 29.3 7.4 14.7 3.7 7.3 
34.9:1 16:1 8.7:1 19.6 39.1 9.8 19.6 4.9 9.8 
43.7:1 20:1 10.8:1 24.5 48.8 12.3 24.4 6.2 12.2 
52.4:1 24:1 13.0:1 29.4 58.6 14.7 29.3 7.4 14.7 
61.1:1 28:1 15.1:1 34.2 68.4 17.1 34.2 8.6 17.1 
69.8:1 32:1 17.3:1 39.1 78.1 19.6 39.1 9.8 19.5 
MS09/Chol (1:1) 19.3:1 12:1 6.5:1 14.7 29.3 7.4 14.7 3.7 7.3 
25.8:1 16:1 8.7:1 19.6 39.1 9.8 19.6 4.9 9.8 
32.2:1 20:1 10.8:1 24.5 48.8 12.3 24.4 6.2 12.2 
38.7:1 24:1 13.0:1 29.4 58.6 14.7 29.3 7.4 14.7 
45.1:1 28:1 15.1:1 34.2 68.4 17.1 34.2 8.6 17.1 
51.6:1 32:1 17.3:1 39.1 78.1 19.6 39.1 9.8 19.5 
MS09/DOPE/PEG 28.4:1 12:1 6.5:1 14.7 30.0 7.4 15.0 3.7 7.5 
37.9:1 16:1 8.7:1 19.6 40.0 9.8 20.0 4.9 10.0 
47.3:1 20:1 10.8:1 24.5 50.0 12.3 25.0 6.2 12.5 
56.8:1 24:1 13.0:1 29.4 60.0 14.7 30.0 7.4 15.0 
66.2:1 28:1 15.1:1 34.2 70.0 17.1 35.0 8.6 17.5 
75.7:1 32:1 17.3:1 39.1 80.0 19.6 40.0 9.8 20.0 
MS09/Chol/PEG 
(1:1) 
21.6:1 12:1 6.5:1 14.7 30.0 7.4 15.0 3.7 7.5 
28.8:1 16:1 8.7:1 19.6 40.0 9.8 20.0 4.9 10.0 
35.9:1 20:1 10.8:1 24.5 50.0 12.3 25.0 6.2 12.5 
43.1:1 24:1 13.0:1 29.4 60.0 14.7 30.0 7.4 15.0 
50.3:1 28:1 15.1:1 34.2 70.0 17.1 35.0 8.6 17.5 
57.5:1 32:1 17.3:1 39.1 80.0 19.6 40.0 9.8 20.0 
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(µl) (µg) (pmol) 
96-well 1.8 
58 0.08 6.0 5 100 
29 0.04 3.0 5 100 
14 0.02 1.5 5 100 
48-well 4.0 
58 0.2 15.0 10 250 
29 0.1 7.5 10 250 
14 0.05 3.7 10 250 
*Quantities pertain to a single well  
 
3.2.11.2 Transfection with LF3K 
Cells were transfected with the LF3K reagent according to the manufacturer’s protocol, dated 10 
February 2016 (Publication No. MAN0009872). For a single-well transfection in a 48-well plate, 
The LF3K reagent (0.75 µl) was added to antibiotic and serum-free EMEM (12.5 µl) and 
vortexed briefly (3 s). The siRNA (0.1 µg, 7.5 pmol) was diluted in antibiotic and serum-free 
EMEM (12.5 µl), added to an equal volume of the LF3K-medium mixture and incubated (room 
temperature, 10 min). The transfecting complex (25 µl) was introduced to semi-confluent cells in 
fresh complete medium (0.25 ml) to give a final siRNA concentration of 25 nM. Cells were 
incubated at 37 ˚C until assay-specific end-points. Quantities were appropriately scaled-up or 
down to accommodate larger or smaller well formats as necessary (Table 3.5). LF3K was used as 
a positive control in all experiments conducted under standard cell culture conditions. 




seeding  density 










(µl) (µg) (pmol) 
96-well 1.8 0.04 3.0 0.3 10 100 
48-well 4.0 0.1 7.5 0.75 25 250 
24-well 8.0 0.2 15.0 1.5 50 500 
12-well 15.0 0.4 30.0 3.0 100 1000 
6-well 29.0 1.0 75.0 7.5 250 2000 
*Quantities pertain to a single well 
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3.2.12 Cytotoxicity testing 
Semi-confluent cells in 48-well plates were treated with lipoplexes assembled from siGENOME 
non-targeting siRNA at final concentrations of 57 nM, 29 nM and 14 nM as described in 3.2.11. 
Treatment groups which received naked siRNA at the same final concentrations were also 
included. Untreated cells were included as positive (100 % cell viability) controls. At 48 h post-
transfection, growth medium was aspirated and cell viability was assessed by the MTT (3.2.12.1) 
and AB (3.2.12.2) assays.  
3.2.12.1 MTT assay 
Cells were incubated (37 ˚C, 4 h) with 200 µl each of medium and MTT solution (5 mg/ml in 
PBS) per well. Wells were drained, and formazan crystals were dissolved in DMSO 
(200 µl/well) to give purple-coloured solutions. Absorbance was read at 540 nm in a Mindray 
microplate reader, MR-96A (Vacutec, Hamburg, Germany), against pure DMSO as a blank. The 
percentage cell viability was calculated as follows: 
[A540	nm	(treated cells) – A540	nm	(blank)] 
[A540	nm (untreated cells) – A540	nm	(blank)] 
		× 100 
3.2.12.2 AB assay 
Cells were incubated (37 ˚C, 4 h) with medium (200 µl/well) and AB reagent (20 µl/well). A 
cell-free control containing the aforementioned quantities of medium and AB reagent was treated 
in the same way. Medium was transferred into 96-well flat-bottom black plates and fluorescence 
intensities were read using the GloMax® Multi+ Detection System (Promega Biosystems, 
Sunnyvale, CA, USA) at excitation and emission wavelengths of 570 nm and 585 nm, 
respectively. The percentage cell viability was calculated as follows: 
[RFU	(treated	cells) – RFU	(cell-free	control)] 
[RFU(untreated cells) – RFU	(cell-free	control)]   × 100    ….. where	RFU	is	relative	fluorescence	units	
	
3.2.13 Cellular uptake experiments 
3.2.13.1 Quantitative assays 
Semi-confluent cells in 96-well plates were treated with lipoplexes assembled from BLOCK-iT™ 
Fluorescent Oligo, to give final siRNA marker concentrations of 57 nM, 29 nM and 14 nM, as 
described in section 3.2.11. After 24 h, medium was removed and cells were washed twice with 
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PBS (60 µl/well). Cells were lysed with 1× lysis buffer (5 mM Tris-phosphate, pH 7.8; 0.4 mM 
dithiothreitol; 0.4 mM 1,2-diaminocyclohexane-N-N-Nʹ-Nʹ-tetra-acetic acid; 2 % v/v glycerol; 
0.2 % v/v Triton X-100; 60 µl/well) and gentle agitation (10 rpm, 10 min) on a platform shaker 
(Stuart Scientific STR6, Surrey, UK). Wells were gently scraped with a micropipette tip to 
dislodge any remaining cells, and lysates were transferred into 96-well flat-bottom black plates. 
Fluorescence intensities were quantified with the GloMax® Multi+ Detection System (Promega 
Biosystems, Sunnyvale, CA, USA) at excitation and emission wavelengths of 494 nm and 
519 nm, respectively. The soluble protein concentration of lysates was determined by the BCA 
assay, with BSA as the protein standard (refer to 3.2.13.2). Fluorescence readings were 
normalised against protein content, and results were expressed as RFU per mg protein. 
3.2.13.2 BCA assay 
Standard BSA solutions (ranging from 0 to 30 µg/50 µl in increments of 5 µg/50 µl) were 
prepared in a final volume of 50 µl with ultrapure water. These were mixed with the BCA 
working reagent (BCA solution:copper (II) sulfate solution, 50:1 v/v; 1 ml) and maintained at 
37 ˚C for 30 min. Solutions were cooled to room temperature, and absorbance was measured at 
540 nm (Mindray microplate reader, MR-96A, Vacutec, Hamburg, Germany). This data was 
used to construct a protein standard curve. Lysates were centrifuged (12 000 × g, 4 ˚C, 30 s) in 
an Eppendorf 5424 R instrument to pellet cellular debris. The supernatants (50 µl) were mixed 
with the BCA working reagent (1 ml) and incubated (37 ˚C, 30 min). The soluble protein 
concentration of cell lysates was obtained via extrapolation from the standard curve. 
3.2.14 Final siRNA and lipid dose for application of anti-c-myc lipoplexes 
After analysing data from cellular uptake experiments, the following parameters were chosen for 
gene expression assays: 
• Experiments were to be limited to the two c-myc-overexpressing cell lines i.e. MCF-7 
and HT-29. 
• An MS09/Chol (1:1) lipoplex suspension assembled at the MS09:siRNA (w/w) ratio of 
16:1, was to be evaluated as a new anti-c-myc delivery system. An MS09/DOPE lipoplex 




The strategy adopted was to apply the anti-c-myc agents at the minimum final siRNA 
concentration at which maximum cellular uptake was achieved. In order to select the most 
appropriate final siRNA and lipid concentrations, cellular uptake experiments were performed 
with the above-mentioned lipoplexes, within a narrower final siRNA marker concentration 
range, i.e. 18 nM to 4 nM in decrements of 2 nM, according to the method given in 3.2.13. An 
AB assay (as outlined in 3.2.12.2) was performed to confirm the absence of cytotoxic effects at 
the new siRNA and lipid concentrations. siRNA quantities and volumes applicable to 
experiments in 48- and 96-well format are shown in Table 3.6. The associated final cytofectin 
and lipid concentrations are given in Table 3.7. Data is presented as a comparison with all other 
final siRNA concentrations explored.  
Table 3.6: siRNA quantities and volumes for transfection with MS09/Chol (1:1) and MS09/DOPE 
















(µl) (µg) (pmol) 
96-well 1.8 
18 0.026 1.9 5 100 
16 0.023 1.7 5 100 
12 0.017 1.3 5 100 
10 0.014 1.1 5 100 
8 0.011 0.7 5 100 
6 0.008 0.6 5 100 
4 0.005 0.4 5 100 
48-well 4.0 
18 0.065 4.9 10 250 
16 0.058 4.3 10 250 
12 0.043 3.2 10 250 
10 0.035 2.6 10 250 
8 0.028 1.7 10 250 
6 0.020 1.5 10 250 
4 0.013 1.0 10 250 










Table 3.7: Final cytofectin and lipid concentrations introduced to cells at final siRNA concentrations of 
18-4 nM 
Liposome formulation MS09/Chol (1:1) MS09/DOPE 





















18 MS09 (µM) 
6.3 6.3 
Total lipid (µM) 12.5 12.5 
16 MS09 (µM) 
5.6 5.6 
Total lipid (µM) 11.1 11.1 
12 MS09 (µM) 
4.1 4.1 
Total lipid (µM) 8.2 8.2 
10 MS09 (µM) 
3.4 3.4 
Total lipid (µM) 6.8 6.8 
8 MS09 (µM) 
2.7 2.7 
Total lipid (µM) 5.4 5.4 
6 MS09 (µM) 
2.0 2.0 
Total lipid (µM) 3.9 3.9 
4 MS09 (µM) 
1.3 1.3 
Total lipid (µM) 2.5 2.5 
 
In all experiments to follow, MS09/Chol (1:1) and MS09/DOPE lipoplexes 
(MS09:siRNA w/w = 16:1) were introduced to cells at final siRNA concentration of 12 nM. 
Quantities were adjusted for transfections in different well formats as shown in Table 3.8. 
 
Table 3.8: siRNA quantities and volumes for transfection in different well formats with and 
















(µl) (µg) (pmol) 
96-well 1.8 12 0.017 1.3 5 100 
48-well 4.0 12 0.043 3.3 10 250 
24-well 8.0 12 0.085 6.5 20 500 
12-well 15.0 12 0.170 13.0 40 1000 
6-well 30.0 12 0.340 26.0 80 2000 
*Quantities pertain to a single well  
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3.2.15 Qualitative assessment of cellular uptake under conditions selected for gene 
expression assays 
A qualitative assessment of cellular uptake of MS09/Chol (1:1) and MS09/DOPE lipoplexes in 
MCF-7 and HT-29 cells was performed. Semi-confluent cells in 12-well plates were treated with 
lipoplexes assembled with BLOCK-iT™ Fluorescent Oligo at MS09:siRNA (w/w) = 16:1, 
according to the transfection protocol outlined in 3.2.11. Cells received a final siRNA marker 
concentration of 12 nM (Table 3.8). After 24 h, wells were drained and cells were rinsed with 
PBS (400 µl). Intracellular fluorescence was observed with an inverted microscope fitted with a 
CC12 camera, at excitation and emission wavelengths of 494 nm and 519 nm respectively. 
Images were acquired at 200× magnification using Analysis Five Software (Olympus Soft 
Imaging Solutions, Olympus, Japan).  
 
3.2.16 Gene expression assays 
MCF-7 and HT-29 cells were seeded in 6-well plates and grown to semi-confluency. Cells were 
transfected according to the protocol given in section 3.2.11 with MS09/Chol (1:1) and 
MS09/DOPE lipoplexes (MS09:siRNA w/w = 16:1). Lipoplexes were assembled with either 
siGENOME non-targeting siRNA (henceforth referred to as non-targeting siRNA) or 
ON-TARGETplus SMARTpool Human MYC siRNA (henceforth referred to as anti-c-myc 
siRNA) to give a final siRNA concentration of 12 nM (Table 3.8). Transfections were carried out 
in triplicate. Cells were harvested for either total RNA (section 3.2.16.1) or protein (section 
3.2.16.3) 48 h after transfection.  
3.2.16.1 Total RNA extraction 
Total cellular RNA was extracted using TRIzol® Reagent as per manufacturer’s instruction. 
Wells were drained of medium and TRIzol® Reagent (1 ml/well) was added. Cells were drawn 
up and expelled with a pipette, approximately 10 times, to facilitate lysis. The homogenate was 
kept at room temperature for 5 min, and then transferred into a 2 ml RNase-free polypropylene 
microcentrifuge tube, to which chloroform (0.2 ml) was added. The mixture was vigorously 
shaken for 15 s, and rested (room temperature, 3 min). Phase separation was achieved with 
centrifugation (12 000 × g, 4 ˚C, 15 min), in an Eppendorf 5424 R temperature-controlled 
centrifuge (Merck, Darmstadt, Germany). The upper aqueous phase was transferred into another 
microcentrifuge tube and treated (room temperature, 10 min) with 100 % isopropanol (0.5 ml). 
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RNA was deposited as a gel-like pellet after centrifugation (12 000 × g, 4 ˚C, 10 min). The pellet 
was washed by low-speed vortexing (room temperature, 30 s) in 75 % (v/v) ethanol (1 ml) 
followed by centrifugation (7 500 × g, 4 ˚C, 5 min). The ethanol was removed, and the pellet was 
left to air-dry (room temperature, 10 min) in a laminar-flow cabinet. The pellet was resuspended 
in RNase-free water (30 µl) by passing the suspension approximately 5 times through a 
micropipette tip, followed by heating (55 ˚C, 15 min). The NanoDrop 2000c spectrophotometer 
(Thermo Scientific, Wilmington, DE, USA) was used to measure total RNA concentration, and 
assess RNA purity. RNA was obtained in good yield (0.58-0.74 µg/µl) and high purity (A260/A280 
was between 2.03 and 2.11; A260/A230 was between 2.0 and 2.30). The integrity of RNA isolates 
was assessed by agarose gel electrophoresis as described in section 3.2.5.1.3. 28S rRNA, 18S 
rRNA and 5S rRNA/tRNA bands were clearly evident in all instances. Samples were normalised 
to 0.057 µg/µl total RNA with RNase-free water and stored, in aliquots (30 µl), in RNase-free 
tubes, at -80 ˚C, for no more than a month.  
3.2.16.2 RT-qPCR 
3.2.16.2.1 cDNA synthesis 
cDNA synthesis was carried out using the gDNA Clear cDNA Synthesis Kit as per 
manufacturer’s instruction. For a single reaction, the RNA sample (0.8 µg, 14 µl) was mixed 
with a master mix (2 µl) which contained DNase I (0.5 µl) and DNase buffer (1.5 µl) solutions. 
Reaction mixtures (16 µl) were prepared, on ice, in PCR tube strips and reactions were carried 
out in a C1000 Touch™ Thermal Cycler (Bio-Rad Laboratories (PTY) Ltd., Richmond, USA). 
The DNase reaction was performed as follows: DNA digestion (25 ˚C, 5 min), DNase 
inactivation (75 ˚C, 5 min), and samples were maintained at 4 ˚C for 10 min. The RT supermix 
(4 µl) was added and cDNA synthesis was carried out as follows: priming (25 ˚C, 5 min), reverse 
transcription (46 ˚C, 20 min), RT inactivation (95 ˚C, 1 min) and samples were held at 4 ˚C for 
10 min. Two cDNA synthesis reactions per RNA isolate were performed in parallel i.e. one 
reaction containing the RT supermix and a no-RT control in which the no-RT supermix was 
added instead. cDNA samples were diluted to a final concentration of 25 ng/µl in nuclease-free 
water and stored at 4 ˚C, for no more than a week. 
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3.2.16.2.2 RT-qPCR reactions 
The product of each cDNA synthesis reaction was subjected to RT-qPCR. A single reaction 
mixture (20 µl) contained the following: SsoAdvanced™ Universal SYBR® Green Supermix 
(10 µl); primers (1 µl) specific for either the target gene, c-myc (PrimePCR™ SYBR® Green 
Assay: MYC, Human) or reference gene, β-actin (PrimePCR™ SYBR® Green Assay: ACTB, 
Human); cDNA sample (25 ng, 1 µl) and nuclease-free water (8 µl). Reaction mixtures in which 
DNA templates (either PrimePCR™ Template for SYBR® Green Assay: MYC, Human; or 
PrimePCR™ Template for SYBR® Green Assay: ACTB, Human; 1 µl) were substituted for 
cDNA served as positive controls. Reaction mixtures in which nuclease-free water (1 µl) was 
substituted for either primers or cDNA were included as negative controls. All reactions were 
performed in triplicate. Reaction mixtures were prepared, on ice, in Hard-Shell® 96-well plates 
and sealed with Microseal® 'B' adhesive seals. Plates were briefly centrifuged and loaded in a 
C1000 Touch™ Thermal Cycler (CFX 96 Touch™ Real-Time PCR Detection System, Bio-Rad 
Laboratories (PTY) Ltd.). Reaction conditions were as follows: activation (95 ˚C, 2 min, 
1 cycle), denaturation (95 ˚C, 5 s, 40 cycles), annealing/extension (60 ˚C, 30 s, 40 cycles), melt 
curve (65 ˚C – 95 ˚C in 0.5 ˚C increments, 5 s/step). Data was analysed with CFX Manager™ 
Software version 3.0 (Bio-Rad Laboratories). c-myc expression was normalised to β-actin using 
the ∆∆Cq comparative quantification algorithm.  
ΔΔCq = ΔCq(test) ‐ ΔCq(calibrator)  
ΔCq(test) = Cq(target, test) ‐ Cq(ref, test)  
ΔCq(calibrator) = Cq(target, calibrator) – Cq(ref, calibrator)  
where Cq denotes quantification cycle, target denotes c‐myc, test denotes treated cells, ref denotes the 
reference gene, β‐actin and, untreated cells served as the calibrator. 
3.2.16.3 Total protein extraction 
Wells were drained of medium and cells were washed twice with ice-cold PBS (1 ml/well). Cold 
(4 ˚C) RIPA buffer (100 µl/well) was added and cells were placed on ice for 5 min on a platform 
shaker (Stuart Scientific STR6, Surrey, UK) operating at 10 rpm. Wells were scraped with a 
micropipette tip and lysates were transferred to a 0.5 ml sterile microcentrifuge tube. Lysates 
were clarified by centrifugation (14 000 × g, 4 ˚C, 15 min) in an Eppendorf 5424 R instrument 
(Merck, Darmstadt, Germany). Supernatants were collected and a small volume (10 µl) of each 
sample was reserved for total protein determination by the BCA assay as described in 3.2.13.2. 
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Protein concentrations were 2.0-2.6 µg/µl. Lysates were stored at -20 ˚C, for no longer than a 
month. 
3.2.16.4 ELISA 
Protein extracts were immobilised onto the wells of a 96-well flat-bottom multi-well plate with 
50 mM carbonate-bicarbonate coating buffer, pH 9.6, at 4 ˚C, overnight. Three replicates per 
isolate were performed. Each well received 10 µg protein in 100 µl coating buffer. The coating 
buffer was removed and wells were rinsed twice with TBS (20 mM Tris-HCl, pH 7.5, 150 mM 
NaCl) containing 0.1 % Tween 20 (TBST, 100 µl/well). Wells were treated (room temperature, 
1 h) with 5 % non-fat dry milk in TBST (100 µl) with gentle agitation (10 rpm) on a platform 
shaker (Stuart Scientific STR6, Surrey, UK) to saturate unoccupied attachment sites. The 
blocking agent was removed and wells were rinsed twice with TBST (100 µl/well). Either c-Myc 
(1:2000, in TBST) or β-actin (1:10 000, in TBST) primary antibodies were applied (100 µl/well) 
at room temperature for 1 h. Primary antibodies were removed and wells were washed 4 times 
with TBST (100 µl/well) for 5 min each, with agitation (10 rpm). The secondary antibody 
(1:2000, in TBST) was applied (room temperature, 1 h). Wells were drained and washed 4 times 
with TBST as previously described. TMB (100 µl/well) was applied (room temperature, 30 min). 
The reaction was terminated by the addition of 2 M H2SO4 (100 µl/well) and absorbance was 
measured at 450 nm (Mindray microplate reader, MR-96A, Vacutec, Hamburg, Germany) 
against a mixture of TMB (100 µl) and 2 M H2SO4 (100 µl), as a blank. Wells containing BSA 
(10 µg) were treated in the same way, and served as negative controls. Antibody-free and 
substrate-free controls were also included. Control samples gave negligible corrected absorbance 
(i.e. less than 1 % of the corrected absorbance of untreated cells treated with primary antibody, 
secondary antibody and substrate). c-Myc expression was normalised to β-actin and presented 
relative to untreated cells. 
 
3.2.17 Effects of lipoplex-mediated c-myc inhibition 
The effects of c-myc inhibition on cancer cell migration, proliferation and survival was studied 
under conditions which mirrored those of the gene expression assays (3.2.16).  
3.2.17.1 Wound healing assay 
The wound healing assay was adapted from the method reported by Qin and Cheng (2010). 
Semi-confluent cells in 12-well plates were treated with lipoplexes as per transfection protocol in 
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3.2.11 and quantities shown in Table 3.8. At 24 h post-transfection a sterile 200 µl micropipette 
tip was carefully drawn across the diameter of each well so as to create a single, linear wound 
(t = 0 h). Growth medium was aspirated and cells were rinsed with PBS (0.5 ml/well) to remove 
any dislodged cells. Fresh medium (1 ml/well) was added. The wounds created were observed 
with an inverted fluorescence microscope (CKX41, Olympus, Japan), operating in bright field 
mode, at 100× magnification. Images were captured using Analysis Five Software (Olympus 
Soft Imaging Solutions, Olympus, Japan). Positions were discretely marked on the edges of wells 
to permit re-examination of the same field of view at a later stage. Cells were returned to the 
incubator, and wound closure was monitored 24 h later (t = 24 h). The software facilitated 
measurements of wound area against calibrated images and results were reported as follows: 




3.2.17.2 Growth inhibition assays 
Lipoplexes were introduced to semi-confluent cells in 48-well plates as per transfection protocol 
in 3.2.11 and quantities shown in Table 3.8. At 48 h post-transfection, growth inhibition was 
evaluated by the AB assay as described in section 3.2.12.2.  
3.2.17.3 Apoptosis assay 
Lipoplexes were introduced to semi-confluent cells in 24-well plates as per transfection protocol 
in 3.2.11 and quantities shown in Table 3.8. At 48 h post-transfection wells were drained and 
cells were rinsed with PBS (200 µl/well). Live, apoptotic and necrotic cells were distinguished 
by the AO/EtBr dual staining method adapted from Maiyo et al. (2016). Briefly, cells were 
stained with AO/EtBr solution (100 µg/ml AO and 100 µg/ml EtBr in PBS; 10 µl/well) with 
agitation (30 rpm, 25 ˚C, 5 min) on a platform shaker (Stuart Scientific STR6, Surrey, UK). 
Excess stain was removed by rinsing with PBS (100 µl/well). Cellular changes associated with 
apoptosis were observed with an inverted fluorescence microscope (CKX41, Olympus, Japan) at 
excitation and emission wavelengths of 540 nm and 580 nm, respectively. A minimum of 200 
cells per well was counted at random fields of view. Images were acquired at 200× magnification 
using Analysis Five Software (Olympus Soft Imaging Solutions, Olympus, Japan). Results were 





[total	cells	counted] 	× 	100       
 
3.2.18 Serum tolerance of MS09/Chol (1:1) and MS09/DOPE lipoplexes at 
MS09:siRNA (w/w) = 16:1 
Semi-confluent MCF-7 and HT-29 cells in 96-well plates were treated with lipoplexes (5 µl in 
HBS) assembled with BLOCK-iT™ Fluorescent Oligo, to give a final siRNA marker 
concentration of 12 nM (Table 3.8) in growth medium (100 µl) containing 10, 30 or 50 % (v/v) 
FBS. After 4 h at 37 ˚C, wells were drained and routine cell culture medium was added. At 24 h 
post-transfection, intracellular fluorescence was measured and normalised against soluble protein 
content of cell extracts, as described in section 3.2.13. An AB assay was carried out, as outlined 
in section 3.2.12.2, so as to confirm cell viability under the new transfection conditions. 
 
3.2.19 Statistical analysis 
Statistical analyses were performed using one-way analysis of variance (ANOVA), followed by 
Tukey’s Multiple Comparison Test to compare between groups (GraphPad Prism version 5.04, 




CHAPTER 4 - RESULTS AND DISCUSSION 
4.1 Liposome preparation and characterisation 
An effective anti-c-myc siRNA delivery system, with an uncomplicated design and simple 
preparation method, may pave the way for the development of an economically feasible and 
clinically viable onconanotherapeutic agent. This study has focused on a lipid-based delivery 
agent that is arguably the simplest and easiest to prepare i.e. the traditional cationic liposome 
prepared by lipid film hydration.  
MS09 (Figure 4.1a), a cationic lipid that previously gave good in vitro gene silencing capability 
when formulated into liposomes (Daniels et al., 2013), was the chosen cytofectin. Several 
features of this lipid render it suitable for the development of cationic liposomal siRNA carriers. 
Firstly, the molecule is built upon the rigid cholesterol ring system that permits its stable 
incorporation within a lipid bilayer. Secondly, the tertiary amino headgroup, that is protonated at 
physiological pH, permits electrostatic binding of nucleic acids. Moreover, a spacer of 12 atoms 
promotes interaction with nucleic acids by reducing steric hindrance between the headgroup 
region and cholesterol anchor (Singh and Ariatti, 2006). Finally, the carbamoyl bond, which 
tethers the spacer and headgroup elements to the fused ring system is biodegradable following 
release of the nucleic acid and augurs well for the biocompatibility (Gao and Huang, 1991) of 
MS09 liposomal systems. 
To date, MS09 has only been evaluated in co-formulation with the zwitterionic phospholipid, 
DOPE (Figure 4.1b) (Daniels et al., 2013, Singh and Ariatti, 2006). The cone-shaped 
ethanolamine headgroup favours bilayer transition from the ordered lamellar to inverted 
hexagonal phase, and this is advantageous during cellular uptake, release and endosomal escape 
of nucleic acids. As such, DOPE is a commonly used helper lipid in cationic liposome 
formulations (Mochizuki et al., 2013). However, DOPE-containing liposomes may not be 
suitable for intravenous administration. Li and coworkers (1999) demonstrated early on that 
DOPE-containing cationic liposomes rapidly disintegrate upon exposure to serum. This can be 
attributed to the fact that DOPE, which has ionisable groups can interact with serum proteins, 
and this inhibits its activity (Yang et al., 2013). Nonetheless an equimolar mixture of MS09 and 
DOPE, that previously proved effective in in vitro siRNA delivery (Daniels et al., 2013) was 









Figure 4.1: Ball and stick models of lipids a) MS09, b) DOPE, c) Chol and d) DSPE used in liposome 
formulations. In a) the spacer length reported was measured as the internuclear distance between the 
atoms indicated. In d) the yellow arrow shows the point of attachment of the PEG2000 chain to the DSPE 
molecule. Models were generated using ACD/3D Viewer (Advanced Chemistry Development, Inc. 










spacer length = 16.079 Å 
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Early studies showed that the incorporation of Chol (Figure 4.1c) with phospholipids at 
30 mol % or more resulted in the formation of a phase-separated region in the lipid bilayer 
(Huang et al., 1974). This property of Chol liposomes, in the absence of other helper lipids, 
becomes more pronounced with increasing Chol content, and prevents adverse liposome-protein 
interactions, aggregation, improves mechanical strength and stability (Epand et al., 2003, Huang 
et al., 1974) and can extend circulation time in vivo (Semple et al., 1996). 
The effect of increasing Chol content in MS09 liposomes was studied. Liposomes were 
formulated with MS09 and Chol at molar ratios of 1:1, 1:2 and 1:3. Higher ratios were not 
explored, as it was reasoned that incorporating Chol at higher concentrations would reduce the 
number of cytofectin molecules present in the bilayer by more than 60 %. This is a dramatic 
reduction in the number of cationic centres available for siRNA binding. A further consideration 
was that groups which have focused on studying the effect of high Chol content in cationic 
liposome formulations, before the current study was initiated, had done so within the context of 
plasmid DNA (pDNA) delivery only (Yang et al., 2013, Zhang and Anchordoquy, 2004). Given 
that siRNA is markedly smaller than pDNA, it cannot condense further (Spagnou et al., 2004) 
and a larger quantity of liposome is required to bind a fixed quantity of siRNA when compared 
with pDNA (Zhang et al., 2010); Chol content did not exceed 75 mol % in this study. Chol 
concentration below 50 mol % was not investigated in light of the established correlation 
between high Chol content and improved stability of liposomes formulated with a monocationic 
cholesteryl cytofectin, DC-Chol (Yang et al., 2013). 
Transmission electron micrographs show that MS09/DOPE and MS09/Chol (1:1) formulations 
formed unilamellar vesicles. Vesicles of the MS09/DOPE suspension were predominantly round 
(Figure 4.2a), similar to those reported by Daniels et al. (2013). However, substitution of DOPE 
with Chol at the same molar ratio gave some irregularly shaped vesicles (Figure 4.2b). 
Formulations with greater Chol content appeared poorly hydrated and visibly settled out of 
suspension even with extended sonication time. Consequently, images of these formulations 




Figure 4.2: Transmission electron micrographs of non-pegylated cationic liposomes: a) MS09/DOPE, 
b) MS09/Chol (1:1), c) MS09/Chol (1:2), d) MS09/Chol (1:3). Liposome suspensions were stained with 
uranyl acetate and cryopreserved prior to viewing.  
 
Steric stabilisation of liposomes through pegylation was attempted. The simplest method of 
PEG-modification, pre-pegylation, in which PEG chains are attached to the liposomal bilayer 
prior to the introduction of siRNA molecules, was opted for. This is in keeping with one of the 
main themes of the study i.e. to maintain simplicity of carrier design and preparation. Several 
issues were taken into consideration with regard to polymer size, the nature of the PEG-lipid 
conjugate and the amount of PEG-lipid incorporated in liposome formulations. Firstly, pegylated 
lipid derivatives have micelle forming tendencies and this imposes a limit on the concentration at 
which these lipids can be stably incorporated in liposomal bilayers. As the length of a PEG chain 
attached to a hydrocarbon skeleton increases, so too does the ratio of the polar region of the lipid 
relative to its apolar component; and this disturbs the organisation of the bilayer (Photos et al., 










chosen in the form of a commonly used DSPE (Figure 4.1d) lipid conjugate known to stabilise 
the lamellar phase of the bilayer (Che et al., 2015). The commercially available PEG-lipid, 
DSPE-PEG2000, employed in this study has served as a component of the first Food and Drug 
Administration-approved anti-cancer liposomal drug, and is therefore favourable in terms of 
safety and biocompatibility (Allen and Cullis, 2013). A further concern with regard to pre-
pegylation is that the presence of polymer chains on the surface may shield cationic groups and 
hinder the binding of siRNA (Daniels et al., 2013, Zhang et al., 2010). Finally, too high a PEG 
density can interfere with the lipoplex-cell association necessary for cellular uptake (Deshpande 
et al., 2004). 
Buyens et al. (2012) commented that if siRNA molecules are to be complexed with liposomes 
through simple mixing, liposomes should have low PEG densities. In the interest of achieving a 
balance between liposome stability and siRNA-binding through pre-pegylation, DSPE-PEG2000 
was incorporated at what has come to be accepted as a commonly employed concentration for 
both in vitro and in vivo use i.e. 2 mol % (Betker et al., 2013a). At this concentration, PEG 
assumes what is referred to as the “mushroom” conformational regime, in which the polymer 
forms isolated grafts on the bilayer surface. Unlike the “brush” configuration, achieved with 
greater than 5 mol % PEG-lipids, in which polymer chains interact to form a dense hydrated 
network around the liposome; pegylation at 2 mol % permits partial exposure of the bilayer (de 
Gennes, 1980). 
Pegylated MS09/DOPE and MS09/Chol (1:1) formulations formed stable suspensions upon lipid 
film hydration. While tubular vesicles were evident in the MS09/DOPE/PEG suspension 
(Figure 4.3a), the MS09/Chol/PEG (1:1) formulation gave vesicles (Figure 4.3b) which largely 
resembled its non-pegylated counterpart. It is likely that the membrane rigidity conferred by 
Chol, resulted in vesicles that were more resistant to distortion upon the incorporation of a 
relatively small amount of DSPE-PEG2000. 
Pegylated suspensions of MS09/Chol (1:2) and MS09/Chol (1:3) formulations were more readily 
hydrated than their non-pegylated counterparts. Electron micrographs show some unilamellar 
vesicles in both instances (Figure 4.3c,d). However, particles did settle out of suspension after 
two days at 4 ˚C. Hence 2 mol % pegylation failed to abolish the inherent instability of these 
formulations. It appears that unlike the cytofectins DOTMA and DC-Chol, which reportedly 
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formed stable suspensions with up to 80 mol % Chol (Yang et al., 2013, Zhang and 
Anchordoquy, 2004), MS09 is incompatible with more than 50 mol % Chol.  
 
Figure 4.3: Transmission electron micrographs of pegylated cationic liposomes: a) MS09/DOPE/PEG, 
b) MS09/Chol/PEG (1:1), c) MS09/Chol/PEG (1:2), d) MS09/Chol/PEG (1:3). Samples were stained with 
uranyl acetate and cryopreserved prior to viewing.  
 
It appears that stable incorporation of high Chol concentrations is dependent on the interaction of 
Chol with other lipids in the formulation. This notion is supported by an early study with 
pegylated distearoylphosphatidylcholine/Chol liposomes in which high Chol content gave 
fragile, unstable nanoparticles (Maruyama et al., 1992). The incorporation of higher DSPE-
PEG2000 concentrations was not attempted in accordance with the poor siRNA-binding, cellular 
uptake and gene silencing that others have observed with pre-pegylated cationic liposomes 











Liposome preparations were characterised according to size and zeta potential by Z-NTA 
(Figure 4.4a,b). NTA is a recent addition to nanoparticle characterisation. The NTA system 
calculates hydrodynamic diameter by tracking the movement of individual particles in a 
suspension. This provides a more accurate representation of particle size than was possible with 
the intensity-weighted measurements obtained by traditional light scattering techniques (Wilson 
and Green, 2017). Combination of NTA instrumentation with a zeta module i.e. an 
electrophoresis system to apply current to the sample, allows zeta potential to be simultaneously 
measured (Griffiths et al., 2011). 
The visible instability of the MS09/Chol (1:2) and MS09/Chol (1:3) formulations was 
corroborated by the Z-NTA data. The general acceptance is that nanoparticles with zeta 
potentials between +30 and -30 mV are predisposed towards aggregation over time. In both 
instances, particles greater than 300 nm in size were detected with zeta potentials close to zero, 
and this is a clear indication of aggregation tendencies (Griffiths et al., 2011). While PEG-
modification is known to increase the hydrodynamic diameter of nanoparticles and reduce zeta 
potential due to charge shielding (Tomasetti et al., 2016), visible settling of the pegylated 
MS09/Chol (1:2) and MS09/Chol (1:3) formulations cannot be ignored. 
Further proof of vesicle aggregation was obtained from NTA-derived concentration estimates. 
The particle concentration of suspensions with more than 50 mol % Chol was roughly an order 
of magnitude less than that of liposomes formulated from MS09 and Chol in equimolar 
quantities (Figure 4.4c). In contrast, the concentration of MS09/DOPE, MS09/DOPE/PEG, 
MS09/Chol (1:1) and MS09/Chol/PEG (1:1) suspensions, all of which are statistically similar in 
size and zeta potential, did not differ significantly (P > 0.05, for all comparisons).  
Given that the final lipid concentration of all formulations was kept constant, i.e. 8 mM, and, that 
many more lipid molecules would be involved in the formation of large structures as opposed to 
smaller ones, it follows that the particle concentration of pegylated and non-pegylated 
MS09/Chol (1:2) and MS09/Chol (1:3) formulations is much lower than those that were able to 









































































































































Figure 4.4: Liposome a) size, b) ζ potential and c) vesicle concentration, according to Z-NTA. Each column 




With regards to the stable preparations i.e. MS09/DOPE, MS09/DOPE/PEG, MS09/Chol (1:1) 
and MS09/Chol/PEG (1:1), liposome size was far below 200 nm and sufficient to be classified as 
small unilamellar vesicles. While there were no significant differences in size or zeta potential 
across the four preparations, electron micrographs suggest that pegylated vesicles may, in fact, 
be smaller. Here again, the contribution of the hydrophilic PEG-chains, which can extend away 
from the bilayer into the external aqueous environment, to the hydrodynamic radius of a vesicle 
(Tomasetti et al., 2016) provides a likely explanation for the similar sizes of pegylated and non-
pegylated vesicles. It appears that substitution of DOPE with Chol at the same molar ratio had no 
significant effect on size or zeta potential. In this regard, Yang and colleagues (2013) commented 
that Chol is not likely to influence the electrical surface potential of liposomes because it does 
not bear an ionisable group. 
Of note is the fact that all formulations gave negative zeta potentials, contrary to what is 
expected of cationic carriers. Zeta potential measurements are based on the interaction of the 
particle with ions in the medium in which it is dispersed. Therefore, the composition of the 
dispersant influences the zeta potential of a suspended particle. In this instance liposomes were 
dispersed in HEPES buffer. Zwitterions such as HEPES can influence the zeta potential of a 
bilayer depending on the orientation of the molecule’s ionisable groups relative to the membrane 
(Koerner et al., 2011) in the electrical double layer, and this could possibly account for the 
Z-NTA measurements obtained. Therefore, in this instance, negative zeta potential values do not 
necessarily imply that the liposomes would be unable to associate with siRNA molecules. Hence, 
siRNA-binding studies with MS09/Chol (1:1), MS09/Chol/PEG (1:1), MS09/DOPE and 
MS09/DOPE/PEG formulations was carried out. 
 
4.2 siRNA-binding studies 
The gel retardation assay is widely documented as the first step in assessing the siRNA-binding 
capability of cationic lipid-based carriers (Ceballos et al., 2010, Dorasamy et al., 2012, 
Han et al., 2008, Suh et al., 2009). This assay is based on the premise that the migration of 
siRNA on agarose gel is retarded in an electric field when bound to the carrier due to the 
formation of large electroneutral complexes that are unable to permeate the gel matrix. 




   
 
Figure 4.5: Gel retardation study of the binding interactions between siRNA and cationic liposomes. 
Incubation mixtures (10 μl) contained siRNA (0.3 μg) and varying amounts of liposome to correspond 
with increasing amounts of cytofectin. a) MS09/DOPE, lanes 1-8 ( 0, 1.4, 2.8, 4.2, 5.6, 7.0, 8.4, 
9.8 μg MS09); b) MS09/Chol (1:1), c) MS09/DOPE/PEG, d) MS09/Chol/PEG (1:1), lanes 1-8 (0, 2.8, 4.2, 
5.6, 7.0, 8.4, 9.8, 11.2 μg MS09).  
 
As the amount of liposome relative to siRNA was increased across lanes 2 to 8, more siRNA 
became liposome associated. This was observed as a gradual decrease in the intensity of the 
siRNA band that migrated into the gel, accompanied by siRNA retained in the wells in the form 
of lipoplexes. Fluorescence in the wells (Figure 4.5a, lanes 4-8) is indicative of intact siRNA that 
has formed complexes with liposomes. In this study, MS09/DOPE was the only formulation to 
fully prevent the electrophoretic migration of siRNA. 
Figures 4.5b-d show that although the expected gradual decrease in unbound siRNA was 
observed with increasing liposome content, with respect to the MS09/Chol (1:1), 
MS09/DOPE/PEG and MS09/Chol/PEG (1:1) formulations, unbound siRNA was evident at all 





in these instances, it is possible for the lipoplexes to have floated out of the well and into the 
electrophoresis buffer. Together with densitometric analysis (Figure 4.6), it appears that the 
binding of siRNA by these liposome formulations increased up until a point, whereupon free 
siRNA in the gel persisted despite further addition of liposome. This MS09:siRNA (w/w) ratio 
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Figure 4.6: siRNA-binding capacity of liposome formulations at varying MS09:siRNA (
w
/w) ratios, as 
determined by densitometry following gel retardation electrophoresis. Data is presented as the 
mean ± SD (n = 3). The point at which each formulation best bound siRNA is indicated by an arrow. 
###
P < 0.001 vs. non-pegylated counterpart, 
●●●
P < 0.001 vs. DOPE-containing counterpart at the 
respective MS09:siRNA (
w
/w) ratio at which maximum siRNA was bound. 
 
Densitometry showed that, for pegylated preparations, the amount of free siRNA in the gel, 
beyond the point of maximum binding, was nearly constant. However, in the case of the 
MS09/Chol (1:1) formulation, an increase in liposome content beyond end-point was 
accompanied by a decrease in the amount of liposome-bound siRNA. A similar aberration in 
siRNA binding patterns was observed by Khatri and coworkers (2014) at high lipid:siRNA 
ratios. This group suggested that, in some instances, incomplete charge titration at very high 
ratios may attract additional siRNA as a second, more loosely bound layer around the liposome 
and this is observed as an increase in free siRNA on agarose gel. 
 81 
 
The association of siRNA with liposomes was also studied in fluorescence quenching assays. In 
this set of experiments, one of two nucleic acid intercalating dyes, either EtBr or SYBR Green II, 
was employed. The assays are based on the concept that the dyes fluoresce strongly when 
associated with siRNA, but are displaced with the addition of cationic liposomes which bind to 
the siRNA. Dye displacement is manifested as a drop in fluorescence. Upon successive addition 
of liposome, fluorescence is gradually quenched. Eventually a point of inflection, which 
represents complete or maximum siRNA-binding, is reached when fluorescence stabilises 
irrespective of further addition of liposome. Figure 4.7 shows that all four liposomes in this study 
were able to displace the siRNA-associated dyes, albeit to different extents, depending on their 
affinity for siRNA. Had the observed drop in fluorescence occurred as a result of siRNA 
degradation rather than complex formation, it is likely that fluorescence readings would have 
eventually approximated the baseline measurements that were taken prior to the introduction of 
siRNA in incubation mixtures. As suggested by gel retardation experiments, the MS09/DOPE 
formulation demonstrated the best siRNA-binding capability. Although the points of inflection 
for dye displacement assays of MS09/Chol (1:1) and MS09/DOPE/PEG were attained at the 
same and marginally lower MS09:siRNA (w/w) ratios respectively, MS09/DOPE achieved the 
greatest degree of dye displacement. 
The maximum dye displacement (Table 4.1) and the MS09:siRNA (w/w) ratio at which this value 
was recorded (Table 4.2) for individual liposome formulations, using both dyes, were in good 
agreement. However, points of inflection were more clearly defined in assays in which SYBR 
Green II served as the intercalating dye. This could be explained by the fact that SYBR Green is 








































































Figure 4.7: Dye displacement assays of liposome formulations. Incubation mixtures contained HBS, 
siRNA (1 μg) and either a) EtBr or b) SYBR Green II. Liposomes were introduced stepwise, in aliquots 
(1 μl). Data is shown as the mean ± SD (n = 3). The point of inflection i.e. maximum siRNA-binding, in 
each case, is shown by an arrow. 
###
P < 0.001 vs. non-pegylated counterpart, 
●●●
P < 0.001 vs. DOPE-containing counterpart at point of inflection.
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Table 4.1: Maximum dye displacement achieved by liposome formulations 
Liposome formulation 
Maximum dye displacementa (%) 
EtBrb  SYBR Green IIb,c 
MS09/DOPE 54.3 ± 0.1 57.4 ± 1.6 
MS09/Chol (1:1) 38.9 ± 0.8 42.3 ± 3.2 
MS09/DOPE/PEG 49.4 ± 0.1 50.3 ± 1.8 
MS09/Chol/PEG (1:1) 32.2 ± 0.1 35.3 ± 1.3 
Notes: 
aMaximum dye displacement (%) = 100 % – relative fluorescence (%) recorded at point of inflection 
bEach value represents the mean ± SD (n = 3) 
cIn all instances, P > 0.05 for maximum dye displacement recorded as per SYBR Green II displacement vs. EtBr displacement 
 
Table 4.2: Comparison of gel retardation and dye displacement assays in evaluating liposome siRNA-binding capability 
Liposome formulation 
Point of maximal siRNA-binding 
Gel retardation assaya 
Dye displacement assays 

























MS09/DOPE 52.4:1 24.0:1 13.0:1 27.5:1 12.6:1 6.8:1 27.5:1 12.6:1 6.8:1 
MS09/Chol (1:1) 32.2:1 20.0:1 10.8:1 20.3:1 12.6:1 6.8:1 20.3:1 12.6:1 6.8:1 
MS09/DOPE/PEG 56.8:1 24.0:1 13.0:1 29.1:1 12.3:1 6.7:1 29.1:1 12.3:1 6.7:1 
MS09/Chol/PEG (1:1) 50.3:1 28.0:1 15.2:1 26.5:1 14.8:1 8.0:1 26.5:1 14.8:1 8.0:1 
Note: 
aThe point of maximal-binding reported is as per densitometric analysis of agarose gels 
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Often, dye displacement assays are performed in conjunction with gel retardation assays to 
provide supporting information (Dorasamy et al., 2012, Naicker et al., 2014, Singh and Ariatti, 
2006). However, in this study, the assays were in poor agreement. Table 4.2 shows that 
MS09:siRNA (w/w) ratios at which maximum siRNA-binding was obtained by gel retardation 
were roughly twice those obtained by dye displacement. This discrepancy, as well as the 
apparent incomplete siRNA-binding observed by gel retardation, may be accounted for by the 
fact that siRNA can be coaxed off a fully-formed nanoparticle under conditions of 
electrophoresis, due to weak siRNA-carrier interactions (Hattori et al., 2013, Hattori et al., 
2014). Therefore, according to Hattori and colleagues (2013), it can be accepted that siRNA 
lipoplexes are fully-formed at MS09:siRNA (w/w) ratios above that at which maximum dye 
displacement was recorded. Nonetheless, both assays showed similar trends in the comparative 
siRNA-binding capabilities of the four formulations i.e. 
MS09/DOPE > MS09/DOPE/PEG > MS09/Chol (1:1) > MS09/Chol/PEG (1:1). 
The aforementioned comparative siRNA-binding capabilities were further corroborated by 
considering the effect of increasing ionic strength on liposome-siRNA interactions (Figure 4.8). 
Given that the interaction between siRNA and cationic liposomes is electrostatic, excess 
counterions in solution disturbs this association and causes release of siRNA. siRNA release was 
monitored, through its interaction with the SYBR Green II dye, as an increase in fluorescence; 
and the ability of lipoplexes to resist destabilisation by NaCl was taken as a measure of the 
strength of the liposome-siRNA interaction. MS09/DOPE, which demonstrated the best binding 
affinity, required more NaCl than the other formulations to weaken the liposome-siRNA 
interaction, and released less siRNA at the highest concentration explored. Release of siRNA by 
MS09/Chol (1:1) and MS09/DOPE/PEG formulations was initiated at the same point i.e. 
320 mM NaCl. However, the extent of lipoplex destabilisation at this point, as evidenced by the 
difference in relative fluorescence increase, was greater (P < 0.05) with MS09/Chol (1:1); and 
this indicates a comparatively weaker association with siRNA. As expected, the 
MS09/Chol/PEG (1:1) formulation, which showed the weakest siRNA-binding capability, was 












































Figure 4.8: The effect of increasing ionic strength on liposome-siRNA interactions. Changes in 
fluorescence were monitored after stepwise addition of 5 M NaCl to a mixture of SYBR Green II and 
lipoplexes in HBS. Lipoplexes were assembled at the following MS09:siRNA (
w/w) ratios: MS09/DOPE, 
12.6:1; MS09/Chol (1:1), 12.6:1; MS09/DOPE/PEG, 12.3:1; and MS09/Chol/PEG (1:1), 14.8:1. Each point 
represents the mean ± SD (n = 3). A significant increase in relative fluorescence compared with the initial 
SYBR Green II-lipoplex mixture at 150 mM NaCl was taken as the point at which lipoplex destabilisation 
was initiated, and is indicated by an arrow.
 **
P < 0.01 vs. relative fluorescence increase at 150 mM 
NaCl; P < 0.05 vs. MS09/DOPE, #P < 0.05 vs. non-pegylated counterpart, ●P < 0.05 vs. DOPE-containing 
counterpart, at 400 mM NaCl. 
 
Consistent with data obtained in related studies (Daniels et al., 2013, Zhang et al., 2010), all 
assays reported thus far show that pegylation of liposomes reduced siRNA-binding affinity. This 
is because, PEG chains, when tethered to the liposomal bilayer, may conceal cationic groups on 
the surface (Zhao and Song Zhuang, 2011), and this can impede the association with the siRNA 
molecules. In fact, Zhang and colleagues (2010) showed that the incorporation of as little as 
1 mol % PEG with a DC-Chol/DOPE formulation, gave liposomes which did not completely 
retard the migration of siRNA on agarose gel. 
Interestingly, replacing DOPE with Chol at the same molar ratio in MS09 formulations had a 
more profound effect on siRNA-binding than the incorporation of 2 mol % PEG. That is, the 
siRNA interaction with MS09/Chol (1:1) was weaker than that displayed by both MS09/DOPE 
and MS09/DOPE/PEG liposomes. It is possible that Chol may have induced arrangement of 
cytofectin molecules during vesicle formation, such that a greater number of cationic centres 
were positioned inwards rather than on the surface of the bilayer. A further explanation may arise 
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from the fact that Chol is a more rigid lipid than DOPE and results in liposomal bilayers that are 
less malleable. Therefore, during the process of lipoplex formation, the Chol-containing 
liposomes may not change conformation as easily as their DOPE-containing counterparts to 
completely encompass siRNA molecules. This could result in residual or poorly-associated 
siRNA that can easily migrate in an agarose gel or associate with an intercalating dye. In relation 
to this, an early study with DOTAP/Chol liposomes demonstrated that Chol widened the 
interlamellar spaces of the resultant lipoplexes and, as such, reduced the association with ASOs 
(Weisman et al., 2004). 
However, a weak liposome-siRNA interaction does not necessarily imply that the formulation in 
question will perform poorly overall and does not provide sufficient grounds to prevent its 
further testing. In some instances, weakly bound siRNA may be more easily released from the 
lipoplex within the cell, to give better transfection activity - provided that the liposome can 
adequately protect its cargo, the lipoplex remains stable in circulation and has the appropriate 
physical characteristics to permit cellular entry, among other factors (Nguyen et al., 2008). For 
this reason, all four formulations were evaluated further. Prior to performing the siRNA-binding 
studies, the aim was to clearly establish the minimum amount of liposome required for total 
binding of a fixed amount of siRNA, and to apply this optimum MS09:siRNA (w/w) ratio to the 
subsequent experiments. To compensate for the lack of a clear end-point in the gel retardation 
assays, and its poor correlation with the fluorescence quenching experiments, it was decided that 
liposome-siRNA complexes prepared across a range of MS09:siRNA (w/w) ratios i.e. 12:1-32:1, 
encompassing end-points obtained with both gel retardation and dye displacement assays, would 
be evaluated further. 
 
4.3 Lipoplex characterisation 
Electron microscopy gave visual proof of the formation of liposome-siRNA complexes with all 
four formulations at all MS09:siRNA (w/w) ratios explored. Figures 4.9-4.12 show that, overall, 
lipoplexes assumed structures that were different from the liposomal vesicles shown in 
Figures 4.2a,b and 4.3a,b, and emphasise the heterogeneity of the liposome-siRNA complexes. 
This is a consequence of the way in which liposomes and siRNA assemble to form lipoplexes.  
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Figure 4.9: Transmission electron micrographs of MS09/DOPE lipoplexes assembled at MS09:siRNA (
w/w) 
ratios of a) 12:1, b) 16:1, c) 20:1, d) 24:1, e) 28:1 and f) 32:1. The black arrow shows a bilamellar lipoplex 
structure.  
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Figure 4.10: Transmission electron micrographs of MS09/Chol (1:1) lipoplexes assembled at 
MS09:siRNA (
w/w) ratios of a) 12:1, b) 16:1, c) 20:1, d) 24:1, e) 28:1 and f) 32:1. The black arrow shows a 
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Figure 4.11: Transmission electron micrographs of MS09/DOPE/PEG lipoplexes assembled at 
MS09:siRNA (
w/w) ratios of a) 12:1, b) 16:1, c) 20:1, d) 24:1, e) 28:1 and f) 32:1. The black arrow indicates 
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Figure 4.12: Transmission electron micrographs of MS09/Chol/PEG (1:1) lipoplexes assembled at 
MS09:siRNA (
w/w) ratios of a) 12:1, b) 16:1, c) 20:1, d) 24:1, e) 28:1 and f) 32:1. The white and black 

















Research by Desigaux et al. (2007) and Geusens et al. (2009) suggested that, during lipoplex 
formation, the siRNA is sandwiched between successive lipid bilayers to form multilayered 
structures. Bilamellar structures were observed with all formulations at high MS09:siRNA (w/w) 
ratios (Figures 4.9d, 4.10d, 4.11d, 4.12f). However, the most prominent siRNA lipoplex 
structures noted in this study were irregular aggregates of smaller vesicles (for example, 
Figures 4.9a,b,c) that were similar to those reported by others (Daniels et al., 2013, Dorasamy et 
al., 2012). 
Structures that resembled liposomal vesicles were observed in some MS09/Chol/PEG (1:1) 
lipoplex suspensions (Figure 4.12a,b,e). While it is possible for free liposomes to exist when the 
relative proportion of lipid to nucleic acid is high in a lipoplex suspension (Xu et al., 1999), this 
does not account for their presence at the lower MS09:siRNA (w/w) ratios of 12:1 and 16:1. A 
possibility was presented by Khatri and coworkers (2014) who showed that pegylated 
DOTAP/DOPE/hydrogenated soybean phosphatidylcholine/Chol liposomes permitted only a 
single monolayer interaction with siRNA and assumed spherical, unilamellar structures. This 
indication of surface-attachment of siRNA on the liposomal bilayer is additional proof of the 
weak binding interaction between MS09/Chol/PEG (1:1) liposomes and siRNA. 
Collectively, the aforementioned published works show that differences in liposome 
composition, the behavior of individual lipids and the relative proportions of liposome and 
siRNA are important factors governing the structures that are formed when liposomes associate 
with siRNA. Consistent with these studies, the lipoplex morphology observed varied according 
to the liposome formulation involved and the MS09:siRNA (w/w) ratio at which the lipoplexes 
were assembled. 
Besides lipoplex morphology, size and zeta potential represent two important physical 
parameters by which lipoplexes are characterised. As discussed in a review of lipid-based siRNA 
delivery by Schroeder and colleagues (2010) , these properties are valuable as determinants of 
lipoplex performance because they impact on the circulation time of lipoplexes in the body, 
accumulation at target sites, interaction with cells, the efficacy of cellular uptake and, ultimately, 
gene silencing activity. The size and zeta potential of lipoplexes as measured by Z-NTA is 















































































































































Figure 4.13: Characterisation of lipoplexes by Z-NTA. The a) size, b) ζ potential and c) concentration of 
lipoplexes assembled at varying MS09:siRNA (
w/w) ratios was measured. For comparative purposes, liposome 
concentrations plotted represent vesicle concentrations in incubation mixtures (10 μl) for the preparation of 





P < 0.01, 
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P < 0.001 vs. non-pegylated counterpart; 
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P < 0.001 vs. DOPE-containing counterpart.  
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The association of liposomal vesicles and change in conformation of cationic bilayers upon 
siRNA binding often produces complexes that are larger in size than the free liposomal vesicles 
(Desigaux et al., 2007, Geusens et al., 2009, Weisman et al., 2004). While cryo-TEM gave 
visual proof of changes in vesicle morphology upon lipoplex formation, all lipoplexes were not 
significantly different in size from the parent liposomal vesicles, with the exception of 
MS09/DOPE lipoplexes at MS09:siRNA (w/w) ratios of 28:1 and 32:1. This could be ascribed to 
the particle sizing technique employed in this study. In general, earlier studies relied on light 
scattering techniques which are known to give size measurements that are more representative of 
larger particles in a sample. This is especially true of samples with high heterogeneity, such as 
lipoplexes. NTA, however, which provides number-weighted measurements, is free from such 
bias and better suited for determining lipoplex size (Wilson and Green, 2017). 
Although the addition of siRNA to liposomes, in most instances, did not appear to alter particle 
size, it did have a bearing on nanoparticle concentration (Figure 4.13c). The value of 
nanoparticle concentration as an additional parameter for the characterisation of lipid-based 
nanoparticles was recently demonstrated (de Morais Ribeiro et al., 2018). In this study, 
noticeable differences between the concentration of lipoplex and parent liposome suspensions 
confirmed an interaction between liposomes and siRNA, and provided information that 
correlates with cryo-TEM characterisation. A significant reduction in particle number upon 
introduction of siRNA to a fixed volume of liposome suggests the involvement of several 
vesicles in the formation of a single siRNA lipoplex (Table B4, Appendix B). This supports the 
observed morphologies of lipoplexes as composites of smaller vesicles and bilamellar structures. 
The only instances in which lipoplex concentration was statistically similar to that of the parent 
liposome, were MS09/Chol/PEG (1:1) complexes at MS09:siRNA (w/w) ratios of 12:1, 16:1 and 
28:1. Interestingly, these were the lipoplex suspensions in which “free” vesicles were evident by 
cryo-TEM (Figure 4.12a,b,e). Concentration measurements of these suspensions support the 
previously mentioned possibility of large numbers of single vesicles to which siRNA is likely to 
be surface-attached. 
It is clear that NTA and cryo-TEM provided complementary data towards complete 
characterisation of lipoplexes. However, representations of particle size were often in poor 
agreement. Some representative lipoplexes appeared either larger (for example, Figures 4.9a,b; 
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4.10a,b) or smaller (for example, Figure 4.12d) than the NTA measurements indicate. This is 
mainly because TEM gives a limited view of the sample. Even multiple images of a sample at 
different positions on a TEM grid may fail to provide as accurate a representation of particle size 
as NTA, which resolves and accounts for individual particles. Furthermore, it is possible for 
samples to either spread out or shrink on the grid during sample preparation (Almgren et al., 
2000). Although cryo-TEM does provide very useful information regarding the structure of 
siRNA lipoplexes (Kuntsche et al., 2011), particle sizes are likely to be inaccurately represented  
if a study relies on cryo-TEM alone (Gaumet et al., 2008). 
All lipoplexes were below 200 nm in size (Figure 4.13a). More specifically, all lipoplexes were 
smaller than 150 nm with the exception of MS09/DOPE lipoplexes assembled at 
MS09:siRNA (w/w) ratios of 24:1-32:1, and MS09/Chol/PEG (1:1) lipoplexes at the 
MS09:siRNA (w/w) ratio of 20:1. This is of importance for passive targeting of tumour cells via 
the enhanced permeability and retention (EPR) effect, a strategy that takes advantage of the 
irregularities of tumour vasculature for the accumulation of therapeutic nanoparticles. This 
approach is primarily based on designing nanoparticles of suitable size such that they will not 
pass through the tight junctions of normal blood vessels, but can access tumour cells by passing 
through their more permeable vasculature, and are retained because of reduced lymphatic 
drainage (Greish, 2010). In a review of liposome-based systems for systemic delivery, Buyens 
and coworkers (2012) stated that lipoplexes greater than 150 nm can easily accumulate in 
tumours. In a more recent publication, 200 nm was reported as the general upper limit for tumour 
cell entry via EPR (Kobayashi et al., 2014). While, this augurs well for the performance of these 
lipoplexes, their ability to maintain a small size in a biological system is a significant factor 
governing their overall efficacy. 
Like the free liposome suspensions, all lipoplexes displayed negative zeta potential which ranged 
from –16 mV to -44 mV (Figure 4.13b). Although it is accepted that the net positive charge of 
lipoplexes allows for binding to anionic membrane-associated proteoglycans to initiate cellular 
uptake (Mislick and Baldeschwieler, 1996), it is also possible for siRNA lipoplexes with 
negative zeta potential to enter cells and successfully facilitate gene silencing. Resina and 
colleagues (2009) showed that cells take up anionic lipoplexes through an energy independent 
pathway and hypothesised that this occurred via lipid exchange at the plasma membrane. More 
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recently, however, Kapoor and colleagues showed that siRNA lipoplexes with negative zeta 
potentials were internalised by breast cancer cells via endocytosis and, that cellular uptake was 
dependent upon the activity of microtubules and actin (Kapoor and Burgess, 2013, Kapoor and 
Burgess, 2012). In fact, negatively charged lipid-based siRNA nanocomplexes may be useful as 
they can avoid aggregation through interaction with erythrocytes and anionic proteins in 
biological fluids, and have also been associated with lower toxicities than complexes that carry a 
net positive charge (Hattori et al., 2014, Tagalakis et al., 2014). Hence, the physical properties 
displayed by the lipoplexes under investigation thus far warrant further assessment. 
 
4.4 Assessment of batch-to-batch variation 
Lipid-film hydration is among the simplest methods by which liposomes can be prepared 
(Zhang, 2017). To assess whether or not this method can yield liposome suspensions of 
consistent quality, the effect of batch-to-batch variation on the physical characteristics and 
siRNA-binding ability of liposomes was studied. Z-NTA data (Figure 4.14) showed that there 
was no significant difference in the size, zeta potential and vesicle concentration of 
independently prepared batches of the same liposome formulation. Figure 4.15 shows that 
maximum dye displacement and the MS09:siRNA (w/w) ratio at which this was achieved was 
consistent across all three batches of a given formulation. The results suggest that the pegylated 
and non-pegylated MS09/DOPE and MS09/Chol (1:1) formulations can be reproducibly 
prepared by lipid-film hydration under standard laboratory conditions. Importantly, this confirms 
that data generated from the preparation of additional liposomes, as was required during the 


















































































































































Figure 4.14: Effect of batch-to-batch variation on vesicle a) size, b) ζ potential and c) concentration of 
liposome suspensions. Each column represents the mean ± SD (n = 3). In all instances, P > 0.05 with respect to 





























































































































































Figure 4.15: Effect of batch-to-batch variation on siRNA-binding capability of liposomes a) MS09/DOPE, b) MS09/Chol (1:1), c) MS09/DOPE/PEG 
and d) MS09/Chol/PEG (1:1). siRNA-binding was assessed by the SYBR Green dye displacement assay. Each point represents the mean ± SD 
(n = 3). In each case, an arrow indicates the point of inflection. P > 0.05 with respect to the following: Batch 2 and 3 vs. Batch 1, and Batch 3 vs. 
Batch 2, at point of inflection.
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4.5 Liposome storage stability studies 
In a recent review of liposomes for drug delivery, Yadav et al. (2017) commented that the shelf-
life and stability of a liposome suspension has a bearing on its suitability as a pharmaceutical 
agent. Often, in order to achieve a thermodynamically favourable state, liposomal vesicles 
aggregate when stored, and this can reduce therapeutic efficacy. For this reason, the effect of the 
routine storage conditions employed in this study on the physical characteristics and siRNA-
binding abilities of liposome suspensions was investigated. No significant changes in vesicle size 
(Figure 4.16a), zeta potential (Figure 4.16b) or concentration (Figure 4.16c) were noted after a 
5 month-long storage at 4 ˚C. Furthermore, the siRNA-binding affinity of each formulation 
(Figure 4.17) was not appreciably altered. The results confirm that all four liposome suspensions 
remained stable for at least 5 months when stored in the refrigerator. 
However, some changes did occur after a further 5 months at 4 ˚C with the MS09/DOPE 
formulation. A significant increase in the size of MS09/DOPE vesicles was observed after 
10 months, and this was associated with a change in zeta potential (less negative and closer to 0). 
This evidence of aggregation was further corroborated by a drop in concentration. This is 
consistent with the inverse relationship between size and nanoparticle concentration validated by 
de Morais Ribeiro et al. (2018) when monitoring the stability of lipid-based nanoparticles. 
Although the above-mentioned changes did not affect the overall maximum dye displacement 
attainable by the MS09/DOPE formulation, a shift in the point of inflection was observed i.e. 
more liposome was required to achieve the original degree of dye displacement (Figure 4.17a). 
This is a likely consequence of vesicle aggregation. Due to the fact that multiple small liposomes 
collectively provide a larger surface area than when fused as a single large liposome, it is 
possible that vesicle aggregation may have reduced the surface area for siRNA-binding. This 
could account for the larger quantity of liposome required to bind the same amount of siRNA as 
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Figure 4.16: Effect of long-term storage at 4 ˚C on vesicle a) size, b) ζ potential and c) concentration of 
liposome suspensions. Each column represents the mean ± SD (n = 3). *P < 0.05 vs. t = 0 months; 
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Figure 4.17: Effect of long-term storage at 4 ˚C on siRNA-binding ability of liposomes a) MS09/DOPE, b) MS09/Chol (1:1), c) MS09/DOPE/PEG and 
d) MS09/Chol/PEG (1:1). siRNA-binding was assessed by the SYBR Green dye displacement assay. A black arrow shows the point of inflection for 
freshly prepared (t = 0 months) liposome suspensions in each instance. Any change in the point of inflection is highlighted by a red arrow. 
Results are presented as the mean ± SD (n = 3).  P > 0.05 with respect to the following t = 5 and 10 months vs. t = 0 months, and t = 5 months vs. 
t = 10 months, at point of inflection. 
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In contrast, extended storage at 4 ˚C did not significantly affect the physical characteristics or 
siRNA-binding capabilities of both pegylated formulations and the non-pegylated Chol-
containing formulation. It appears that substitution of DOPE with Chol had a similar effect on 
maintaining stability of MS09 liposomes as 2 % pegylation within the monitored timespan. 
On a positive note, NTA confirmed that no degradation, as would have been shown by a 
decrease in concentration without an accompanied increase in particle size, (de Morais Ribeiro et 
al., 2018) of vesicles in any of the formulations occurred during storage. 
  
4.6 Nuclease protection assays 
Attempts at lipid-mediated siRNA delivery are often frustrated by adverse interactions with 
serum. To this end, the siRNA-protecting capability of each liposome preparation was evaluated 
after a 4 h long incubation in serum, at the concentration used in routine cell culture, at 
physiological temperature. siRNA was released with a detergent treatment and its integrity on 
agarose gels gave an indication of the degree of protection afforded by each liposome 
formulation. Figure 4.18 shows that, while naked siRNA was entirely degraded under the 
experimental conditions employed (lane 2 of each gel), intact siRNA bands, less intense than the 
untreated control, were clearly visible in all instances. This shows that all formulations partially 
protected siRNA at the respective MS09:siRNA (w/w) ratios explored. 
siRNA released from non-pegylated liposomes migrated as a single band and to the same extent 
in the gel as untreated siRNA (Figure 4.18a,b). However, in gels showing the serum nuclease 
protection capability of pegylated liposomes (Figure 4.18c,d) two distinct siRNA bands, one 
with slower mobility and markedly less intense than native siRNA, were noted. Zhang et al. 
(2006) observed a similar phenomenon following SDS-mediated release of siRNA from a 
pegylated liposome formulation. According to this group, the slower moving band should be less 
negatively charged or have higher molecular weight than native siRNA. Two possibilities were 
put forward. Firstly, in the event that detergent treatment did not completely destroy the lipid 
component of lipoplexes, siRNA could bind to a few intact cytofectin molecules. Secondly, since 
SDS is anionic it may bind to cationic lipids in aqueous solution, and a triple complex made up 
of siRNA, SDS and remaining cytofectin molecules could account for the appearance of such a 





Figure 4.18: Nuclease protection capability of a) MS09/DOPE, b) MS09/Chol (1:1), c) MS09/DOPE/PEG 
and d) MS09/Chol/PEG (1:1) liposomes in FBS at 37 ˚C for 4 h. In each gel, lane 1 contained undigested 
siRNA, lane 2, serum-digested siRNA and lanes 3-8, serum-exposed lipoplexes at varying 
MS09:siRNA (
w/w) ratios (12:1, 16:1, 20:1, 24:1, 28:1 and 32:1, respectively). Intact siRNA and a second 
siRNA band with reduced mobility are shown by black and blue arrows, respectively. 
 
Densitometric analysis of gels (Figure 4.19) gave further insight into the comparative siRNA-
protecting capabilities of liposomes.  
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Figure 4.19: siRNA-protecting capacity of liposomes in the presence of 10 % serum, at 37 ˚C for 4 h. 
Intact siRNA associated with lipoplexes was quantified following nuclease digestion assays, and 
expressed as a percentage of untreated siRNA. Data is presented as the mean ± SD (n = 3). 
###
P < 0.001 
vs. non-pegylated counterpart, 
●●
P < 0.01, 
●●●
P < 0.001 vs. DOPE-containing counterpart. 
 
It was observed that individual liposome formulations achieved the best protection of siRNA 
(Table 4.3) at MS09:siRNA (w/w) ratios which gave lipoplexes with bilamellar structure 
(Figures 4.9d, 4.10d, 4.11d, 4.12f). This is consistent with the fact that siRNA concealed within 
stable lamellar structures is more likely to avoid interaction with serum than surface-bound 
siRNA (Khatri et al., 2014).  
 
Table 4.3: MS09:siRNA (w/w) ratios at which liposomes attained maximum siRNA protection 
Liposome formulation MS09:siRNA (w/w) siRNA protecteda (%) 
MS09/DOPE 24:1 86 ± 3 
MS09/Chol (1:1) 24:1 73 ± 3c 
MS09/DOPE/PEG 24:1 82 ± 1b 
MS09/Chol/PEG (1:1) 32:1 77 ± 2b 
Notes: 
aEach value represents the mean ± SD (n = 3) 
bP > 0.05 vs. non-pegylated counterpart 
cP < 0.05 vs. DOPE-containing counterpart 
 
In contrast, the lowest siRNA protection efficiencies were recorded with structures that 
resembled free vesicles. These were the MS09/Chol/PEG (1:1) lipoplexes at MS09:siRNA (w/w) 
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ratios of 12:1, 16:1 and 28:1, which protected only 49, 56 and 57 % siRNA, respectively. This is 
consistent with the previously mentioned weak, surface-association of siRNA and liposomal 
vesicles prevalent at these ratios, given that the exposed siRNA is highly susceptible to nuclease 
attack (Khatri et al., 2014).  
At the lowest MS09:siRNA (w/w) ratio explored, i.e. 12:1, the extent to which siRNA was 
protected by a given formulation correlates with the relative siRNA-binding affinities 
demonstrated in section 4.2. However, this relationship does not hold true at the higher ratios. In 
fact, maximum protection of siRNA achieved by the MS09/DOPE formulation at the 
MS09:siRNA (w/w) ratio of 24:1 was not significantly different from that achieved by 
MS09/DOPE/PEG liposomes at the same ratio. Similarly, the highest levels of intact siRNA 
maintained by MS09/Chol (1:1) and MS09/Chol/PEG (1:1) were comparable albeit at different 
ratios. 
The results show that while pegylation of liposomes gave lower siRNA-binding affinity, it did 
not impact on the maximum siRNA-protecting capabilities attainable by these formulations, 
provided that due attention is paid to optimising the lipid:siRNA mixing ratio. Given that PEG 
chains prevent destabilisation of lipoplexes by acting as a barrier between the lipoplex and serum 
components, the effect of pre-pegylation at 2 mol % towards conferring stability in serum 
appears to compensate for the associated reduction in siRNA-binding. 
The effect of substituting Chol with DOPE on the serum stability of MS09 formulations was also 
considered. Maximum intact siRNA of 73 % afforded by MS09/Chol (1:1) liposomes at the 
MS09:siRNA (w/w) ratio of 24:1 was significantly less than that of MS09/DOPE. Figure 4.6 of 
section 4.2 shows that, at this ratio, 25 % of siRNA was likely to be surface-associated, as it was 
so loosely bound that it was coaxed off during electrophoresis. Such siRNA is readily detached 
from the liposomal bilayer upon exposure to serum and is acted upon by nucleases (Buyens et 
al., 2008). However, differences in maximum siRNA protection achieved by 
MS09/Chol/PEG (1:1) and MS09/DOPE/PEG liposomes were not significant. Given that, 
according to the gel retardation pattern, only 60 % of siRNA appeared to have been bound by the 
MS09/Chol/PEG (1:1) formulation, the results imply that the PEG chains can shield even weakly 
associated siRNA. Hence, pegylation appears useful for maintaining siRNA-protecting 
 105 
 
capabilities of liposomes in the presence of a substitution which, in this instance, reduces siRNA-
binding and protection of MS09 liposomes when introduced alone. 
Of relevance is the fact that maximum siRNA protection for DOPE-containing formulations was 
recorded at the MS09:siRNA (w/w) ratio at which siRNA was best retarded on agarose gel 
(Figure 4.6). Here lipoplexes capable of optimum siRNA-binding, were also capable of optimum 
protection within the range of MS09:siRNA (w/w) ratios explored. In the case of Chol-containing 
formulations, lipoplexes assembled at MS09:siRNA (w/w) higher than that at which the best 
retardation of siRNA was achieved, gave the best protection of siRNA. This can be ascribed to 
the lower affinity of these liposomes for siRNA, even at the point of maximum binding, such that 
additional liposome is required to produce structures in which more of siRNA molecules are 
concealed, and is therefore less accessible to serum nucleases.  
 
4.7 Cell lines and maintenance 
Four adherent cell lines were used in this study, namely, HEK293, Caco-2, MCF-7 and HT-29. 
Healthy quiescent cells express low levels of steady state mRNA (Lindsten et al., 1988) and the 
associated protein is barely detectable (Kyo et al., 2000). However, regulated transient increases 
in c-myc expression do occur as cells proliferate (Eisenman, 2014). In this study, a non-
transformed cell line, HEK293, which was shown to express c-myc very weakly by western blot 
(Liu et al., 2008a), was used as a control. 
The human breast adenocarcinoma, MCF-7, and colorectal adenocarcinoma, HT-29, cell lines 
were selected as in vitro models of cancers with deregulated c-myc expression. The MCF-7 cell 
line was introduced by Soule and colleagues (1973), and has since become the most widely used 
breast cancer cell line. This is mainly because it provides a convenient model for the study of the 
oestrogen receptor (ER), hormone-response and ER-targeted treatment (Lee et al., 2015). Of 
significance to this study, amplification of the c-myc oncogene was shown in the MCF-7 cell line 
(Rummukainen et al., 2001). Furthermore, MCF-7 cells harbour palindromic rearrangements 
which are believed to drive amplification of this oncogene (Guenthoer et al., 2012). Finally, 
c-myc overexpression in this cell line was statistically correlated with amplification of the 
oncogene (Hyman et al., 2002). 
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Early studies showed that HT-29 cells harbour between 4 and 6 copies of the c-myc locus, and 
express oncogenic c-Myc under all culture conditions (Forgue-Lafitte et al., 1989). HT-29 cells 
also bear a mutant, truncated APC tumour suppressor gene (Hsi et al., 1999), and this contributes 
towards sustained c-myc expression in most colon carcinomas (He et al., 1998). These features, 
defects in the APC/β-catenin pathway (Sparks et al., 1998) and/or c-myc gene amplification 
(Augenlicht et al., 1997) are common to colorectal carcinomas, making HT-29 a good 
representative of this type of cancer. 
A second human colorectal adenocarcinoma cell line, Caco-2, has the ability to regulate 
expression of c-myc (Hulla et al., 1995). A recent study showed that endogenous c-myc 
expression is lower in this cell line than in HT-29 (Mazzoccoli et al., 2016). Caco-2 cells were 
selected for two main reasons: firstly, for testing the effects of lipoplexes in different cell lines 
derived from cancer of the same organ, i.e. for comparison with HT-29; and secondly, for testing 
the effects of lipoplexes in a cancer cell line capable of regulable c-myc expression. 
All cell lines were successfully propagated after reconstitution by routinely changing growth 
medium and performing trypsinisation. Sufficient stock of each cell line was maintained with 
regular cryopreservation. Images of semi-confluent and trypsinised cells are shown in 





Figure 4.20: Semi-confluent a) HEK293, b) Caco-2, c) MCF-7 and d) HT-29 cells. Cells were viewed using 













Figure 4.21: Trypsinised a) HEK293, b) Caco-2, c) MCF-7 and d) HT-29. Cells were viewed using an 











4.8 The effect of lipoplexes on cell growth 
Any new liposome-siRNA delivery system must be investigated for potential cytotoxic effects. 
In a review of the toxicity associated with siRNA nanoparticles, Xue et al. (2014) commented 
that even seemingly harmless lipids can cause toxicity when combined with other lipids. 
Moreover, for the purposes of this study, it was important that any growth inhibitory effects in 
cancer cells be attributed solely to the RNAi effects of successfully delivered anti-c-myc siRNA, 
and not due to any intrinsic harmful effect of the liposomal carrier complexes. 
In this study, cellular tolerance of lipoplexes was evaluated according to two assays, namely the 
MTT and AB assays. This is in keeping with suggestions that the use of more than one assay is 
necessary to generate meaningful cytotoxicity profiles (Rampersad, 2012). The MTT assay is 
based on the principle that enzymes of the mitochondria and other organelles (Stockert et al., 
2012) of living cells reduce soluble MTT, a tetrazolium salt, to purple formazan crystals 





























Figure 4.22: Reduction of a) MTT and b) resazurin to formazan and resorufin products, respectively. 
Redrawn and adapted from Riss et al. (2004) using ChemWindow
®
 6.0, Bio-Rad Laboratories (Sadtler 





Once solubilised, the intensity of the resultant purple solution correlates with the extent of MTT 
reduction and, as a consequence, the number of living cells present (Fotakis and Timbrell, 2006). 
The active agent of AB is resazurin, a blue non-fluorescent dye that is permeable to biological 
membranes. Resazurin is reduced by cytoplasmic and mitochondrial enzymes to a pink, strongly 
fluorescent product, resorufin (Figure 4.22b), that is subsequently excreted (O'Brien et al., 2000). 
The amount of resorufin in the growth medium is an indicator of metabolic activity and is 
proportional to the number of viable cells (Fields and Lancaster, 1993). 
Cytotoxicity testing was performed under the same conditions as those employed in cellular 
uptake and gene silencing experiments, except that lipoplexes were assembled with non-targeting 
siRNA so as to rule out the possibility of cell death due to silencing of any functional genes. 
Care was taken to reduce the possibility of the assays being influenced by osmotic effects by 
assembling siRNA lipoplexes in HBS (Singh et al., 2007). This buffer maintains optimum 
osmolarity (290 mosmol/kg) for cultured human cells because it mirrors that of human plasma 
(Freshney, 2005). Furthermore, MTT and AB assays were performed in parallel, to minimise 
technical errors associated with plating of cells and preparation of lipoplex suspensions. 
A comparison of Figures 4.23-4.28 shows that, in general, the AB assay confirmed trends in cell 
survival that were observed by the MTT assay. However, in some instances, cell viability as per 
the MTT assay appeared higher. This is apparent, for example, by comparing the MTT and AB 
cell viability data of the MS09/DOPE/PEG formulation at MS09:siRNA (w/w) ratios of 
12:1-24:1, with 57 nM siRNA in the HEK293 cell line (Figures 4.23a, 4.24a). There is evidence 
to suggest that larger cells with more mitochondria reduce MTT at a higher rate (Jabbar et al., 
1989), and that defective mitochondria may retain the ability to reduce MTT (Sieuwerts et al., 
1995). In addition, it is possible for cells that have detached from the culture vessel to continue 
reducing MTT, leading to overestimated cell viabilities by this assay (Hamid et al., 2004). In 
fact, several sources mention that the AB assay is more sensitive (Davoren et al., 2007, O'Brien 
et al., 2000, Patel et al., 2013). Henceforth, the cell viability percentages mentioned refer to data 
























































































































































































































































































Figure 4.23: MTT viability assays with lipoplexes at final siRNA concentration of 57 nM. The growth response of a) HEK293, b) Caco-2, c) MCF-7 
and d) HT-29 cells to lipoplexes, assembled with non-targeting siRNA at varying MS09:siRNA (
w/w) ratios, was assessed 48 h after transfection. 
LF3K denotes Lipofectamine
™
 3000, and transfections were as per manufacturer’s instruction. Each column represents the mean ± SD (n = 3). 
*
P < 0.05, 
**
P < 0.01, 
***
P < 0.001 vs. untreated cells; 
#
P < 0.05, 
##
P < 0.01, 
###
P < 0.001 vs. the non-pegylated counterpart; 
●
P < 0.05, 
●●
P < 0.01, 
●●●























































































































































































































































Figure 4.24: AB viability assays with lipoplexes at final siRNA concentration of 57 nM. The growth response of a) HEK293, b) Caco-2, c) MCF-7 
and d) HT-29 cells to lipoplexes, assembled with non-targeting siRNA at varying MS09:siRNA (
w/w) ratios, was assessed 48 h after transfection. 
LF3K denotes Lipofectamine
™
 3000, and transfections were as per manufacturer’s instruction. Each column represents the mean ± SD (n = 3). 
*
P < 0.05, 
**
P < 0.01, 
***
P < 0.001 vs. untreated cells; 
#





























































































































































































































































Figure 4.25: MTT viability assays with lipoplexes at final siRNA concentration of 29 nM. The growth response of a) HEK293, b) Caco-2, c) MCF-7 
and d) HT-29 cells to lipoplexes, assembled from liposomes and non-targeting siRNA at varying MS09:siRNA (
w
/w) ratios, was assessed 48 h after 
transfection. LF3K denotes Lipofectamine
™
 3000, and transfections were as per manufacturer’s instruction. Each column represents the mean ± 
SD (n = 3). 
*
P < 0.05, 
**
P < 0.01, 
***
P < 0.001 vs. untreated cells; 
#
P < 0.05, 
##
P < 0.01, 
###
P < 0.001 vs. the non-pegylated counterpart; 
●
P < 0.05, 
●●●























































































































































































































































Figure 4.26: AB viability assays with lipoplexes at final siRNA concentration of 29 nM. The growth response of a) HEK293, b) Caco-2, c) MCF-7 
and d) HT-29 cells to lipoplexes, assembled from liposomes and non-targeting siRNA at varying MS09:siRNA (
w
/w) ratios, was assessed 48 h after 
transfection. LF3K denotes Lipofectamine
™
 3000, and transfections were as per manufacturer’s instruction. Each column represents the mean ± 
SD (n = 3). 
*
P < 0.05, 
**
P < 0.01, 
***
P < 0.001 vs. untreated cells; 
##
P < 0.01, 
###
P < 0.001 vs. the non-pegylated counterpart; 
●
P < 0.05 vs. the DOPE-















































































































































































































































Figure 4.27: MTT viability assays with lipoplexes at final siRNA concentration of 14 nM. The growth response of a) HEK293, b) Caco-2, c) MCF-7 
and d) HT-29 cells to lipoplexes, assembled from liposomes and non-targeting siRNA at varying MS09:siRNA (
w
/w) ratios, was assessed 48 h after 
transfection. LF3K denotes Lipofectamine
™
 3000, and transfections were as per manufacturer’s instruction. Each column represents the mean ± 















































































































































































































































Figure 4.28: AB viability assays with lipoplexes at final siRNA concentration of 14 nM. The growth response of a) HEK293, b) Caco-2, c) MCF-7 
and d) HT-29 cells to lipoplexes, assembled from liposomes and non-targeting siRNA at varying MS09:siRNA (
w
/w) ratios, was assessed 48 h after 
transfection. LF3K denotes Lipofectamine
™
 3000, and transfections were as per manufacturer’s instruction. Each column represents the mean ± 
SD (n = 3). P > 0.05 vs. untreated cells, non-pegylated and DOPE-containing counterparts. 
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As expected, no significant reduction in viability was detected upon treatment of all cell lines 
with naked siRNA at the same concentrations as contained in lipoplexes. Cells retained viability 
of at least 88 % with exposure to LF3K-siRNA complexes. However, the cellular growth 
response to MS09 lipoplexes varied with liposome composition, the MS09:siRNA (w/w) ratio, 
final siRNA and lipid concentration and, were often cell-specific. 
Maximum growth inhibition of 67 % was recorded with the MS09/DOPE formulation at an 
MS09:siRNA (w/w) ratio of 24:1, at 57 nM siRNA in HEK293 cells (Figure 4.24a). Significant 
cell death with this formulation was also noted in Caco-2 (Figure 4.24b) and MCF-7 cells 
(Figure 4.24c). Poor cell survival at high MS09:siRNA (w/w) ratios can be attributed to the 
sensitivity of these cell types to the high cytofectin concentrations applied. Cationic lipids induce 
cytotoxicity mainly by association with the plasma membrane and consequent inhibition of 
protein kinase C (Farhood et al., 1992, Zelphati and Szoka, 1996). This causes the formation of 
transmembrane pores and possibly disturbs signal transduction (Das et al., 2016). Other adverse 
effects of cationic lipids include vacuolisation of cytoplasm, slow cell division, cell shrinkage, 
lysis and necrosis (Lappalainen et al., 1994, Mishra et al., 2004). Interestingly, significant cell 
death was also observed at the lowest MS09:siRNA (w/w) ratio explored, i.e. 12:1, in Caco-2 and 
MCF-7 cells. It is possible that these lipoplexes were well suited for cellular uptake in the 
aforementioned cell lines and, when used in such quantities so as to deliver 57 nM siRNA, 
accumulated within the cells at high concentrations that impeded cell growth. Hence the effective 
lipid dose with these lipoplexes could have been higher than with other lipoplexes assembled 
from the same formulation. 
Besides the effect of lipid concentration, the effective siRNA dose, i.e. the actual number of 
siRNA molecules that successfully enter the cell in an intact form, can also impact adversely on 
cell survival. There is evidence to suggest that excess intracellular siRNA can saturate the RNAi 
machinery and cause toxicity by competitively inhibiting miRNA-mediated silencing pathways 
(Grimm, 2011). RISC concentration in the cell is estimated at 3-5 nM, which corresponds to 
approximately 103-104 protein complexes per cell. Therefore, RISC saturation can, in theory, 
occur with as few as 103-104 intact and successfully delivered siRNA molecules (Alagia and 
Eritja, 2016). However, the unfavourable effects of RISC saturation can be avoided by applying 
siRNA at the lowest effective dose possible (Grimm, 2011, Jackson and Linsley, 2010). Halving 
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the siRNA and associated lipid concentrations abolished any growth inhibitory effects with 
MS09/DOPE lipoplexes in MCF-7 cells (Figure 4.26c) and improved cell survival in the 
HEK293 (Figure 4.26a) and Caco-2 cell lines (Figure 4.26b). A further 50 % reduction in siRNA 
and lipid dose was necessary to avoid cytotoxic effects in the latter cell lines (Figures 4.28a,b). 
In general, cell survival after exposure to the MS09/Chol (1:1) formulation was better than its 
DOPE-containing counterpart. Significant loss of cell viability was noted only in three instances 
i.e. in Caco-2 cells at MS09:siRNA (w/w) ratios of 28:1 and 32:1 (Figure 4.24b) and MCF-7 cells 
at a ratio of 32:1 (Figure 4.24c), at 57 nM siRNA. The observation that this formulation was 
better tolerated than MS09/DOPE could be ascribed to Chol being an endogenous lipid. Another 
possibility is presented by the fact that DOPE is pH-sensitive while Chol is not. Interestingly, 
this property of DOPE, which is often marked as important for transfection, has also been 
associated with toxicity, because it causes destabilisation of lysosomes and release of debris 
within the cell. Consequently, replacing DOPE with a pH-insensitive lipid, which is unable to 
interfere with the lysosomal membrane, was shown to reduce the toxicity of cationic liposomes 
(Filion and Phillips, 1997). 
Pegylated formulations did not significantly inhibit cell growth with the exception of 
MS09/DOPE/PEG and MS09/Chol/PEG (1:1) lipoplexes at MS09:siRNA (w/w) ratios of 32:1 and 
28:1, respectively, in Caco-2 cells (Figure 4.24b) and only at the highest siRNA and lipid 
concentrations at which these complexes were applied. The favourable overall cell survival 
permitted by pegylated lipoplexes could be a consequence of poor cellular entry due to PEG-
inhibited lipoplex-cell interactions. 
Differences in the growth response of Caco-2 and HT-29 highlight the issue of cell-specific 
cytotoxicity. Both cell lines are derived from tumours of the intestinal epithelium. However, 
Caco-2 cells differentiate to absorptive cells which resemble enterocytes (Rousset, 1986), while 
HT-29 cells are primarily undifferentiated in culture with some mucous-secreting and columnar 
absorptive sub-populations (Huet et al., 1995). Despite their similar origins, HT-29 cells were 
more resilient to lipoplex treatment than Caco-2 cells. According to the AB assay, no significant 
drop in viability of HT-29 cells was noted with any formulation at all MS09:siRNA (w/w) ratios, 
final siRNA and lipid concentrations explored.  
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4.9 Cellular uptake studies 
The cellular uptake of lipoplexes is often correlated with transfection activity (Wang et al., 
2013a). In order to assess the ability of lipoplexes to enter cells and deliver siRNA, lipoplexes 
were assembled with BLOCK-iT™ Fluorescent Oligo, a fluorescein-labelled siRNA marker (Han 
et al., 2008) that embodies the structural features of a typical siRNA molecule. The oligo permits 
RISC-independent assessment of siRNA delivery. Once successfully internalised the oligo 
localises mainly to the nucleus (Fisher et al., 1993) and can be detected through fluorescence 
measurements. As shown in Figures 4.29-4.31, normalised intracellular fluorescence that was 
significantly greater than that of control 2, in which cells were treated with the naked oligo alone, 
was taken to represent successful siRNA delivery. 
The best intracellular accumulation of the siRNA marker was observed with non-pegylated 
liposomes in MCF-7 and HT-29 cells at all siRNA concentrations explored. In fact, some non-
pegylated lipoplexes achieved significantly better siRNA delivery than the standard in vitro 
transfection reagent, LF3K. As expected, differences in siRNA delivery were noted with varying 
MS09:siRNA (w/w) ratio, because this parameter influences the physical characteristics of 
lipoplexes (Khatri et al., 2014, Wang et al., 2013a). These physical features, in turn, have a 
major bearing on the cellular uptake of lipoplexes (Ma et al., 2007, Rejman et al., 2004a). 
Maximum siRNA delivery achieved with MS09/DOPE and MS09/Chol (1:1) liposomes was 
comparable (P > 0.05) at all final siRNA concentrations explored in the MCF-7 and HT-29 cell 
lines, respectively. However, the mechanisms by which cells internalised lipoplexes assembled 
from these formulations are likely to have been very different. Alshehri et al. (2018) identified, 
through use of a variety of pharmacological inhibitors, several entry routes for non-pegylated 
siRNA lipoplexes which contained a monocationic cholesteryl derivative and DOPE. These 
included clathrin-mediated endocytosis, macropinocytosis and cell membrane cholesterol-
dependent processes. With regard to lipoplexes formulated with Chol, it has been suggested that 
the formation of cholesterol nanodomains in the liposomal bilayer can contribute toward cellular 
uptake (Xu and Anchordoquy, 2008, Xu and Anchordoquy, 2010). Although the exact 
mechanisms by which they encourage uptake have not yet been elucidated, it has been put 
forward that cholesterol domains could interact with cell membrane components such as lipids 



































































































































































































































































































































































































Figure 4.29: siRNA delivery by MS09 lipoplexes at final siRNA concentration of 57 nM in a) HEK293, b) Caco-2, c) MCF-7, and d) HT-29 cells. Cells were 
treated with lipoplexes, which were assembled with BLOCK-iT
™
 Fluorescent Oligo at varying MS09:siRNA (
w
/w) ratios, for 24 h after which intracellular 
fluorescence was measured. LF3K denotes Lipofectamine
™
 3000, and transfections were as per manufacturer’s instruction. Control 1 contained cells 
only, while control 2 contained cells treated with the naked oligo. Each column represents the mean ± SD (n = 3). 
*
P < 0.05, 
**
P < 0.01, 
***
P < 0.001 vs. 






































































































































































































































































































































































































Figure 4.30: siRNA delivery by MS09 lipoplexes at final siRNA concentration of 29 nM in a) HEK293, b) Caco-2, c) MCF-7, and d) HT-29 cells. Cells were 
treated with lipoplexes, which were assembled with BLOCK-iT
™
 Fluorescent Oligo at varying MS09:siRNA (
w
/w) ratios, for 24 h after which intracellular 
fluorescence was measured. LF3K denotes Lipofectamine
™
 3000, and transfections were as per manufacturer’s instruction. Control 1 contained cells 
only, while control 2 contained cells treated with the naked oligo. Each column represents the mean ± SD (n = 3). 
*
P < 0.05, 
**
P < 0.01, 
***
P < 0.001 vs. 












































































































































































































































































































































































Figure 4.31: siRNA delivery by MS09 lipoplexes at final siRNA concentration of 14 nM in a) HEK293, b) Caco-2, c) MCF-7, and d) HT-29 cells. Cells were 
treated with lipoplexes, which were assembled with BLOCK-iT
™
 Fluorescent Oligo at varying MS09:siRNA (
w
/w) ratios, for 24 h after which intracellular 
fluorescence was measured. LF3K denotes Lipofectamine
™
 3000, and transfections were as per manufacturer’s instruction. Control 1 contained cells 
only, while control 2 contained cells treated with the naked oligo. Each column represents the mean ± SD (n = 3). 
*
P < 0.05, 
**
P < 0.01, 
***
P < 0.001 vs. 
control 2; P < 0.01, P < 0.001 vs. LF3K. 
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Others have shown that Chol-containing lipoplexes may be internalised by fusion with the cell 
membrane (Pozzi et al., 2012). This is supported by more recent work which identified direct 
membrane fusion as the dominant mechanism for siRNA delivery by Chol-containing, non-
pegylated cationic liposomes, in HeLa cells (Lazebnik et al., 2016). In this way, Chol lipoplexes 
can deliver siRNA directly into the cytoplasm and altogether avoid the endolysosomal network. 
This is a major advantage, given that pathways which involve trafficking via intracellular 
vesicles are often associated with significant loss of internalised siRNA. It has been estimated 
that less than 2 % of siRNA escapes from endosomes into the cytoplasm (Gilleron et al., 2013). 
This occurs shortly after cellular uptake, and prior to endosomal maturation and endolysosomal 
fusion which direct the entrapped siRNA for degradation (Wittrup et al., 2015). 
Taken together with an earlier study by Lu et al. (2009) who demonstrated that the delivery of 
functional siRNA molecules, i.e. the siRNA molecules that successfully interact with RISC in 
the cell by cationic liposomes, occurs via a mechanism that involves fusion of liposomal and cell 
membranes; these findings bode well for the potential efficacy of MS09/Chol (1:1) lipoplexes in 
gene silencing applications. 
By comparison, delivery of the siRNA marker with MS09/DOPE and MS09/Chol (1:1) 
liposomes in HEK293 and Caco-2 cells was less effective. In the case of MS09/DOPE lipoplexes 
at 57 and 29 nM final siRNA this can, in most instances, be attributed to poor cell survival at the 
applied concentrations, as was demonstrated in growth inhibition experiments. In other instances, 
it is likely that the lipoplex characteristics were not conducive to cellular uptake in these cell 
lines. Although cell viability was preserved in the presence of MS09/DOPE lipoplexes at 14 nM 
siRNA, no significant siRNA delivery was noted at any of the MS09:siRNA (w/w) ratios 
explored. It is possible that, at this low concentration, lipoplexes interacted either minimally or 
not at all with these cells. Nonetheless, the MS09/DOPE formulation performed better than its 
Chol-containing counterpart in HEK293 and Caco-2 cell lines, even though MS09/Chol (1:1) 
was, in general, non-toxic. The data suggest that different cell types may harbour preferences for 
the uptake of lipoplexes depending on both lipid composition and the MS09:siRNA (w/w) ratio at 
which these are assembled. This could be associated with the concept that different lipoplexes 
may be internalised by different pathways (Ma et al., 2007, Rejman et al., 2004a) and, that some 
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cells are better suited towards different modes of uptake than others (Elouahabi and Ruysschaert, 
2005). 
Pegylated formulations failed to successfully transfer siRNA into MCF-7 and HT-29 cells at all 
MS09:siRNA (w/w) ratios, final lipid and siRNA concentrations explored. It is likely that, in these 
cell lines, PEG chains prevented cellular uptake altogether through inhibition of the lipoplex-
plasma membrane association (Deshpande et al., 2004). This adds credence to the notion that 
favourable cell survival in the presence of pegylated lipoplexes is due to their lack of interaction 
with the cells. A further possibility, especially in the case of the MS09/DOPE/PEG formulation, 
is that the lipoplexes may have been endocytosed, but could not escape endolysosomal 
degradation due to the effects of PEG and DSPE, both of which prevent destabilisation of 
internal compartments (Fuxin et al., 2002, Song et al., 2002, Rejman et al., 2004b).  
Modest delivery of siRNA by pegylated liposomes was, however, noted in the Caco-2 and 
HEK293 cell lines. In HEK293 cells, only the MS09/Chol/PEG (1:1) formulation gave 
appreciable normalised fluorescence levels, and this was achieved at high MS09:siRNA (w/w) 
ratios, i.e. 28:1 and 32:1, with 57 and 29 nM final siRNA explored (Figures 4.29a, 4.30a). In 
contrast, MS09/Chol/PEG (1:1) lipoplexes assembled at lower ratios were taken up by Caco-2 
cells (Figures 4.29b, 4.30b). Caco-2 cells are the only cells in this study in which an 
MS09/DOPE/PEG lipoplex was able to facilitate siRNA delivery, and its performance was 
comparable with the Chol-containing counterpart. Here again the idea of cells demonstrating 
different affinities for different liposome formulations could account for the fact that pegylated 
lipoplexes were, in general, taken up more effectively in this cell line than the other three cell 
types. Halving the siRNA dose from 57 to 29 nM did not have a significant effect on siRNA 
delivery by pegylated lipoplexes in both cell lines. However, intracellular accumulation of the 
siRNA marker was negligible in both cell lines when the dose was halved once more. 
Collectively, this implies that there exists a minimum lipoplex concentration necessary for 
cellular uptake, that a limit exists on the amount of a given lipoplex that can accumulate within 




4.10 Selection of an appropriate anti-c-myc liposomal agent 
To demonstrate the gene silencing effect of anti-c-myc siRNA lipoplexes, the two cancer cell 
lines with deregulated high c-myc expression were chosen i.e. MCF-7 and HT-29. Lipoplexes to 
be investigated as anti-c-myc agents were selected based on the following criteria: 
• Lipoplexes should be capable of high siRNA delivery at low siRNA and lipid dose in the 
test cell lines. 
• Lipoplexes should be non-cytotoxic in the test cell lines. 
• Lipoplexes should have negligible effect in control cell lines. 
 
From the broad final siRNA concentration range investigated (Figures 4.29-4.31), it is evident 
that the lipoplexes which achieved the highest siRNA delivery at lowest siRNA and lipid 
concentration, with negligible effect on normal cell growth were assembled from the 
MS09/Chol (1:1) formulation and its DOPE-containing counterpart, at the MS09:siRNA (w/w) 
ratio of 16:1. At 14 nM siRNA, these lipoplexes were taken up as readily as they were at higher 
concentrations by both MCF-7 and HT-29 cells, which imply that both cell types have high 
affinity for these complexes. Hence, these lipoplexes were investigated further. A summary of 
the characteristics of MS09/Chol (1:1) and MS09/DOPE lipoplexes at the MS09:siRNA (w/w) 
ratio of 16:1, is presented in Appendix E, Table E1. Of note is the observation that, in the case of 
both formulations, this ratio is below that at which siRNA was best protected and retarded on 
agarose gels. Internalised siRNA levels detected at these ratios, in both cell lines, were either 
comparable with or significantly lower than that which was achieved at the MS09:siRNA (w/w) 
ratio of 16:1. This observation was made at all final siRNA concentrations explored, and ties in 
with previous comments that a weaker liposome-siRNA association may be useful for siRNA 
release in the cell (Nguyen et al., 2008). 
At a final siRNA concentration of 14 nM, non-pegylated MS09 lipoplexes at the 
MS09:siRNA (w/w) ratio of 16:1 were shown to be ineffective at delivering the siRNA marker 
into HEK293 and Caco-2 cells (Figure 4.31a,b) and did not interfere with cell growth 
(Figure 4.28a,b). This could suggest preferential accumulation of these lipoplexes in cancer cells 
characterised by deregulated c-myc expression, and this could be exploited for the selective 
treatment of such cancers. Furthermore, the fact that both lipoplexes, at 14 nM siRNA, had 
negligible effect in the non-transformed cell line, taking into account both the effect on cell 
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growth and introduction of siRNA, is an added advantage. Although normal cells are able to 
tolerate c-myc inhibition (Soucek et al., 2008), a c-myc-directed system that does not enter non-
cancerous cells, may potentially alleviate any short-term effects of c-myc inhibition in healthy 
cells. The results suggest that it may be possible to achieve cancer cell selectivity of MS09 
lipoplexes in the absence of additional liposome modifications, through optimising the 
lipid:siRNA mixing ratio for lipoplex assembly, lipid and siRNA dose. 
It was noted that, in HT-29 cells, siRNA delivery by each non-pegylated liposome was 
comparable at MS09:siRNA (w/w) ratios of 16:1 and 20:1 (P > 0.05). However, the lipoplex 
suspensions at 16:1 were chosen for further study in light of the fact that, at 20:1, a higher lipid 
concentration would have to be applied. Although lipoplexes at this concentration were found to 
be harmless in all cell lines tested in this study, a lower lipid dose would be more economically 
feasible in a clinical setting. Furthermore, given that testing the effects of lipoplexes on cell lines 
modelled upon all possible cell types in the human body falls beyond the scope of this study, the 
lower lipid dose is favourable as it reduces the risk of adverse effects in other types of cells. 
Similar ideas were put forward by Xue et al. (2014) in a review of the toxicity of siRNA-based 
nanomedicine. Consequently, further attention was given to the final siRNA dose at which the 
































































































































































































































































































































Figure 4.32: Delivery of siRNA by MS09/DOPE and MS09/Chol (1:1) formulations at MS09:siRNA (
w
/w) = 16:1 when introduced at varying final 
siRNA concentrations. a) MCF-7, b) HT-29, c) HEK293 and d) Caco-2 cells were exposed to lipoplexes assembled with BLOCK-iT™ Fluorescent 
Oligo for 24 h. Controls 1 and 2 represent untreated cells and cells treated with naked BLOCK-iT™ oligo, respectively. Data is presented as the 
mean ± SD (n = 3). 
*
P < 0.05, 
**
P < 0.01, 
***
P < 0.001 vs. control 2; 
♦
P < 0.05 vs. 57 nM, 29 nM and 14 nM siRNA; 
#
P < 0.05, 
##




In order to ascertain whether or not a final siRNA concentration of 14 nM was, in fact, the 
minimum applied concentration necessary for maximum lipoplex uptake and siRNA 
accumulation, cellular uptake experiments with MS09/DOPE and MS09/Chol (1:1) lipoplexes at 
MS09:siRNA (w/w) of 16:1 were carried out within a narrower siRNA concentration range. 
Figure 4.32a,b shows that there was no significant difference in siRNA delivery via both 
lipoplexes at final concentrations ranging from 57-12 nM siRNA in MCF-7 and HT-29 cells. 
Hence, final siRNA concentration of 12 nM was verified to be the lowest required for maximum 
cellular uptake of both lipoplexes in both cell lines. Further reduction of siRNA concentration 
significantly decreased siRNA marker delivery in both cell lines. At 6 nM, the siRNA and 
associated lipid concentration appeared to be too low to facilitate significant uptake with 
MS09/DOPE lipoplexes in both cell lines. In contrast, internalisation of MS09/Chol (1:1) 
lipoplexes was detectable at up to 6 nM and 4 nM final siRNA in HT-29 and MCF-7 cells, 
respectively. Importantly, it was confirmed that the markedly lower normalised intracellular 
fluorescence measurements obtained, at the newly tested siRNA and lipid concentrations, were 
not due to cell death (Appendix F, Figure F1a,b) and are, therefore, directly attributable to a 
dose-dependent decrease in cellular uptake at concentrations below 12 nM. 
As proof of principle, the same siRNA concentration range was also tested in the non-target cell 
lines. Figure 4.32c,d, confirms that no siRNA delivery by MS09/DOPE and MS09/Chol (1:1) 
lipoplexes occurred in HEK293 and Caco-2 cells at siRNA concentrations below 14 nM. In 
addition, no significant loss of viability was recorded in these cell lines (Appendix F, 
Figure F1c,d). Hence, as with lipoplexes introduced at 14 nM final siRNA, it was confirmed that 
lipoplexes have no significant effect in the HEK293 and Caco-2 cell lines at 12 nM siRNA. 
Further proof that the lipoplexes of interest can effectively enter MCF-7 and HT-29 cells, at 
12 nM final siRNA, was provided by fluorescence microscopy. The successfully delivered 
siRNA marker was observed as green fluorescence within the cells (Figures 4.33, 4.34). 
Fluorescence signals were weak due to the low final concentration of the siRNA marker applied. 
The possibility of these signals arising from artifacts was ruled out on the grounds that untreated 
cells were non-fluorescent. Although qualitative assessment by microscopy alone is limited by 
the field of view, the images presented served as visual evidence of cellular uptake and supported 




Figure 4.33: Cellular uptake of a fluorescein-labelled siRNA marker in MCF-7 cells, after transfection with 
MS09/DOPE and MS09/Chol (1:1) lipoplexes. Cells were transfected with lipoplexes assembled with 
BLOCK-iT
™
 Fluorescent oligo (MS09:siRNA 
w
/w = 16:1) at final concentration of 12 nM for 24 h. LF3K 
denotes Lipofectamine
™
 3000, and transfection was as per manufacturer’s instruction. Intracellular 
fluorescence was monitored using an inverted fluorescence microscope at 200× magnification. The scale 
bar represents 50 μm in all images. 














Figure 4.34: Cellular uptake of a fluorescein-labelled siRNA marker in HT-29 cells, after transfection with 
MS09/DOPE and MS09/Chol (1:1) lipoplexes. Cells were transfected with lipoplexes assembled with 
BLOCK-iT
™
 Fluorescent oligo (MS09:siRNA 
w
/w = 16:1) at final concentration of 12 nM for 24 h. LF3K 
denotes Lipofectamine
™
 3000, and transfection was as per manufacturer’s instruction. Intracellular 
fluorescence was monitored using an inverted fluorescence microscope at 200× magnification. The scale 
bar represents 50 μm in all images. 













Consequently the MS09/Chol (1:1) lipoplex assembled at an MS09:siRNA (w/w) ratio of 16:1 
was investigated as a new anti-c-myc agent, at a final siRNA concentration of 12 nM, in 
comparison with its DOPE-containing counterpart. 
 
4.11 Gene silencing mediated by MS09/Chol (1:1) lipoplexes 
Thus far, it has been confirmed that siRNA associated with MS09/Chol (1:1) and MS09/DOPE 
liposomes at an MS09:siRNA (w/w) ratio of 16:1 successfully traverses the plasma membrane and 
enters MCF-7 and HT-29 cells, at the highest level possible for these formulations in the cell 
lines tested, when applied at a final concentration of 12 nM. However, the question as to whether 
the siRNA delivered successfully reaches and engages with the RNAi machinery to inhibit 
oncogene expression, is critical to this study.  
Given that the initial RNAi effect is exerted at the mRNA level, the effect of transfection with 
anti-c-myc lipoplexes on c-myc transcripts in cancer cells was studied using RT-qPCR. 
Figure 4.35 shows a decrease in c-myc mRNA only in instances in which a transfecting agent 
was used to deliver anti-c-myc siRNA sequences. Quantification of cellular c-Myc protein by 
ELISA (Figure 4.36) showed that a drop in c-myc mRNA levels was, in all instances, 
accompanied by a concomitant reduction in protein expression. Complexes assembled with non-
targeting siRNA were without effect. This confirms that the observed reduction in c-myc mRNA 
is directly attributable to the RNAi effect of successfully delivered anti-c-myc siRNA. 
Furthermore, the fact that naked anti-c-myc siRNA did not influence c-myc expression in any 
way, emphasises that the delivery vehicle is a necessity. 
MS09/Chol (1:1) and MS09/DOPE lipoplexes produced significantly more potent gene silencing 
effects than LF3K in both cell lines. More specifically, in the MCF-7 cell line, MS09 lipoplexes 
achieved 8- and 3.5-fold greater knockdown of oncogenic c-myc than LF3K at the mRNA and 
protein levels, respectively. In HT-29 cells, the decrease in c-myc mRNA and protein was 5- and 
2.8-fold more intense with MS09 lipoplexes. This is consistent with the fact that both MS09 
lipoplexes were taken up more effectively than LF3K (P < 0.01) in MCF-7 and HT-29. The 
superior performance of MS09 lipoplexes is further highlighted by the fact that these were 































































































































Figure 4.35: The effect of anti-c-myc lipoplexes on c-myc mRNA expression in a) MCF-7 and b) HT-29 
cells, 48 h after transfection with MS09/DOPE and MS09/Chol (1:1) lipoplexes. Lipoplexes were 
assembled at MS09:siRNA (
w
/w) ratio of 16:1 and cells received final siRNA concentration of 12 nM. 
c-myc expression was quantified by RT-qPCR and normalised to the β-actin reference gene using the 
ΔΔCq comparative quantification algorithm. Each column represents the mean ± SD (n = 3).
 *
P < 0.05, 
***
P < 0.001 vs. naked siRNA; 
♦
P < 0.05, 
♦♦♦
P < 0.001 vs. non-targeting siRNA; 
##
P < 0.01, 
###
P < 0.001 vs. 

































































































































Figure 4.36: The effect of anti-c-myc lipoplexes on c-Myc protein expression in a) MCF-7 and b) HT-29 
cells, 48 h after transfection with MS09/DOPE and MS09/Chol (1:1) lipoplexes. Lipoplexes were 
assembled at MS09:siRNA (
w
/w) ratio of 16:1 and cells received final siRNA concentration of 12 nM. 
c-Myc expression was quantified by ELISA, and normalised to the internal control, β-actin. Each column 
represents the mean ± SD (n = 3). *P < 0.05, ***P < 0.001 vs. naked siRNA; ♦P < 0.05, ♦♦♦P < 0.001 vs. non-
targeting siRNA; #P <0.05, ##P < 0.01, ###P < 0.001 vs. anti-c-myc LF3K. P > 0.05, with respect to 




In HT-29 cells cellular uptake of MS09/Chol (1:1) and MS09/DOPE lipoplexes was comparable 
(P > 0.05). The similar reduction in c-myc mRNA and protein observed implies that the MS09 
lipoplexes facilitated RISC-engagement of intact anti-c-myc siRNA molecules with near-equal 
efficiency. In contrast, in the MCF-7 cell line, the MS09/Chol (1:1) lipoplex, at 12 nM final 
siRNA, facilitated more effective siRNA delivery than its DOPE-containing counterpart 
(P < 0.05), but did not give a more pronounced gene silencing effect. Taking into account that, at 
the point of maximum cellular uptake, a greater number of siRNA molecules enter MCF-7 cells 
with the MS09/Chol (1:1) lipoplex, saturation of the RNAi machinery is a possibility, especially 
given the likelihood that this complex releases siRNA directly into the cytoplasm. RISC 
saturation within a broad siRNA concentration range of 5-100 nM has been reported, and is 
dependent upon the potency of the siRNA molecules involved (Daniels et al., 2013). Given the 
catalytic nature of siRNA activity, the results suggest that the MS09/Chol (1:1) lipoplex could 
give useful, or perhaps as effective, gene silencing at final siRNA concentrations below 12 nM in 
MCF-7 cells. In support of this notion, siRNA delivery by the MS09/Chol (1:1) lipoplex in 
MCF-7 cells was detectable with as little as 4 nM final siRNA (Figure 4.32a).  
It was observed that c-myc inhibition at both levels of expression by all transfecting agents was 
more pronounced in MCF-7 cells than in HT-29 cells (P < 0.05). This is underscored by the fact 
that the HT-29 cell line is considerably more difficult to transfect than other human cell lines 
(Alameh et al., 2010, Cerda et al., 2015, Hsi et al., 2000). In fact, manufacturers of the LF3K 
reagent have reported that the HT-29 cell line was among the least efficiently transfected in a 
wide range of tested mammalian cell lines 
(http://www.thermofisher.com/us/en/home/brands/product-brand/lipofectamine/lipofectamine-
3000.html#sup). This explains the markedly lower cellular uptake (Figure 4.31d) and oncogene 
knockdown (1.4-fold reduction of c-myc at both levels of expression) obtained with LF3K in 
HT-29 cells. On a more positive note, the fact that MS09 lipoplexes have performed better in a 
recalcitrant cell line than a standard transfection reagent, could point to their applicability as 
oncogene silencing agents in other difficult-to-transfect cancer cells, and this adds credence to 
their potential as broad range anti-c-myc agents. 
For comparative evaluation as anti-c-myc agents, both MS09/Chol (1:1) and MS09/DOPE 
lipoplexes were tested at the same MS09:siRNA (w/w) ratio, final lipid and siRNA concentration. 
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Although the siRNA-binding and protecting capability, under standard in vitro conditions, of 
MS09/Chol (1:1) was shown to be markedly weaker than its DOPE-containing counterpart at the 
MS09:siRNA (w/w) ratio of 16:1, the MS09/Chol (1:1) lipoplex has proved to be as effective an 
siRNA carrier and c-myc-silencing agent. This could be ascribed to the aforementioned role of 
cholesterol nanodomains in transfection (Xu and Anchordoquy, 2008, Xu and Anchordoquy, 
2010) and the usefulness of Chol-mediated fusion with the cell membrane as a mode of 
delivering intact siRNA directly to the RNAi apparatus in the cytoplasm (Pozzi et al., 2012).  
 
4.12 Anti-cancer effects of anti-c-myc lipoplexes 
Cancer cell motility is associated with invasiveness and metastatic potential (Paul et al., 2017). 
Oncogenic c-Myc supports cell migration in several ways. For example, oncogenic c-Myc drives 
the expression of integrins (Boudjadi et al., 2016), long non-coding RNA (Hu and Lu, 2015) and 
microRNA (Li et al., 2013) that are known to encourage cell migration. In fact, the truncated 
form of c-Myc, Myc-nick, was recently shown to accelerate the migration of colon cancer cells 
by inducing fascin expression and activating the Rho GTPase Cdc42 (Anderson et al., 2016). 
The impact of transfection with anti-c-myc lipoplexes on cell migration was assessed by 
monitoring the movement of cells into a wound that was created in the cell monolayer (Liang et 
al., 2007). Figures 4.37 and 4.38 show that all complexes containing anti-c-myc siRNA were 
associated with a defect in cell motility. In fact, in cells treated with anti-c-myc MS09/Chol (1:1) 
and MS09/DOPE lipoplexes, the normalised wound area measured after 24 h was wider 
(P < 0.01) (Figure 4.39) and wound margins at 24 h appeared less defined than at 0 h. This could 
point to loss of cell viability. To confirm this, the AB viability assay was performed. 
The AB assay (Figure 4.40) showed that, all transfections with anti-c-myc siRNA, with the 
exception of LF3K in HT-29 cells, were associated with a significant drop in cell viability. This 
is consistent with a wealth of evidence, as reviewed by Bretones et al. (2015) that, 






                   
                   
 
 
                                                              
                                                              
Figure 4.37: Effect of lipoplexes on MCF-7 cell migration. Wounds were created after transfection with MS09/DOPE and MS09/Chol (1:1) lipoplexes 
(MS09:siRNA 
w
/w = 16:1) at a final siRNA concentration of 12 nM. LF3K denotes Lipofectamine
™
 3000 and transfection was as per manufacturer’s instruction. 
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Figure 4.38: Effect of lipoplexes on HT-29 cell migration. Wounds were created after transfection with MS09/DOPE and MS09/Chol (1:1) lipoplexes 
(MS09:siRNA 
w
/w = 16:1) at a final siRNA concentration of 12 nM. LF3K denotes Lipofectamine
™
 3000 and transfection was as per manufacturer’s instruction. 
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Figure 4.39: Wound healing ability of a) MCF-7 and b) HT-29 cells after treatment with lipoplexes 
assembled with either non-targeting or anti-c-myc siRNA. Data is presented as the mean ± SD (n = 3). 
*
P < 0.05, 
***
P < 0.001 vs. naked siRNA; 
♦
P < 0.05, 
♦♦♦
P < 0.001 vs. non-targeting siRNA. 
#
P < 0.05, 
###










































































































Figure 4.40: Effect of lipoplexes assembled with anti-c-myc siRNA on the growth of a) MCF-7 and 
b) HT-29 cells. Cells were tested for viability by the AB assay 48 h post-transfection. Data is presented as 
the mean ± SD (n = 3). 
**
P < 0.01, 
***
P < 0.001 vs. naked siRNA;
 ♦
P < 0.05, 
♦♦
P < 0.01, 
♦♦♦





P < 0.01 vs. anti-c-myc LF3K. P > 0.05 with respect to 
anti-c-myc MS09/Chol (1:1) vs. anti-c-myc MS09/DOPE. 
 
Cell death can occur by several mechanisms and this is dependent upon the stimulus that cells 
receive. In treating cancer, a desirable feature is for the treatment to induce death of cancer cells 
without causing harm to surrounding healthy tissue. For this reason several anti-cancer 
approaches have attempted to exploit a natural mechanism of cell death such as apoptosis that, 
under normal conditions, facilitates elimination of damaged and/or harmful cells in a regulated 
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fashion (Baig et al., 2016). To test whether or not the anti-c-myc lipoplexes result in cell death 
via this potentially useful pathway, AO/EtBr dual staining was performed. 
The AO/EtBr method is based on the principle that AO enters cells with intact plasma 
membranes and binds to DNA to emit green fluorescence, while EtBr enters cells with defective 
membrane integrity and fluoresces red-orange when bound to DNA. Differentiation between 
normal, early apoptotic, late apoptotic and necrotic cells was made based on observations of 
nuclear morphology (Figures 4.41, 4.42). Live cells were characterised by a bright green nucleus 
in the centre of the cell. The nuclei of early apoptotic cells, with undamaged membranes, also 
stained green, but appeared to be fragmented or condensed. In contrast, the nuclei of late 
apoptotic cells, with compromised membrane integrity, stained orange with evidence of 
fragmentation or condensation. Finally, necrotic cells were characterised by an intact bright 
orange nucleus (Ribble et al., 2005). 
Figure 4.43 shows that the major mechanism of cell death that was observed by the AB assay 
after 48 h in cells treated with anti-c-myc lipoplexes is, in fact, apoptosis. This observation is 
supported by several studies which have demonstrated that inhibition of c-myc in cancer cells 
leads to apoptosis (Chen et al., 2010, Wang et al., 2005, Zhang et al., 2009), and this is largely 
due to the phenomenon of oncogene addiction (Felsher, 2010). Importantly, necrosis, a non-
specific form of cell death that is associated with an inflammatory response (Kasibhatla and 
Tseng, 2003), was negligible in all instances i.e. necrotic cells accounted for less than 3 % of 
total cells per sample. This implies that MS09/Chol (1:1) and MS09/DOPE-mediated anti-c-myc 





          
          
Figure 4.41: Apoptotic potential of anti-c-myc and non-targeting lipoplexes in MCF-7 cells. Live and apoptotic cells were visualised by AO/EtBr dual staining, 48 h after 
transfection with MS09/DOPE and MS09/Chol (1:1) lipoplexes (MS09:siRNA 
w
/w = 16:1) at 12 nM final siRNA concentration. Transfections with Lipofectamine
™
 3000 (LF3K) were 
as per manufacturer’s instruction. Cells were observed using an inverted fluorescence microscope at 200× magnification, and one representative field of view per sample is 
given. Labelled arrows denote the following: L = live, EA = early apoptotic, LA = late apoptotic, N = necrotic. The scale bar represents 100 μm in all images. Treatment groups 
were as follows: 
a) No treatment 
b) Naked non-targeting siRNA f) Naked anti-c-myc siRNA 
c) LF3K with non-targeting siRNA g) LF3K with anti-c-myc siRNA 
d) MS09/DOPE lipoplex with non-targeting siRNA h) MS09/DOPE lipoplex with anti-c-myc siRNA 
e) MS09/Chol (1:1) lipoplex with non-targeting siRNA i) MS09/Chol (1:1) with anti-c-myc siRNA 
a) 



























             
          
Figure 4.42: Apoptotic potential of anti-c-myc and non-targeting lipoplexes in HT-29 cells. Live and apoptotic cells were visualised by AO/EtBr dual staining, 48 h after 
transfection with MS09/DOPE and MS09/Chol (1:1) lipoplexes (MS09:siRNA 
w
/w = 16:1) at 12 nM final siRNA concentration. Transfections with Lipofectamine
™
 3000 (LF3K) were 
as per manufacturer’s instruction. Cells were observed using an inverted fluorescence microscope at 200× magnification, and one representative field of view per sample is 
given. Labelled arrows denote the following: L = live, EA = early apoptotic, LA = late apoptotic, N = necrotic. The scale bar represents 100 μm in all instances. Treatment groups 
were as follows: 
a) No treatment 
b) Naked non-targeting siRNA f) Naked anti-c-myc siRNA 
c) LF3K with non-targeting siRNA g) LF3K with anti-c-myc siRNA 
d) MS09/DOPE lipoplex with non-targeting siRNA h) MS09/DOPE lipoplex with anti-c-myc siRNA 
e) MS09/Chol (1:1) lipoplex with non-targeting siRNA i) MS09/Chol (1:1) with anti-c-myc siRNA 
a) 
b) c) d) e) 













































































































































































Figure 4.43: Quantification of apoptotic potential of anti-c-myc and non-targeted lipoplexes in a) MCF-7 
and b) HT-29 cells. Live, early apoptotic, late apoptotic and necrotic cells were visualised by fluorescence 
microscopy after AO/EtBr dual staining. At least 200 cells per sample were counted. Data is presented as 
the mean ± SD (n = 3).
 **
P < 0.01, 
***
P < 0.001 vs. naked siRNA; 
♦♦♦
P < 0.001 vs. non-targeting siRNA; 
##
P < 0.01, 
###





A significant decrease in c-myc expression was correlated with anti-cancer effects, which 
included inhibition of cancer cell migration, loss of cell viability and elimination of cancer cells 
through apoptosis, in all instances, with the exception of anti-c-myc LF3K in HT-29 cells. Here, 
modest c-myc inhibition slightly impeded cancer cell migration but was too low to induce 
significant apoptosis and reduce cancer cell numbers within a 48 h period. Of importance, is the 
observation that lipoplexes assembled with non-targeting siRNA, which had no effect on c-myc 
expression, did not impede the normal migration of cancer cells, and did not significantly 
influence their growth in any way. The application of anti-c-myc siRNA in the absence of a 
transfecting agent also did not exhibit any anti-cancer activity. Taken together, this confirms that 
all anti-cancer effects can be ascribed to the RNAi activity of successfully introduced anti-c-myc 
siRNA.  
In keeping with the trend observed in the gene silencing experiments, anti-c-myc 
MS09/Chol (1:1) and MS09/DOPE lipoplexes gave better anti-cancer activity than the LF3K 
reagent, in a given cell line. Furthermore the comparable gene silencing activity mediated by 
MS09/Chol (1:1) and MS09/DOPE lipoplexes in individual cell lines was coupled with anti-
cancer effects of near-equal potency. Although c-myc inhibition with MS09 lipoplexes was more 
pronounced (i.e. 3.8- and 2.8-fold differences at the mRNA and protein levels, respectively) in 
MCF-7 cells than in HT-29 cells, the associated impact on cell migration, cell growth and extent 
to which apoptosis was induced, was similar. Here two possible explanations can be put forward. 
The first is that the level of c-myc inhibition required to elicit a given degree of anti-cancer 
activity differs among cell lines. The second is that, more potent oncogene knockdown does not 
necessarily correspond with enhanced anti-cancer activity. This notion correlates with previous 
comments that a lower final siRNA dose may prove as effective in the easier to transfect, MCF-7 




4.13 Predicting in vivo efficacy of the MS09/Chol (1:1) lipoplex 
Thus far, it has been demonstrated that both MS09/DOPE and MS09/Chol (1:1) formulations are 
able to successfully deliver anti-c-myc siRNA to the RNAi apparatus, into cancer cells known to 
overexpress this oncogene. Both formulations were able to achieve knockdown of oncogenic 
c-myc and elicit anti-cancer effects that surpassed the performance of LF3K. Hence, both 
formulations performed well under standard cell culture conditions, i.e. with 10 % serum. In 
order to predict in vivo efficacy, a serum stability study was performed in higher serum 
concentrations to resemble physiological conditions more closely (Templeton, 2003, Eliyahu et 
al., 2002). 
Figure 4.44 shows the results of cellular uptake experiments performed in medium containing 
10, 30 and 50 % serum, with 50 % serum representing physiological concentration (Zhang and 
Anchordoquy, 2004). If present at higher than normal concentrations, serum could either lead to 
an abnormal increase in the growth of cultured cells or adversely impact on viability (EL-
Ensahsy, 2009). In light of this, 24 h exposure to lipoplexes, as was carried out in all previous 
cellular uptake experiments, in medium with high serum concentration was deemed impractical. 
For this reason, cells were exposed to lipoplexes in medium containing the relevant serum 
concentration for a shorter duration, i.e. 4 h, after which normal growth medium was 
re-introduced. It was demonstrated that the shorter exposure time did not have a significant effect 
on cellular uptake of the siRNA marker following transfection in both cell lines (P > 0.05, 4 h vs. 
24 h in 10 % serum). This implies that lipoplexes are either completely taken up, or at least 
attached to cell membranes within 4 h of application. In addition, this observation validates the 
exposure time fixed in this set of experiments. Moreover, the new set of transfection conditions 
employed had no effect on cell growth as confirmed by the AB assay (Appendix F, Figure F2). 
Hence, any observed reduction in siRNA uptake was as a consequence of the performance of the 
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Figure 4.44: The effect of serum concentration on siRNA delivery by MS09/DOPE and MS09/Chol (1:1) 
lipoplexes in a) MCF-7 and b) HT-29 cells. Cells were exposed to lipoplexes assembled with BLOCK-iT
™
 
Fluorescent Oligo at MS09:siRNA (
w
/w) ratio of 16:1 for 4 h in medium containing 10, 30 or 50 % serum. 
Cells received a final oligo concentration of 12 nM. Intracellular fluorescence was measured 24 h post-
transfection. Control 1 contained cells only, while control 2 contained cells treated with the naked oligo. 
Each column represents the mean ± SD (n = 3). 
***
P < 0.001 vs. control 2; 
##
P < 0.01, 
###
P < 0.001 vs. siRNA 






Although a significant reduction in siRNA delivery was noted with both formulations in MCF-7 
and HT-29 cells when serum concentration was increased from 10 to 30 %, the effect on 
MS09/DOPE-mediated delivery was more dramatic. In fact, siRNA delivery by MS09/DOPE 
was negligible in 30 % and 50 % serum in both cell lines. It appears therefore, that the siRNA 
delivery capability of MS09/DOPE is limited to standard in vitro conditions. In contrast, no 
significant (P > 0.05) drop in siRNA delivery by MS09/Chol (1:1) was noted in either cell line 
when serum concentration was increased from 30 to 50 %. 
Despite the weaker siRNA-binding affinity of the MS09/Chol (1:1) formulation, it retains the 
ability to deliver siRNA at physiological serum concentration due to Chol-conferred stability. Of 
note, is the fact that normalised intracellular fluorescence after the introduction of 
MS09/Chol (1:1) lipoplexes in 50 % serum, was significantly (P < 0.05) greater, in both cell 
lines, than levels achieved with the LF3K transfection reagent under standard in vitro conditions. 
This implies that the anti-c-myc MS09/Chol (1:1) lipoplex, at MS09:siRNA (w/w) ratio of 16:1, 
would be capable of oncogene silencing and anti-cancer activity at physiological serum 




CHAPTER 5 – SUMMARY AND CONCLUSION 
Overexpression of the c-myc proto-oncogene features prominently in most human cancers. Early 
studies established that inhibiting oncogenic c-myc expression produced anti-cancer effects. This 
gave rise to the notion that an appropriate c-myc silencing system may provide a broadly 
applicable and more effective form of cancer treatment, than is currently available. In this regard, 
several nucleic acid-mediated, antigene and antisense strategies have been explored. Among 
them c-myc silencing approaches based on the use of siRNA molecules, which mediate the 
natural RNAi mechanism, represent a promising and current area of research (Whitfield et al., 
2017). 
In theory, siRNA molecules with sequences that are complementary to the c-myc mRNA 
transcript will inhibit c-myc expression by causing cleavage of c-myc mRNA through interaction 
with the RNAi machinery in the cytoplasm. However, the success of this strategy is largely 
dependent upon efficient intracellular delivery of siRNA. Consequently the association of 
anti-c-myc siRNA with a variety of carrier agents has been explored, many of which are 
elaborate multi-component nanosystems. The current study took into account the fact that lipid-
based nanoparticles represent the most widely explored class of siRNA carriers to date, and this 
provided a massive body of knowledge upon which to improve. Moreover, a carrier system with 
a straightforward design is better suited for routine clinical application, because it is more likely 
to be easily and economically produced. Hence, this study focused on what is arguably the 
simplest lipid-based siRNA delivery agent, i.e. the traditional cationic liposome, as the 
framework for the development of an uncomplicated, but effective anti-c-myc 
onconanotherapeutic agent.   
An existing cationic lipid, MS09, which previously demonstrated efficacy within the context of 
in vitro siRNA delivery, served as the foundation for the formulation of novel cationic 
liposomes. In the interest of developing liposomes capable of maintaining stability and resisting 
damage within biological fluids, Chol, which provides mechanical strength to lipid bilayers, was 
included as a helper lipid in novel formulations. As a further stabilising feature, PEG-
modification in the form of DSPE-PEG2000 was introduced. Liposomes containing equimolar 
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quantities of MS09 and the conventional helper lipid, DOPE, were included for comparative 
purposes.   
The process of developing an appropriate MS09-based siRNA carrier began with the 
optimisation of the Chol content of MS09 formulations. Within the range of MS09:Chol molar 
ratios explored, MS09 was found to be compatible with only 50 mol % Chol, in the presence or 
absence of DSPE-PEG2000 at 2 mol %. Therefore, the study proceeded with four preparations, i.e. 
the 2 % pegylated and non-pegylated MS09/Chol (1:1) formulations and their DOPE-containing 
counterparts. Films of these lipid mixtures were successfully hydrated to form small unilamellar 
liposomes, less than 140 nm in size, with zeta potential between -27 and -36 mV. The lipid film 
hydration liposome preparation method employed gave liposome suspensions of consistent 
quality under standard laboratory conditions. Moreover, the substitution of DOPE with Chol 
and/or incorporation of PEG improved the stability of MS09 liposomes with extended storage 
time.  
The siRNA-binding affinity of liposomes was evaluated based on their ability to retard the 
migration of siRNA on agarose gels and displace siRNA-intercalated dyes. Although Chol- and 
PEG-containing liposomes showed weaker siRNA-binding capability than MS09/DOPE, these 
formulations were carried forward in the study on the grounds that a weaker siRNA-binding 
interaction may be useful for the release of siRNA at a later stage in the transfection process. 
Cryo-TEM gave visual proof that all formulations formed complexes with siRNA at 
MS09:siRNA (w/w) ratios of 12:1-32:1. Further evidence of lipoplex formation was obtained by 
Z-NTA-derived concentration estimates which confirmed the involvement of several liposomal 
vesicles in a single complex, except in instances in which the liposome-siRNA interaction was 
markedly tenuous. Lipoplexes were smaller than 200 nm, with zeta potential between -16 
and -44 mV. Liposome composition and the MS09:siRNA (w/w) ratio at which the complexes 
were assembled influenced both lipoplex morphology and the degree of protection that siRNA 
was afforded in the presence of serum. Lipoplexes with bilamellar structures were found to be 
most effective at protecting siRNA against nuclease attack.  
Having confirmed that all formulations formed nanostructures in which siRNA was protected, 
and which displayed biophysical characteristics conducive to cellular uptake, the interaction of 
lipoplexes with several human cell lines was investigated. These were the MCF-7 breast cancer 
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and HT-29 colon cancer cells, both of which overexpress c-myc; Caco-2 colon cancer cells that 
are able to regulate c-myc expression; and a non-transformed cell line, HEK293. In order to 
select the best performing lipoplex, cells received lipoplexes assembled at all characterised 
MS09:siRNA (w/w) ratios (i.e. 12:1-32:1) and these were applied at broad range final siRNA 
concentrations (i.e. 57-14 nM). Cell viability assays showed that lipoplex-mediated growth 
inhibition was cell-specific and dependent upon several variables. These included the liposome 
composition, the MS09:siRNA (w/w) ratio at which lipoplexes were formed and the final siRNA 
and lipid dose. These factors also had a bearing on cellular uptake and siRNA delivery 
efficiency. Although well tolerated, pegylated lipoplexes gave negligible siRNA delivery in 
MCF-7 and HT-29 cells. This was largely ascribed to the inhibitory effect of PEG chains on the 
interaction between the lipoplex and biological membranes. In this regard, the use of cleavable 
PEG-lipids, designed to shed the polymer upon exposure to specific extra- or intracellular 
conditions, has been suggested (Fang et al., 2017). 
By contrast, non-pegylated lipoplexes proved effective even at low final siRNA concentration. 
The MS09/Chol (1:1) lipoplex at the MS09:siRNA (w/w) ratio of 16:1 was most effectively taken 
up by MCF-7 and HT-29 cells, without compromising cell viability at 14 nM final siRNA. 
Moreover, at the applied dose, this lipoplex appeared selective for c-myc-overexpressing cancer 
cells, having no significant impact in non-cancerous cells and cancer cells that are able to 
regulate c-myc expression i.e. HEK293 and Caco-2, respectively. Therefore, the 
MS09/Chol (1:1) lipoplex (MS09:siRNA (w/w) ratio = 16:1) was investigated further as a 
potential c-myc silencing agent. A final siRNA concentration of 12 nM was found to be the 
minimum dose required for maximum cellular uptake of this lipoplex in MCF-7 and HT-29 cells. 
It was also confirmed that, at this dose, lipoplexes were not internalised by HEK293 and Caco-2 
cells and no significant drop in cell numbers was recorded.  
Anti-c-myc lipoplexes were assembled using a pool of four siRNA duplexes, each with 
complementarity to a different region of the c-myc transcript. At 12 nM final siRNA, the 
MS09/Chol (1:1) lipoplex dramatically reduced c-myc expression at the mRNA and protein 
levels within a 48 h period in both cell lines. Lipoplex-mediated c-myc silencing inhibited the 
motility of cancer cells and induced cell death. Importantly, cancer cell death was found to occur 
primarily via the innocuous mechanism of apoptosis which preserves the integrity of normal, 
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healthy tissue. In all instances, the MS09/Chol (1:1) lipoplex produced more potent c-myc 
silencing and anti-cancer effects than the commercially available transfection reagent, LF3K. 
Although the DOPE-containing counterpart performed with comparable efficacy under standard 
cell culture conditions, it will not be effective in vivo. This was highlighted by the demonstration 
that an increase in serum concentration, both approaching and at physiological levels, abolished 
siRNA delivery by MS09/DOPE. In contrast, the MS09/Chol (1:1) lipoplex retained 
approximately 70 % siRNA delivery capability in MCF-7 and HT-29 cells when transfections 
were conducted in 50 % serum. Given the catalytic, non-stoichiometric activity of siRNA, this 
lipoplex is likely to give clinically useful outcomes in vivo. Moreover, the performance of the 
MS09/Chol (1:1) lipoplex at physiological serum concentration, in the absence of pegylation, ties 
in with previous work which suggested the use of large quantities of Chol as an alternative to 
pegylation (Nchinda et al., 2002, Templeton et al., 1997, Yang et al., 2013, Zhang and 
Anchordoquy, 2004). It is also worth mentioning that further studies with primary cells, which 
require high serum concentrations to grow, could provide strong supporting data in evaluating 
lipoplex performance in vivo. The current study can be profitably extended by repeating the 
cellular uptake experiments, as described, in primary cells derived from c-myc-driven tumours 
and, finally, appling the anti-c-myc MS09/Chol (1:1) lipoplex to assess oncogene knockdown at 
physiological serum levels.  
The fact that the MS09/Chol (1:1) lipoplex, in the absence of any additional modifications, 
appears to display specificity for c-myc-overexpressing cancer cells, is a point of interest and 
worthy of further investigation. In order to confirm this phenomenon it is suggested that the 
cellular uptake of the lipoplex be assessed in several more cell lines, that are representative of 
other cancers characterised by c-myc overexpression. Taking into account that c-myc 
overexpression drives aberrant lipid metabolism (Eberlin et al., 2014, Hall et al., 2016, Perry et 
al., 2013) and the postulate that cholesterol domains of the lipoplex could facilitate cellular 
uptake via interaction with plasma membrane components (Betker et al., 2013b); it is possible 
that even subtle differences in composition of the plasma membrane of such cancer cells, as 
opposed to cells which can regulate c-myc levels, may account for the observed affinity for this 
lipoplex. A comparison of lipid profiles of cells which overexpress c-myc and those which do 
not, combined with an in-depth analysis of the lipoplex uptake mechanism could confirm 
whether or not this holds true. Such a study could open up further possibilities for targeting the 
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vast majority of cancers in which c-myc is overexpressed while maintaining a simple carrier 
design. 
In summary, several features of the anti-c-myc MS09/Chol (1:1) lipoplex point towards its 
potential as a simple, safe and effective onconanotherapeutic agent. Firstly, the lipoplex is an 
uncomplicated three-component nanostructure obtained in a convenient two-stage process i.e. 
reproducible lipid-film hydration of MS09 and Chol to form a stable liposome suspension, 
followed by electrostatic association with siRNA. Secondly, the lipoplex mediated potent c-myc 
silencing at a relatively low final siRNA and lipid dose, and this destroys cancer cells in a 
manner that is unlikely to injure healthy cells. Its effectiveness as an anti-cancer agent was 
highlighted by its ability to facilitate efficient siRNA delivery and oncogene knockdown in 
recalcitrant cancer cells. Moreover, the physical features of the lipoplex point towards a tendency 
for selective accumulation at tumour sites. Thirdly, the lipoplex has apparent specificity for 
c-myc-overexpressing cancer cells without adversely affecting non-cancerous cells. Finally, the 
lipoplex remains capable of siRNA delivery at physiological serum concentrations. These 
features, taken together, suggest that the anti-c-myc MS09/Chol (1:1) lipoplex reported is worthy 
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 Supplementary Z-NTA data 
1. Number of lipid molecules that constitute liposomal vesicles 
Table B1: Estimated number of lipid molecules per liposomal vesicle 
Formulation 
Average number of lipid moleculesa 
(× 105/vesicle) 
Total lipid MS09 DOPE Chol DSPE-PEG2000 
MS09/DOPE 8.56 4.28 4.28 - - 
MS09/Chol (1:1) 11.60 5.80 - 5.80 - 
MS09/DOPE/PEG 11.00 5.39 5.39 - 0.22 
MS09/Chol/PEG (1:1) 8.75 4.29 - 4.29 0.22 
Note: 
aEstimates were made based on the lipid concentration of liposome stock suspensions and NTA-derived 




2. Summarised data 
 










d 164.2 ± 4.7 133.5 ± 15.2 81.1 ± 17.2 95.8 ± 5.5 134.9 ± 5.7 259.3 ± 15.8  
12:1 125.6 ± 12.2 98.4 ± 11.6 43.6 ± 18.8 78.4 ± 5.2  98.1 ± 7.1 163.8 ± 35.1 
16:1 127.6 ± 24.4 92.4 ± 24.5 68.5 ± 25.3 61.9 ± 24.7 103.8 ± 15.7 218.8 ± 63.7 
20:1 156.9  ± 10.6 128.0 ± 17.1 57.6 ± 3.3 101.0 ± 7.1 135.6 ± 9.7 224.5 ± 15.7 
24:1 203.1 ± 11.1 166.9 ± 21.8 72.9 ± 14.6 115.6 ± 13.2 183.1 ± 3.2 290.2 ± 28.0 
28:1 202.4 ± 20.9 195.7 ± 21.0 69.6 ± 15.0 112.9 ± 16.4 191.7 ± 21.2 288.0 ± 38.7 




d 167.6 ± 3.3 137.5 ± 10.8 69.2 ± 7.7 104.2 ± 3.4 143.6  ±2.2 246.2 ± 6.3 
12:1 130.6 ± 10.0 117.5 ± 12.6 42.0 ± 12.3 79.6 ± 3.6 119.5 ± 7.6 181.8 ± 23.2 
16:1 228.8 ± 11.2 126.8 ± 7.3 147.7 ± 20.3 87.4 ± 29.0 165.7 ± 1.3 322.2 ± 185.4  
20:1 184.4 ± 12.6 140.0 ± 14.2 89.0 ± 15.6 91.0 ± 10.9 146.6 ± 14.0 290.8 ± 27.5 
24:1 145.1 ± 64.5 93.3 ± 2.2  105.4 ± 100.3 62.9 ± 1.2 93.6 ± 12.2 316.9 ± 258.6 
28:1 160.5 ± 9.5 133.1 ± 6.4 71.6 ± 1.9 91.7 ± 3.7 136.6 ± 12.2 252.9 ± 21.8 




d 149.7 ± 14.7 125.3 ±  4.3 56.5 ± 6.7 95.1 ± 10.1 128.7 ± 16.5 225.6 ± 14.5 
12:1 158.0 ± 10.1 125.3 ±  4.3 51.6 ± 10.2 104.3 ± 5.6 140.0 ± 7.9 215.1 ± 13.5 
16:1 161.2 ± 3.2 133.6 ± 14.3 55.9 ± 7.1 101.0 ± 2.7 139.6 ± 2.6 213.2 ± 7.6 
20:1 166.7 ± 4.1 131.5 ± 4.0 57.2 ± 3.6 104.6 ± 0.2 147.4 ± 4.1 239.9 ± 23.0 
24:1 153.9 ± 2.4 145.3 ± 8.8 54.4 ± 3.5 102.8 ± 1.2 135.0 ± 0.4 211.3 ± 16.9 
28:1 156.9 ± 4.7 127.1 ± 5.0 48.8 ± 3.3 101.9 ± 2.3 140.5 ± 5.8 220.9 ± 7.1 





d 174.7 ± 17.8 125.1 ± 5.4 87.0 ± 16.7 95.2 ± 6.3 137.1 ± 7.3 304.9 ± 34.8 
12:1 163.6 ± 12.9 138.6 ± 6.1 61.1 ± 13.4 100.1 ± 13.4 138.1 ± 10.1 251.2 ± 28.3 
16:1 169.2 ± 22.4 115.5 ± 17.6 101.5 ± 40.3 84.0 ± 4.6 131.1 ± 2.8 266.3 ± 54.2 
20:1 187.5 ± 11.6 155.0 ± 14.6 84.9 ± 21.9 101.2 ± 15.4 160.8 ± 7.9 280.7 ± 44.3 
        Table B2 continued on next page 
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 Size (nm) 




24:1 152.3 ± 12.4 122.7 ± 3.7 58.0 ± 19.8 94.4 ± 4.6 128.0 ± 9.1 234.8 ± 59.5 
28:1 166.0 ± 0.9 124.0 ± 24.3 59.2 ± 6.2 102.8 ± 11.3 143.9 ± 1.3 244.4 ± 26.3 
32:1 175.4 ± 7.6 153.9 ± 35.2 65.6 ± 1.2 107.0 ± 4.5 154.6 ± 15.3 280.1 ± 28.6 
MS09/Chol (1:2) - d 386.3 ± 10.9 356.5 ± 17.6 90.2 ± 0.2 202.2 ± 3.7 343.6 ± 9.3 502.7 ± 48.2 










 418.5 ± 9.9 357.5 ± 57.3 76.7 ± 18.8 149.3 ± 18.9 360.8 ± 59.1 457.4 ± 78.7 
MS09/DOPE  
Batch 2 
t = 0 months 
-
 d





 169.5  ± 0.7 132.2  ± 15.0 85.7 ± 2.5 97.7 ± 0.9 132.3  ± 4.5 267.0  ± 1.4 
MS09/Chol (1:1) 
Batch 2 
t = 0 months 
-
 d
 165.1 ± 2.1 139.6 ± 10.6 
 





 171.6 ± 3.3 134.8 ± 10.7 71.8 ± 3.7 105.2 ± 4.7 146.9 ± 1.2 269.5 ± 2.4 
MS09/DOPE/PEG 
Batch 2 
t = 0 months 
-
 d





 142.8 ± 9.0 128.9 ± 8.5 60.3 ± 6.3 86.8 ± 4.1 133.2 ± 5.0 227.3 ± 5.4 
MS09/Chol/PEG 
(1:1), Batch 2 
t = 0 months 
-
 d
 167.6 ± 1.2 127.4 ± 4.1 70.4 ± 1.1 106.3 ± 0.9 146.4 ± 4.8 251.5 ± 5.6 
MS09/Chol/PEG 
(1:1), Batch 3 
-
 d
 170.3 ± 2.0 128.7 ± 5.6 89.6 ± 1.8 93.2 ± 0.9 139.0 ± 1.5 303.5 ± 6.5 
        
        
Table B2 continued 










Meana Modea SDa,b D10a,c D50a,c D90a,c 
MS09/DOPE 
Batch 2 
t = 5 months 
-
 d
 153.8 ± 5.5 141.7 ± 5.9 68.3 ± 8.8 89.2 ± 5.1 145.2 ± 13.0 229.9 ± 10.5 
MS09/DOPE 
Batch 2 
t = 10 months 
-
 d
 167.1 ± 6.4 162.7 ± 3.1 69.3 ± 8.4 92.2 ± 8.1 154.9 ± 5.1 251.2 ± 16.8 
MS09/Chol (1:1) 
Batch 2 
t = 5 months 
-
 d
 159.8 ± 8.7 135.4 ± 4.5 64.5 ± 5.0 95.4 ± 4.4 133.2 ± 3.5 244.1 ± 6.9 
MS09/Chol (1:1) 
Batch 2 
t = 10 months 
-
 d
 159.2 ± 8.4  141.1 ± 5.5 80.7 ± 6.0 93.9 ± 1.6 141.1 ± 8.0 267.2 ± 10.6 
MS09/DOPE/PEG 
Batch 2 
t = 5 months 
-
 d
 148.4 ± 5.8 132.0 ± 2.3 43.3 ± 2.2 86.7 ± 3.9 137.4 ± 2.2 237.3 ± 5.4 
MS09/DOPE/PEG 
Batch 2 
t = 10 months 
-
 d
 144.9 ± 4.3 136.1 ± 7.8 48.9 ± 3.0 95.6 ± 2.3 134.0 ± 2.4 244.9 ± 5.0 
MS09/Chol/PEG 
(1:1), Batch 2 
t = 5 months 
-
 d
 156.9 ± 5.0 128.6 ± 2.5 76.9 ± 2.7 93.3 ± 2.6 132.4 ± 1.5 278.6 ± 0.8 
MS09/Chol/PEG 
(1:1), Batch 2 
t = 10 months 
-
 d
 146.8 ± 8.2 128.6 ± 2.0 77.6 ± 4.9 91.1 ± 1.4 142.6 ± 10.4 278.9 ± 3.0 
Notes:  
aEach value represents the mean ± S.D (n = 3) 
bThe SD value is a measure of the width of the size distribution profile 
cThe D10, D50 and D90 values indicate the percent under-size 
dThe associated values are those of liposomes alone 
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ζ potential (mV) 





-26.1 ± 5.4 -27.9 ± 5.4 24.2 ± 1.8 -52.8 ± 5.0 -27.2 ± 5.3 0.0 ± 6.9 
12:1 -30.0 ± 0.4 -28.9 ± 1.0 26.0 ± 0.8 -58.6 ± 0.9 -30.7 ± 0.7 -2.3 ± 0.9 
16:1 -34.1 ± 3.9 -33.6 ± 4.5 28.4 ± 9.4 -62.7 ± 1.3 -35.1 ± 4.4 -5.9 ± 4.4 
20:1 -16.4 ± 4.7 -15.1 ± 3.9 20.9 ± 1.3 -39.8 ± 3.3 -16.6 ± 4.7 -4.4 ± 7.4 
24:1 -21.0 ± 2.5 -18.8 ± 2.7 17.4 ± 0.6 -41.4 ± 3.6 -20.8 ± 2.4 -3.1 ± 2.2 
28:1 -19.8 ± 1.2 -17.2 ± 0.7 16.5 ± 2.3 -38.9 ± 2.0 -19.6 ± 1.2 -3.0 ± 4.1 





-27.7 ± 1.6 -30.3 ± 3.8 25.8 ± 1.2 -56.5 ± 2.7 -28.4 ± 1.5 0.2 ± 1.6 
12:1 -30.0 ± 0.8 -33.9 ± 1.6 25.8 ± 2.6 -58.0 ± 2.1 -30.5 ± 0.8 -2.7 ± 3.7 
16:1 -40.4 ± 3.6 -43.9 ± 5.4 24.6 ± 5.1 -64.7 ± 2.4 -42.9 ± 3.2 -13.8 ± 9.4 
20:1 -32.2 ± 0.8 -32.3 ± 1.5 22.1 ± 0.7 -55.2 ± 1.3 -32.9 ± 1.2 -9.4 ± 0.4 
24:1 -32.1 ± 1.7 -35.2 ± 0.8 29.6 ± 2.8 -64.7 ± 3.7 -33.6 ± 1.1 -5.6 ± 1.8 
28:1 -27.7 ± 0.7 -27.7 ± 2.7 21.5 ± 0.3 -50.5 ± 0.6 -28.2 ± 1.2 -5.5 ± 0 





-28.5 ± 4.1 -27.5 ± 2.9 24.4 ± 1.1 -56.1 ± 5.9 -28.9 ± 3.7 -2.4 ± 3.6 
12:1 -32.9 ± 6.3 -32.3 ± 6.5 22.3 ± 0.3 -57.3 ± 7.1 -33.3 ± 6.2 -9.3 ± 5.8 
16:1 -36.7 ± 3.0 -35.8 ± 2.8 22.5 ± 0.5 -62.1 ± 3.4 -37.1 ± 3.0 -12.7 ± 2.3  
20:1 -34.3 ± 0.7 -32.9 ± 1.0 20.5 ± 0.5 -57.0 ± 1.0 -34.6 ± 0.6 -13.0 ± 1.0 
24:1 -17.8 ± 0.6 -17.1 ± 0.9 23.5 ± 0.2 -44.5 ± 0.8 -18.3 ± 0.6 7.6 ± 0.3 
28:1 -25.5 ± 2.9 -24.0 ± 3.1 20.8 ± 0.5 -48.5 ± 2.2 -25.9 ± 0.3 -3.8 ± 3.1 






-36.6 ± 1.0 -36.2 ± 4.9 25.0 ± 0.3 -64.5 ± 0.2 -37.4 ± 2.0 -9.0 ± 0.8 
12:1 -23.2 ± 0.3 -21.2 ± 0.7 21.9 ± 1.9 -47.3 ± 4.1 -23.0 ± 0.3 -0.5 ± 2.4 
16:1 -22.1 ± 1.8 -22.6 ± 2.1 25.2 ± 1.4 -50.5 ± 3.9 -22.5 ± 1.7 5.1 ± 1.7 
20:1 -18.8 ± 0.5 -18.0 ± 2.0 21.7 ± 1.7 -42.7 ± 1.6 -19.0 ± 0.9 3.6 ± 1.0 
24:1 -20.1 ± 0.1 -19.9 ± 1.6 21.7 ± 0.4 -43.6 ± 1.3 -20.6 ± 0.2 2.8 ± 0.6 
28:1 -17.2 ± 0.8 -16.0 ± 2.3 21.7 ± 1.3 -41.5 ± 2.3 -17.6 ± 1.0 5.4 ± 1.1 
32:1 -16.0 ± 0.2 -15.6 ± 0.3 21.5 ± 1.5 -39.9 ± 1.9 -16.5 ± 0.3 7.5 ± 1.6 
        Table B3 continued on next page 
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ζ potential (mV) 
Meana Modea SDa,b D10a,c D50a,c D90a,c 
MS09/Chol (1:2) - d -14.4 ± 3.8 -13.7 ± 2.1 22.4 ± 1.8 -39.6 ± 1.6 -15.0 ± 4.0 3.5 ± 5.2 










 -6.3 ± 2.6 -6.6 ± 2.4 15.5 ± 5.9 -24.8 ± 10.1 -7.1 ± 2.7 10.1 ± 3.5 
MS09/DOPE  
Batch 2 
t = 0 months 
-
 d





 -29.5 ± 3.1 -27.5 ± 7.2 25.9 ± 0.2 -50.6 ± 1.4 -26.6 ± 0.5 -0.8 ± 1.2 
MS09/Chol (1:1) 
Batch 2 
t = 0 months 
-
 d





 -27.0 ± 1.1 -28.5 ± 11.9 27.5 ± 1.5 -57.6 ± 1.5 -30.6 ± 1.7 0.6 ± 2.1 
MS09/DOPE/PEG 
Batch 2 
t = 0 months 
-
 d





 -28.6 ± 1.1 -26.6 ± 3.5 25.0 ± 0.9 -59.0 ± 1.2 -30.4 ± 2.0 -3.8 ± 2.1 
MS09/Chol/PEG 
(1:1), Batch 2 
t = 0 months 
-
 d
 -36.8 ± 0.8 -37.5 ± 8.8 25.5 ± 0.6 -64.9 ± 0.1 -37.2 ± 0.6 -5.4 ± 1.1 
MS09/Chol/PEG 
(1:1), Batch 3 
-
 d
 -30.6 ± 1.1 -37.2 ± 4.4 27.0 ± 0.2 -60.7 ± 0.5 -30.1 ± 1.2 -3.5 ± 1.2 
MS09/DOPE 
t = 5 months 
-
 d
 -31.3 ± 1.1 -32.5 ± 1.3 25.4 ± 1.8 -56.4 ± 1.0 -30.9 ± 1.7 -2.9 ± 1.8 
MS09/DOPE 
t = 10 months 
-
 d
 -18.5 ± 3.2 -17.2 ± 0.9 23.3 ± 2.6 -54.0 ± 4.1 -20.0 ± 4.8 -30.0 ± 2.1 
   
Table B3 continued 








ζ potential (mV) 
Meana Modea SDa,b D10a,c D50a,c D90a,c 
MS09/Chol (1:1) 
Batch 2 
t = 5 months 
-
 d
 -26.9 ± 2.4 -27.6 ± 1.1 25.5 ± 0.8 -56.4 ± 1.0 -27.7 ± 1.4 -0.8 ± 2.3 
MS09/Chol (1:1) 
Batch 2 
t = 10 months 
-
 d
 -28.8 ± 1.6 -26.5 ± 1.2 22.3 ± 1.2 -54.7 ± 5.7 -24.3 ± 0.5 -2.4 ± 1.4 
MS09/DOPE/PEG 
Batch 2 
t = 5 months 
-
 d
 -30.2 ± 1.6 -27.4 ± 3.0 25.8 ± 2.0 -62.2 ± 3.4 -29.3 ± 1.5 -6.0 ± 2.7 
MS09/DOPE/PEG 
Batch 2 
t = 10 months 
-
 d
 -36.8 ± 1.2 -30.4 ± 4.0 19.1 ± 3.2 -48.3 ± 2.1 -36.5 ± 1.6 -5.3 ± 1.1 
MS09/Chol/PEG 
(1:1), Batch 2 
t = 5 months 
-
 d
 -38.9 ± 2.5 -38.5 ± 3.1 23.3 ± 0.9 -64.2 ± 2.3 -38.5 ± 1.9 -0.9 ± 4.7 
MS09/Chol/PEG 
(1:1), Batch 2 
t = 10 months 
-
 d
 -38.9 ± 4.3 -38.3 ± 7.5 25.5 ± 0.7 -70.7 ± 2.0 -55.1 ± 2.6 -8.5 ± 1.2 
Notes:  
aEach value represents the mean ± S.D (n = 3) 
bThe SD value is a measure of the width of the zeta potential distribution profile 
cThe D10, D50 and D90 values indicate the percent of particles under the given zeta potential value 
dThe associated values are those of liposomes alone
Table B3 continued 
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3. Additional NTA concentration-derived estimates 
 
Table B4: Estimated number of liposomal vesicles and siRNA molecules per liposome-siRNA 
nanocomplex 
Liposome formulation MS09:siRNA 
(w/w) 
Average number of 
vesicles/nanocomplex 
Average number of siRNA 
molecules/nanocomplex 
MS09/DOPE 12:1a 3 n/a 
16:1 3 4500 
20:1 2 1800 
24:1 2 2100 
28:1 3 2400 
32:1 5 4000 
MS09/Chol (1:1) 
 
12:1a 3 n/a 
16:1 3 3900 
20:1 3 4500 
24:1 3 4000 
28:1 3 2000 
32:1 2 1700 
MS09/DOPE/PEG 
 
12:1a 3 n/a 
16:1 3 3100 
20:1 3 2400 
24:1 3 1900 
28:1 2 1700 
32:1 2 1700 
MS09/Chol/PEG (1:1) 
 
12:1a,b 1 n/a 
16:1b 1 1700 
20:1 3 3100 
24:1 3 3000 
28:1b 1 1000 
32:1 2 1500 
Notes: 
aComplete dye displacement was not achieved at these MS09:siRNA (w/w) ratios 
bsiRNA was likely to have been surface-associated in these samples 
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4. Flow Profiles 
4.1 Liposome suspensions 
A) MS09/DOPE B) MS09/Chol (1:1)  
 














C) MS09:siRNA (w/w) = 20:1 D) MS09:siRNA (w/w) = 24:1 
 
E) MS09:siRNA (w/w) = 28:1 F) MS09:siRNA (w/w) = 32:1 
 
MS09/Chol (1:1) LIPOPLEXES 




I) MS09:siRNA (w/w) = 20:1 J) MS09:siRNA (w/w) = 24:1 
 
K) MS09:siRNA (w/w) = 28:1 L) MS09:siRNA (w/w) = 32:1 
 
MS09/DOPE/PEG LIPOPLEXES 




O) MS09:siRNA (w/w) = 20:1 P) MS09:siRNA (w/w) = 24:1 
 
Q) MS09:siRNA (w/w) = 28:1 R) MS09:siRNA (w/w) = 32:1 
 
MS09/Chol/PEG (1:1) LIPOPLEXES 
 





U) MS09:siRNA (w/w) = 20:1  V) MS09:siRNA (w/w) = 24:1 
  
 
W) MS09:siRNA (w/w) = 28:1 X) MS09:siRNA (w/w) = 32:1 
 
Note the following: 













5. Zeta potential and size vs. concentration graphs 
5.1 Liposome suspensions 
A) MS09/DOPE  
 














A) MS09:siRNA (w/w) = 12:1 
 
B) MS09:siRNA (w/w) = 16:1 
 




D) MS09:siRNA (w/w) = 24:1
 
E) MS09:siRNA (w/w) = 28:1 
 




MS09/Chol (1:1) LIPOPLEXES 
G) MS09:siRNA (w/w) = 12:1 
 
H) MS09:siRNA (w/w) = 16:1
 




J) MS09:siRNA (w/w) = 24:1
 
K) MS09:siRNA (w/w) = 28:1
 





M) MS09:siRNA (w/w) = 12:1 
 
N) MS09:siRNA (w/w) = 16:1 
 




P) MS09:siRNA (w/w) = 24:1 
 
Q) MS09:siRNA (w/w) = 28:1 
 




MS09/Chol/PEG (1:1) LIPOPLEXES 
S) MS09:siRNA (w/w) = 12:1 
 
T) MS09:siRNA (w/w) = 16:1 
 




V) MS09:siRNA (w/w) = 24:1 
 
W) MS09:siRNA (w/w) = 28:1 
 
X) MS09:siRNA (w/w) = 32:1 
 
Note the following:  
1. Graphs representative of a single experimental run per sample are shown. 




APPENDIX C  
Miscellaneous calculations 
1. Estimation of the average number of lipid molecules per vesicle 
Example: MS09/DOPE formulation 
• Lipid concentration of liposome suspension = 8 μmol/ml 
 
• 1 mol = 6.022 × 1023 lipid molecules 
1 μmol = 6.022 × 1017 lipid molecules 
8 μmol = 6.022 × 1017 × 8 lipid molecules = 4.82 × 1018  
Therefore, lipid concentration of liposome suspension  
= 4.82 × 1018 lipid molecules/ml 
•
 Average number of liposomal vesicles/ml (value plotted in Figure 4.4c) 
= 4.93 × 1012 
 
•
 Average number of lipid molecules/vesicle =  ].^_ ×`abc].de ×`abO =  8.56 × 10f 
 
•
 Estimation of the average numbers of individual lipid components per vesicle was 
made assuming that the ratio at which these were combined in lipid mixtures was 
maintained in each vesicle of a given formulation. 
 
•
 Average number of MS09 molecules/vesicle = 0.5 × 8.56 × 105 = 4.28 × 105 
•
 Average number of DOPE molecules/vesicle = 0.5 × 8.56 × 105 = 4.28 × 105 
 
2. N/P (+/‐) charge ratio 
Example: Lipoplex assembled at MS09:siRNA (w/w) ratio of 12:1  
Molecular weight of MS09 = 629 g/mol (Singh and Ariatti, 2006) 
• Average molecular weight of ribonucleotide = 340 g/mol (Thermo Fisher Scientific, 
DNA and RNA molecular weights and conversions accessed via 
https://www.thermofisher.com/us/en/home/references/ambion‐tech‐
support/rna‐tools‐and‐calculators/dna‐and‐rna‐molecular‐weights‐and‐
conversions.html as at 4/4/17) 
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• Assumptions (a) 629 ng MS09 = 1 nano equivalent +ve charge 
          (b) 340 ng siRNA = 1 nano equivalent –ve charge 
 
• The complex contained 0.3 g (300 ng) siRNA and 3.6 g (3 600 ng) MS09 
• +ve charge in complex =  e haah_d  =  5.723 nano equivalents  
• ‐ve charge in complex =  eaae]a  =  0.882 nano equivalents  
• N/P (+ ‐i )  =  
f.j_e
a.^^_ = 6.5 
 
3. Final siRNA concentration 
• Average molecular weight of siRNA = 13 400 g/mol (Dharmacon, Lafayette, 
CO, USA) 
Therefore 0.1 μg =  `aa #4`e ]aa #4/#%)+  =  7.46 × 10‐e nmol = 7.46 pmol  
∽ 7.5 pmol 
 
• In a 48‐well plate,  
Total volume = 250 μl (growth medium) + 10 μl (transfecting complex) = 
260 μl 
Transfecting complexes contained 0.2 μg, 0.1 μg or 0.05 μg siRNA 
• When 0.2 μg (14.92 pmol) was introduced:  
siRNA concentration in transfecting complex =  `].d_ × `a‐n R%)+`a × `a‐n o  =  1.49 μM  
Final concentration = `].d_ × `a‐p #%)+_ha ×`a‐n o   =  57.38 nM ~ 57 nM 
• When 0.1 μg  (7.46 pmol) was introduced: 
siRNA concentration in transfecting complex =  j.]h × `a‐n R%)+`a × `a‐n o  =  0.75 μM  
Final concentration = j.]h × `a‐p #%)+_ha ×`a‐n o   =  28.69 nM ~ 29 nM 
• When 0.05 μg  (3.73 pmol) was introduced: 












Lipid	concentration	of	MS09/DOPE	formulation	 = 	5.5	μg/μl	 = 	8	 × 10-e	μmol/μl	
MS09	(i. e. cytofectin)	concentration	in	MS09/DOPE	suspension	 = 	2.52	μg/μl		
• The	lipoplex	contained	(0.2	 × 	12)	μg	 = 	2.4	μg	MS09	
μmol	MS09	 = 	 _.]	R4h_d	R4/R%)+ 	= 	3.815	 × 	10-e		
Final	MS09	concentration		 = 	 e.^`f	×	`a-p	R%)+_ha	×	`a-n	o 	 = 	14.7	μM			
• The	lipoplex	contained	 r_.]	R4	×	f.f	R4/R+_.f_	R4/R+ s 	μg	total	lipid	 = 5.238	μg		
μmol	lipid = t	f._e^	R4	×	(^	×	`a-pR%)+/R+)f.f	R4/R+ u = 	7.619	 ×	10-e		












The average number of liposomal vesicles in the MS09/DOPE stock suspensions was 
calculated in the same way, i.e. 4.93 × 1012 ± 4.85 × 1011 particles/ml. To prepare 
lipoplexes 1 μl stock suspension was used. This implies that, for a well‐dispersed liposome 
suspension, an estimated (4.93 × 1012 ÷1000) = 4.93 × 109 liposomal vesicles was 
introduced into 10 μl. Hence, the estimated average number of MS09/DOPE liposomal 
vesicles involved in the formation of one liposome‐siRNA complex at the MS09:siRNA (w/w) 
ratio of 16:1 is: 
4.93 × 10dliposomal vesicles
1.58 × 10dlipoplexes  =  3.12 ∽  3 
 
6. Estimation of average number of siRNA molecules/nanocomplex 
This example pertains to the MS09/DOPE lipoplex at MS09:siRNA (w/w) ratio of 16:1, 
• The lipoplex suspension was prepared using 1 μl liposome stock suspension 
i.e. 2.52 μg MS09 
• Hence:  
t2.5216 u  μg =  0.1575 μg =  157.5 ng siRNA was added 
• Average molecular weight of siRNA = 13 400 ng/nmol 
• Therefore  
nmoles siRNA in lipoplex suspension =  t 157.513 400u =  1.175 × 10
‐_  
• 6.022 × 1023 molecules in 1 mol siRNA  
= 6.022 × 1014 molecules in 1 nmol siRNA. 
• Hence 1.175 × 10‐2 nmol contains (6.022 × 1014) × (1.175 × 10‐2) siRNA 
molecules 
• = 7.076 × 1012 
 number of siRNA molecules per complex =  #$%&'( )* 0,z{| %)+'/$+'0 ,# `a R+23'(24' #$%&'( )* #2#)/)%-+'}'0 ,# `a R+ 




Set-up for gel retardation and nuclease digestion assays 
Table D1: Preparation of MS09/DOPE-siRNA complexes for gel retardation assay 
MS09:siRNA (w/w) 0 4:1 8:1 12:1 16:1 20:1 24:1 28:1 
siRNA  



















MS09   (µg) 0 1.2 2.4 3.6 4.8 6.0 7.2 8.4 
Liposome  



















HBS  (µl) 8.88 7.93 6.98 6.02 5.07 4.12 3.17 2.21 
Total volume  (µl) 10 10 10 10 10 10 10 10 
asiRNA stock = 0.268 µg/µl 
bMS09/DOPE stock diluted 1:1 (v/v) in HBS = 2.75 µg/µl 
 
 
Table D2: Preparation of MS09/Chol (1:1)-siRNA complexes for gel retardation assay 
MS09:siRNA (w/w) 0 8:1 12:1 16:1 20:1 24:1 28:1 32:1 
siRNA  



















MS09   (µg) 0 2.4 3.6 4.8 6.0 7.2 8.4 9.6 
Liposome  



















HBS  (µl) 8.88 6.98 6.02 5.07 4.12 3.17 2.21 1.26 
Total volume  (µl) 10 10 10 10 10 10 10 10 
asiRNA stock = 0.268 µg/µl 









Table D3: Preparation of MS09/DOPE/PEG-siRNA complexes for gel retardation assay 
MS09:siRNA (w/w) 0 8:1 12:1 16:1 20:1 24:1 28:1 32:1 
siRNA  



















MS09   (µg) 0 2.4 3.6 4.8 6.0 7.2 8.4 9.6 
Liposome  



















HBS  (µl) 8.88 6.93 5.95 4.98 4.0 3.03 2.05 1.08 
Total volume  (µl) 10 10 10 10 10 10 10 10 
asiRNA stock = 0.268 µg/µl 
bMS09/DOPE/PEG stock diluted 1:1 (v/v) in HBS = 2.91 µg/µl 
 
 
Table D4: Preparation of MS09/Chol/PEG (1:1)-siRNA complexes for gel retardation assay 
MS09:siRNA (w/w) 0 8:1 12:1 16:1 20:1 24:1 28:1 32:1 
siRNA  



















MS09   (µg) 0 2.4 3.6 4.8 6.0 7.2 8.4 9.6 
Liposome  



















HBS  (µl) 8.88 6.93 5.95 4.98 4.0 3.03 2.05 1.08 
Total volume  (µl) 10 10 10 10 10 10 10 10 
asiRNA stock = 0.268 µg/µl 












Table D5: Preparation and treatment of MS09/DOPE-siRNA complexes for nuclease digestion assay 
MS09:siRNA (w/w) 0 0 12:1 16:1 20:1 24:1 28:1 32:1 
siRNA  (µl)a 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 
Liposome  (µl)b 0 0 2.86 3.81 4.76 5.71 6.67 7.62 
HBS  (µl) 8.88 8.88 6.02 5.07 4.12 3.17 2.21 1.26 
Total sample (µl) 10 10 10 10 10 10 10 10 
FBS (µl) 0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 
EDTA (µl)c 0 1.15 1.15 1.15 1.15 1.15 1.15 1.15 
SDS (µl)d 0 0 1.15 1.15 1.15 1.15 1.15 1.15 
HBS (µl) 3.4 1.15 0 0 0 0 0 0 
Total volume (µl) 13.4 13.4 13.4 13.4 13.4 13.4 13.4 13.4 
asiRNA stock = 0.268 µg/µl 
bMS09/DOPE stock diluted 1:1 (v/v) in HBS = 2.75 µg/µl 
cEDTA stock = 110 mM in water 
dSDS stock = 6 % (w/v) in water 
 
 
Table D6: Preparation and treatment of MS09/Chol (1:1)-siRNA complexes for nuclease digestion assay 
MS09:siRNA (w/w) 0 0 12:1 16:1 20:1 24:1 28:1 32:1 
siRNA  (µl)a 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 
Liposome  (µl)b 0 0 2.86 3.81 4.76 5.71 6.67 7.62 
HBS  (µl) 8.88 8.88 6.02 5.07 4.12 3.17 2.21 1.26 
Total sample (µl) 10 10 10 10 10 10 10 10 
FBS (µl) 0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 
EDTA (µl)c 0 1.15 1.15 1.15 1.15 1.15 1.15 1.15 
SDS (µl)d 0 0 1.15 1.15 1.15 1.15 1.15 1.15 
HBS (µl) 3.4 1.15 0 0 0 0 0 0 
Total volume (µl) 13.4 13.4 13.4 13.4 13.4 13.4 13.4 13.4 
asiRNA stock = 0.268 µg/µl 
bMS09/Chol (1:1) stock diluted 1:1 (v/v) in HBS = 2.03 µg/µl 
cEDTA stock = 110 mM in water 
dSDS stock = 6 % (w/v) in water 
Room temperature, 30 min 
37 ˚C, 4 h 
55 ˚C, 25 min 
Room temperature, 30 min 
37 ˚C, 4 h 
55 ˚C, 25 min 
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Table D7: Preparation and treatment of MS09/DOPE/PEG-siRNA complexes for nuclease digestion assay 
MS09:siRNA (w/w) 0 0 12:1 16:1 20:1 24:1 28:1 32:1 
siRNA  (µl)a 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 
Liposome  (µl)b 0 0 2.93 3.90 4.88 5.85 6.83 7.80 
HBS  (µl) 8.88 8.88 5.95 4.98 4.0 3.03 2.05 1.08 
Total sample (µl) 10 10 10 10 10 10 10 10 
FBS (µl) 0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 
EDTA (µl)c 0 1.15 1.15 1.15 1.15 1.15 1.15 1.15 
SDS (µl)d 0 0 1.15 1.15 1.15 1.15 1.15 1.15 
HBS (µl) 3.4 1.15 0 0 0 0 0 0 
Total volume (µl) 13.4 13.4 13.4 13.4 13.4 13.4 13.4 13.4 
asiRNA stock = 0.268 µg/µl 
bMS09/DOPE/PEG stock diluted 1:1 (v/v) in HBS = 2.91 µg/µl 
cEDTA stock = 110 mM in water 
dSDS stock = 6 % (w/v) in water 
 
 
Table D8: Preparation and treatment of MS09/Chol/PEG (1:1)-siRNA complexes for nuclease digestion assay 
MS09:siRNA (w/w) 0 0 12:1 16:1 20:1 24:1 28:1 32:1 
siRNA  (µl)a 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 
Liposome  (µl)b 0 0 2.93 3.90 4.88 5.85 6.83 7.80 
HBS  (µl) 8.88 8.88 5.95 4.98 4.0 3.03 2.05 1.08 
Total sample  (µl) 10 10 10 10 10 10 10 10 
FBS (µl) 0 1.1 1.1 1.1 1.1 1.1 1.1 1.1 
EDTA (µl)c 0 1.15 1.15 1.15 1.15 1.15 1.15 1.15 
SDS (µl)d 0 0 1.15 1.15 1.15 1.15 1.15 1.15 
HBS (µl) 3.4 1.15 0 0 0 0 0 0 
Total volume (µl) 13.4 13.4 13.4 13.4 13.4 13.4 13.4 13.4 
asiRNA stock = 0.268 µg/µl 
bMS09/Chol/PEG (1:1) stock diluted 1:1 (v/v) in HBS = 2.21 µg/µl 
cEDTA stock = 110 mM in water 
dSDS stock = 6 % (w/v) in water
37 ˚C, 4 h 
55 ˚C, 25 min 
Room temperature, 30 min 
37 ˚C, 4 h 
55 ˚C, 25 min 




MS09/Chol (1:1) vs. MS09/DOPE at MS09:siRNA (w/w) = 16:1 
 
Table E1: A summary of the properties of MS09/Chol (1:1) and MS09/DOPE lipoplexes at 
MS09:siRNA (w/w) =16:1 
Liposome formulation MS09/DOPE MS09/Chol (1:1) 
MS09:siRNA (w/w) 16:1 16:1 
N/P (+/
-
) 8.7:1 8.7:1 
Number of liposomal vesicles/nanocomplexa 3 3 
Number of siRNA molecules/nanocomplexa 4500 3900 
Number of lipid molecules/nanocomplexa,b 25.7 × 105 34.8 × 105 
siRNA fully bound at given 
ratio? (/) 
Gel retardation    
Dye displacement 
EtBr   
SYBR Green   
Z-NTAc 
Size (nm) 92.4 ± 24.5 126.8 ± 7.3 
ζ potential (mV) -33.6 ± 4.5 -43.9 ± 5.4* 
Protection of siRNA 
in serum (10 % v/v) 
siRNA protected? (/)   
% siRNA protectedc  75.5 ± 5.01 67.8 ± 0.03** 
Dose applied to cells in  
gene expression studies 
siRNA (nM) 12 12 
MS09 (µM) 4.1 4.1 
Total lipid (µM) 8.2 8.2 
Cell survival at given dosec  
(%) 
 
MCF-7 AB 99.8 ± 7.7 98.9 ± 8.4 
HT-29 AB 102.1 ± 7.3 100.6 ± 11.5 
siRNA uptake at given dosec 
(× 103 RFU/mg protein) 
MCF-7 29.1 ± 2.7 41.7 ± 3.2** 
HT-29 28.5 ± 1.8 24.8 ± 2.0 
Notes: 
aReported values are average estimates 
bThis value was estimated based on the estimated average numbers of lipid molecules/vesicle and 
vesicles/nanocomplex 
cData is presented as the mean ± SD (n = 3) 





















































































































































































Figure F1: Tolerance of MS09/DOPE and MS09/Chol (1:1) lipoplexes by a) MCF-7, b) HT-29, c) HEK293 and d) Caco-2 cells. Lipoplexes were 
assembled at MS09:siRNA (
w
/w) = 16:1, and introduced to cells at varying final siRNA concentrations. Non-targeting siRNA was used throughout 
and cell survival was assessed by the AB viability assay 48 h after transfection. Each column represents the mean ± SD (n = 3). P > 0.05 vs. 
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Figure F2: Effect of transfections in high serum concentrations on the growth of a) MCF-7 and b) HT-29 
cells. Cells were subjected to 4 h-long exposure to MS09/DOPE and MS09/Chol (1:1) lipoplexes, 
assembled at MS09:siRNA (
w
/w) = 16:1, to give final siRNA concentration of 12 nM, in varying serum 
concentrations. Non-targeting siRNA was used throughout and cell survival was assessed by the AB 
viability assay at 48 h post-transfection. No treatment refers to cells that were grown in 10 % serum for 
48 h without transfection. Cells only refers to groups exposed to varying serum concentrations without 
transfection. Each column represents the mean ± SD (n = 3). P > 0.05 vs. the No treatment group, in all 
instances.  
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